POLYMERASES FOR ANALYZING OR TYPING POLYMORPHIC NUCLEIC ACID FRAGMENTS AND USES THEREOF

Abstract: The present invention provides methods for use in identifying, analyzing and typing polymorphic DNA fragments, particularly minisatellite, microsatellite or STR DNA fragments. In particular, the invention provides methods using DNA polymerases, more particularly thermostable DNA polymerases, and most particularly Thermotoga polymerases or mutants or derivatives thereof, whereby minisatellite, microsatellite or STR DNA molecules may be amplified and analyzed for polymorphisms. The invention also relatesto polymerases having reduced, substantially reduced or eliminated ability to add non-template 3' nucleotides to a synthesized nucleic acid molecule. In accordance with the invention, such reduction or elimination may be accomplished by modifying or mutating the desired polymerase.

Description: Polymerases for Analyzing or Typing Polymorphic Nucleic Acid Fragments and Uses Thereof FIELD OF THE INVENTION The present invention is in the field of molecular and cellular biology. The invention relates to compositions and methods for use in analyzing and typing polymorphic regions of DNA. More particularly, the invention is directed to compositions of polymerases (preferably DNA polymerases and most preferably thermostable DNA polymerases), and methods using these compositions, whereby polymorphic, minisatellite, microsatellite or STRDNAfragments may be amplified and analyzed. The compositions and methods of the present invention are useful in a variety of techniques employing DNA amplification and polymorphism analysis, including medical genetic, forensic, and plant breeding applications. The present invention also relates to polymerases having reduced, substantially reduced or eliminated ability to add one or more non-templated nucleotides to the 3' terminus of a synthesized nucleic acid molecule. Preferably, the polymerases of the invention are thermostable or mesophilic polymerases. Specifically, the polymerases of the present invention (e.g., DNA or RNA polymerases) have been mutated or modified to reduce, substantially reduce or eliminate such activity (compared to the unmodified, unmutated, or wild type polymerase), thereby providing a polymerase which synthesizes nucleic acid molecules having little or no non-templated 3' terminal nucleotides. Such polymerases thus have enhanced or greater ability to produce a double stranded nucleic acid molecule having blunt ended termini which may facilitate cloning of such molecules. The present invention also relates to cloning and expression of the polymerases of the invention, to nucleic acid molecules containing the cloned genes, and to host cells which express said genes. The polymerases of the present invention may be used in DNA sequencing, amplification, nucleic acid synthesis, and polymorphism analysis. The invention also relates to polymerases of the invention which have one or more additional mutations or modifications. Such mutations or modifications include those which (1) substantially reduce 3'- 5' exonuclease activity; and/or (2) substantially reduce 5'- 3' exonuclease activity. The polymerases of the invention can have one or more of these properties. These polymerases may also be used in nucleic acid analysis including but not limited to DNA sequencing, amplification, nucleic acid synthesis, and polymorphism analysis. BACKGROUND OF THE INVENTION DNA Structure The genetic framework (t ' .e., the genome) of an organism is encoded in the double-stranded sequence of nucleotide bases in the deoxyribonucleic acid (DNA) which is contained in the somatic and germ cells of the organism. The genetic content of a particular segment of DNA °r gene, is only manifested upon production of the protein which the gene ultimately encodes. There are additional sequences in the genome that do not encode a protein (i.e., "noncoding" regions) which may serve a structural, regulatory, or unknown function. Thus, the genome of an organism or cell is the complete collection of protein-encoding genes together with intervening noncoding DNA sequences. Importantly, each somatic cell of a multicellular organism contains the full complement of genomic DNA of the organism, except in cases of focal infections or cancers, where one or more xenogeneic DNA sequences may be inserted into the genomic DNA of specific cells and not into other, non-infected, cells in the organism. Minisatellite and Microsatellite DNA Interspersed throughout the genomic DNA of most eukaryotic organisms are short stretches of polymorphic repetitive nucleotide sequences known as "minisatellite DNA" sequences or fragments (Jeffreys, A.J., etal., Nature 314:61- 73 (1985)). These repeating sequences often appear in tandem and in variable numbers within the genome, and they are thus sometimes referred to as "short tandem repeats" ("STRs") or "variable numbers of tandem repeats" ("VNTRs") (see U.S. Patent No. 5,075,217; Nakamura et al, Science 235:1616-1622 (1987)). Typically, however, minisatellite repeat units are about 9 to 60 bases in length (Nakamura etal, Science 255:1616-1622 (1987); Weber and May, Am. J. Hum. Genet. ¥4:388-396 (1989)) which are repeated in tandem about 20-50 times (Watson, J.D., et al, eds., Recombinant DNA, 2nd ed., New York: Scientific American Books, p. 146 (1992)). Other short, simple sequences which are analogous to minisatellite DNAs, termed "microsatellite DNAs" (Litt, M., and Luty, J.A., Am. J. Hum. Genet 44:291-401 (1989); Weber and May, Am. J. Hum. Genet. 4:388-396 (1989)), are usually about 1-6 bases in repeat unit length and thus give rise to monomeric (Economou, E.T., et al, Proc. Natl. Acad. Sci. USA 57:2951-2954 (1990)), dimeric, trimeric, quatrameric, pentameric or hexameric repeat units (Litt, M., and Luty, J.A., Am. J. Hum. Genet 44:391-401 (1989); Weber and May, Am. J. Hum. Genet. 44:388-396 (1989)). The most prevalent of these highly polymorphic microsatellite sequences in the human genome is the dinucleotide repeat (dC-dA) n »(dG-dT) n (where n is the number of repetitions in a given stretch of nucleotides), which is present in a copy number of about 50,000-100,000 (Tautz, D., andRenz, M.,Nucl. AcidsRes. 72:4127-4138 (1984); Dib, C, et al, Nature 360:152-154 (1996)), although the existence of a variety of analogous repeat sequences in the genomes of evolutionarily diverse eukaryotes has been reported (Hamada, H., et al. , Proc. Natl. Acad. Sci. USA 79:6465-6469 (1982)). The actual in vivo function of minisatellite and microsatellite sequences is unknown. However, because these tandemly repeated sequences are dispersed throughout the genome of most eukaryotes, exhibit size polymorphism, and are often heterozygous (Weber, J.L., Genomics 7:524-530 (1990)), they have been explored as potential genetic markers in assays attempting to distinguish closely related individuals, and in forensic and paternity testing (see, e.g., U.S. Patent No . 5,075,217; Jeffreys, A.J., et al, Nature 332:278-281 (1988)). The finding that mutations often are observed in microsatellite DNA regions in cancer cells (Loeb, LA., Cancer Res. 54:5059-5063 (1994)), potentially linking genomic instability to the carcinogenic process and providing useful genetic markers of cancer, lends additional significance to methods facilitating the rapid analysis and genotyping of polymorphisms in these genomic DNA regions. Methods of Genotyping Minisatellite or STR DNA Sequences To analyze minisatellite, microsatellite or STR DNA sequence polymorphisms, a variety of molecular biological techniques have been employed. These techniques include restriction fragment length polymorphism (RFLP) or "DNA fingerprinting" analysis (Wong, Z., et al., Nucl. Acids Res. 74:4605-4616 (1986); Wong, Z., etal, Ann. Hum. Genet 51 :269-288 (1987); Jeffreys, A.J., et al, Nature 332:278-281 (1988); U.S. Patent Nos. 5,175,082; 5,413,908; 5,459,039; and 5,556,955). Far more commonly employed for STR genotyping than RFLP and hybridization, however, are amplification-based methods, such as those relying on the polymerase chain reaction (PCR) method invented by Mullis and colleagues (see U.S. Patent Nos. 4,683,195; 4,683,202; and 4,800,159). These methods use "primer" sequences which are complementary to opposing regions flanking the polymorphic DNA sequence to be amplified from the sample of genomic DNA to be analyzed. These primers are added to the DNA target sample, along with excess deoxynucleotides and a DNA polymerase (e.g., Tag polymerase; see below), and the primers bind to their target via base-specific binding interactions (i.e., adenine binds to thymine, cytosine to guanine). By repeatedly passing the reaction mixture through cycles of increasing and decreasing temperatures (to allow dissociation of the two DNA strands on the target sequence, synthesis of complementary copies of each strand by the polymerase, and re-annealing of the new complementary strands), the copy number of the minisatellite or STR sequence of DNA may be rapidly increased, and detected by size separation methods such as gel electrophoresis. PCR and related amplification approaches have been used in attempts to develop methods for typing and analyzing STRs or minisatellite regions. For example, PCR has been employed to analyze polymorphisms in microsatellite sequences from different individuals, including (dC-dA)n-(dG-dT)n (Weber, J.L, and May, P.E., Am. J. Hum. Genet. 44:388-396 (1989); Weber, J. L., Genomics 7:524-530 (1990); U.S. Patent Nos. 5,075,217; 5,369,004; and 5,468,613). Similar methods have been applied to a variety of medical and forensic samples to perform DNA typing and to detect polymorphisms between individual samples (U.S. Patent Nos. 5,306,616; 5,364,759; 5,378,602; and 5,468,610). In Vitro Use of DNA Polymerases The above-described amplification-based techniques require the use of DNA polymerases, which catalyze the addition of deoxynucleoside triphosphate (dNTP) bases into the newly forming DNA strands. Together with other enzymes (e.g., helicases, ligases and ATPases), the DNA polymerases ensure rapid and relatively faithful replication of DNA in preparation for proliferation in vivo in prokaryotes, eukaryotes and viruses. DNA polymerases synthesize the formation of DNA molecules which are complementary to a DNA template. Upon hybridization of a primer to the single- stranded DNA template, polymerases synthesize DNA in the 5' to 3' direction, successively adding nucleotides to the 3'-hydroxyl group of the growing strand. Thus, in the presence of deoxyribonucleoside triphosphates (dNTPs) and a primer, a new DNA molecule, complementary to the single stranded DNA template, can be synthesized. In addition to an activity which adds dNTPs to DNA in the 5' to 3' direction (i.e., "polymerase" activity), many DNA polymerases also possess activities which remove dNTPs in the 5' to 3' and/or the 3' to 5' direction (i.e., "exonuclease" activity). This dual activity of certain DNA polymerases is, however, a drawback for some in vitro applications. For example, the in vitro synthesis of an intact copy of a DNA fragment by the polymerase activity, an elongation process which proceeds in a 5' to 3' direction along the template DNA strand, is jeopardized by the exonuclease activities which may simultaneously or subsequently degrade the newly formed DNA. Limitations of PCR-based Genotyping of Minisatellite, Microsatellite and STR DNA Sequences Application of PCR-based methods to analysis of minisatellite or STR DNA sequences has a number of significant limitations. It has been shown, for example, that use of Taq and other thermostable DNA polymerases commonly employed in PCR and related automated amplification methods causes the accumulation of amplification products containing non-templated 3' terminal nucleotides (Clark, J.M., etal, J. Molec. Biol. 198:123-121 (1987); Clark, J.M., Nucl. Acids Res. 76:9677-9686 (1988); Hu, G., DNA Cell Biol. 72:763-770 (1993)). That is, some of the newly synthesized DNA strands produced in each round of amplification have had an extra nucleotide added to their 3' termini, such that the newly synthesized strands may be longer by one base. Non-templated nucleotide addition is a slow process compared to template-directed synthesis (Clark, J.M., Nucl. Acids Res. 76:9677-9686 (1988)), and its extent is sequence-dependent (Hu, G., DNA Cell Biol 72:763-770 (1993); Brownstein, M.J., et al, BioTechniques 20:1004-1010 (1996)). Consequently, the PCR product is often heterogeneous in regard to extra nucleotide addition depending upon the primers and the reaction conditions used by the investigator (Magnuson, V.L., et al, BioTechniques 27:700-709 (1996)). Extra nucleotide addition, in combination with "stutter" due to slippage during PCR amplification (Levinson, G., and Gutman, G.A., Molec. Biol. Evol 4:203-221 (1987); Schlotterer, C, and Tautz, O.,Nucl AcidsRes. 20:211-215 (1992)), often results in complex DNA fragment patterns which are difficult to interpret, especially by automated methods. This can result in improper genotyping analysis, particularly if the percentage of non-templated nucleotide addition is between 30-70% of the PCR product (Smith, J.R., et al, Genome Res. 5:312-317 (1995)). Thus, a need currently exists for a rapid, automated method for identifying, analyzing and typing polymorphic DNA fragments, particularly minisatellite, microsatellite or STR DNA fragments, that will not result in the problematic results described above. The present invention provides such a method. BRIEF SUMMARY OF THE INVENTION The present invention satisfies these needs in the art by providing methods useful in the identification, analysis or typing of polymorphic DNA fragments, particularly minisatellite, microsatellite or STR DNA fragments, in samples of DNA from a cell, particularly a eukaryotic cell. Specifically, the invention provides a method of producing a population of amplified DNA molecules, for use in analyzing or typing a DNA molecule in a DNA sample isolated from a cell, preferably a eukaryotic cell. The method of the present invention comprises contacting a DNA sample with a DNA polymerase (preferably a thermostable DNA polymerases) reduced, substantially reduced or eliminated in the ability to add one or more non-templated nucleotides to the 3' terminus of a DNA molecule, amplifying a polymorphic DNA fragment, preferably a minisatellite, microsatellite or STR DNA fragment, within the DNA sample and analyzing the amplified polymorphic DNA fragment. In the method of the invention, the analysis step may comprise, for example, sizing or sequencing the amplified DNA molecule and optionally comparing the size and/or sequence of the amplified DNA molecule to a different DNA sample which has been amplified according to the invention. In preferred embodiments of the present invention, the thermostable DNA polymerase is a Thermotoga DNA polymerase, preferably a Thermotoga DNA polymerase substantially reduced in 3'-5' exonuclease activity, more preferably a Tne polymerase, a Tma polymerase, or a mutant or derivative thereof, and most preferably a mutant of Tne polymerase selected from the group consisting of Tne NA219, D323A; 7>2e N'Δ283, D323A; Tne NA284, D323A; Tne NA193, D323A; 7 eD137 D323A; J«eD8A D323A; Tne G195D,D323A; Tne G37D, D323 7«eNA283; 7>jeD137A D323 R722K; T«e D137 D323 R722Y; Tne D137A D323A R722L; Tne D137A D323A R722H; Tne D137A D323A R722Q; Tne D137A D323 A, F730Y; Tne D137A D323 K726R; Tne D137A D323A, K726H; 7>ze D137A D323A R722K, F730Y; Tne D137A D323A R722K, K726R; Tne D137A D323A, R722K, K726H; Tne D137A D323A R722H, F730Y; Tne D137A D323A R722H, K726R; Tne D137A D323A R722H, K726H; Tne D137A D323A R722Q, F730Y; Tne D137A D323A R722Q, K726R; Tne D137A D323A R722Q, K726H; Tne D137A D323A R722N, F730Y; Tne D137A D323A R722N, K726R; Tne D137A D323A R722N, K726H; Tne D137A D323A F730S; Tne N'Δ283, D323A R722KH/Q/N/Y L; Tne N'Δ219, D323 R722K; 7we N'Δ219, D323A F730Y; JneN'Δ219,D323 K726R; 7«eN'Δ219,D323 K726H; 7weD137 D323 F730S, R722K/Y/Q/N/H/L, K726R H; Tne D137A D323A F730T, R722KΛ7Q/N/H/L, K726R H; Tne D137A D323A F730T; 7ne F730S; Tne F730A; 7ne K726R; Tne K726H; and 7we D137A D323A R722N. The present invention is particularly directed to the above methods wherein the eukaryotic cell is an plant cell or an animal cell, preferably a mammalian cell, more preferably a normal, diseased, cancerous, fetal or embryonic mammalian cell, and most preferably a human cell. The invention is also directed to the above methods, further comprising isolating the polymorphic, minisatellite, microsatellite or STR DNA fragment and inserting it into a vector, preferably an expression vector. By the present methods, the polymorphic or microsatellite DNA fragment may be amplified prior to being inserted into the vector. The present invention also provides a method of determining the relationship between a first individual and a second individual, comprising contacting a DNA sample from the first and second individuals with a DNA polymerase (e.g. a thermostable DNA polymerase) reduced, substantially reduced or eliminated in the ability to add one or more non-templated nucleotides to the 3' terminus of a DNA molecule, amplifying one or more DNA molecules in the DNA sample to generate a collection of amplified polymorphic DNA fragments, separating the amplified DNA fragments by length, and comparing the pattern of amplified DNA fragments from the first individual to that of the second individual. This method also allows the identification of one or more unique polymorphic DNA fragments, particularly a minisatellite, microsatellite or STR DNA fragment, that is specifically present in only one of the two individuals. This method may further comprise determining the sequence of the unique polymorphic, minisatellite, microsatellite or STR DNA fragment. In this embodiment of the present invention, the thermostable DNA polymerase may be a Thermotoga DNA polymerase, preferably a Thermotoga DNA polymerase substantially reduced in 3'-5' exonuclease activity, more preferably a Tne polymerase, a Tma polymerase, or a mutant or derivative thereof, and most preferably a mutant of Tne polymerase selected from the group consisting of 7 e N l Δ219, D323A; 7weN'Δ283, D323A; 7«e N'Δ284, D323A; Tne N'Δ193, D323A; Tne D137A D323A; Tne D8A D323A; 7we G195D, D323A; Tne G37D, D323A; Tne N'Δ283; Tne D137A D323A R722K; Tne D137A D323A R722Y; Tne D137A D323A R722L; r«eD137 D323 R722H; 7neD137A D323 R722Q; 7«eD137A D323A F730Y; Tne D137A D323 K726R; Tne D137A D323 K726H; Tne D137A D323A R722K, F730Y; Tne D137A D323A R722K, K726R; Tne D137A D323A R722K, K726H; Tne D137A D323A R722H, F730Y; Tne D137A D323A R722H, K726R; Tne D137A, D323A R722H, K726H; Tne D137A D323A R722Q, F730Y; Tne D137A D323A R722Q, K726R; Tne D137A D323A R722Q, K726H; Tne D137A D323A R722N, F730Y; Tne D137A D323A, R722N, K726R; Tne D137A D323A R722N, K726H; Tne D137A D323A F730S; 7«e N'Δ283, D323 R722K/H/Q/N/Y/L; 7«e N'Δ219, D323 R722K; J«eN'Δ219,D323 F730Y; 7,ιeN , Δ219, D323A, K726R; JweN'Δ219, D323A,K726H; 7«eD137AD323 F730S,R722KA /Q/N/H L, K726R/H; Tne D137A, D323A F730T, R722K7Y/Q/N/H/L, K726R/H; Tne D137A D323A F730T; Tne F730S; Tne F730A; Tne K726R; Tne K726H; and Tne D137A D323A, R722N. The present invention is particularly directed to the above methods wherein the first or second individual is an animal or a plant, and most preferably wherein the first or second individual is a human. The present invention also provides isolated nucleic acid molecules encoding mutant Tne DNA polymerase proteins, wherein the mutant Tne DNA polymerase proteins have an amino acid sequence as set forth in any one of SEQ ID NOs: 4-10. The invention also provides mutant Tne DNA polymerase proteins having an amino acid sequence as set forth in any one of SEQ ID NOs:4-10, most preferably a mutant Tne polymerase protein selected from the group consisting of Tne NA283, D323A (SEQ ID NO:4); Tne N'Δ193, D323A (SEQ LD NO:5); Tne D137A D323A (SEQ ID NO:6); Tne D8 D323A (SEQ LD NO:7); Tne G195D, D323A (SEQ ID NO:8); Tne G37D, D323A (SEQ ID NO:9); and Tne N'Δ283 (SEQ ID NO: 10). The invention also relates to nucleic acid molecules and the proteins encoded by such nucleic acid molecules for mutant Tne polymerases selected from the group consisting of Tne n'Δ283; Tne D137A D323A R722K; Tne D137A D323A R722Y; Tne D137A D323A R722L; 7«e D137 D323 R722H; T«eD137A D323A R722Q; 7weD137A D323A F730Y; Tne D137A D323A K726R; Tne D137A D323A K726H; Tne D137A D323A R722K, F730Y; Tne D137A D323A R722K, K726R; Tne D137A D323A R722K, K726H; Tne D137A D323A R722H, F730Y; Tne D137A D323A, R722H, K726R; Tne D137A D323A R722H, K726H; Tne D137A D323A R722Q, F730Y; Tne D137A, D323A R722Q, K726R; Tne D137A D323A R722Q, K726H; Tne D137A D323A R722N, F730Y; Tne D137A D323A R722N, K726R; Tne D137A D323A R722N, K726H; Tne D137A D323A F730S; 7«eNA283, D323A R722K/H/Q/N/Y/L; Tne N'Δ219, D323A R722K; J« N'Δ219, D323 F730Y; 7«eNA219, D323A, K726R; J«eN'Δ219, D323AK726H; J«eD137AD323AF730S,R722K/Y/Q/N/H/L, K726R/H; Tne D137A D323A F730T, R722K/Y/Q/N/H L, K726R/H; Tne D137A D323A F730T; Tne F730S; Tne F730A; Tne K726R; Tne K726H; and Tne D137A D323A R722N. These mutations may be made to sequence LD NO:2 to produce the mutant polymerases having the indicated amino acid mutations (where, for example, "D137A" indicates that the Asp (D) residue at position 137 in SEQ LD NO:2 has been mutated to an Aa (A) residue, and, for example, "R722KΛ7Q/N/H/L" indicates that the Arg (R) residue at position 722 in SEQ LD NO:2 has been mutated to a Lys (K), Tyr (Y), Gin (Q), Asn (N), His (H) or Leu (L) residue). The present invention also provides kits for the identification, analysis or typing of a polymorphic DNA fragment, particularly a minisatellite, microsatellite or STR DNA fragment, comprising a first container containing one or more DNA polymerases reduced, substantially reduced or eliminated in the ability to add non- templated 3' terminal nucleotides. Kits according to the invention may contain additional containers selected from the group consisting of a container containing one or more DNA primer molecules, a container containing one or more deoxynucleoside triphosphates needed to synthesize a DNA molecule complementary to the DNA template, and a container containing a buffer suitable for identifying, analyzing or typing a polymorphic DNA fragment by the methods of the invention. Any number of these components of the kit may be combined in a single or multiple containers to provide the kit of the invention. According to the invention, the DNA polymerase of the kit is preferably a Thermotoga DNA polymerase, more preferably a Thermotoga DNA polymerase substantially reduced in 3'-5' exonuclease activity, still more preferably a 7>?e polymerase, a Tma polymerase, or a mutant or derivative thereof, and most preferably a mutant of 7>?e polymerase selected from the group consisting of Tne N'Δ283; Tne D137A D323A R722K; Tne D137A D323A R722Y; Tne D137A D323A R722L; J«eD137 D323A R722H; J«eD137A D323A 722Q; J«e D137A D323 F730Y; Tne D137A D323 A K726R; Tne D137A D323A K726H; Tne D137A D323A R722K, F730Y; Tne D137A D323A R722K, K726R; Tne D137A D323A R722K, K726H; Tne D137A D323A R722H, F730Y; Tne D137A D323A R722H, K726R; Tne D137A D323A R722H, K726H; Tne D137A D323A R722Q, F730Y; Tne D137A D323A R722Q, K726R; Tne D137A D323A R722Q, K726H; Tne D137A D323A R722N, F730Y; Tne D137A D323A R722N, K726R; Tne D137A D323A R722N, K726H; Tne D137A, D323A F730S; 7weN'Δ283, D323A R722R7H/Q/NΛ7L; 7«eNA219, D323A R722K; 7rø>N'Δ219, D323 F730Y; 7>7eN , Δ219, D323 K726R; 7«eN'Δ219, D323 AK726H; J«eD137A D323 F730S, R722KΛ7Q/N/H/L, K726R/H; Tne D137A D323A F730T, R722KΛ Q/N/H/L, K726R/H; Tne D137A D323A F730T; Tne F730S; Tne F730A; Tne K726R; Tne K726H; and Tne D137A D323A R722N. The present invention also relates generally to mutated or modified polymerases (DNA or RNA polymerases) which have reduced, substantially reduced or eliminated ability to add one or more non-templated nucleotides to the 3' terminus of a synthesized nucleic acid molecule (compared to the corresponding wildtype, unmutated or unmodified polymerase). Preferably, such mutant or modified polymerases have substantially reduced ability to add one or more non- templated nucleotides to the 3' terminus of a synthesized nucleic acid molecule. Such polymerases of the invention may be thermostable or mesophilic polymerases. Thus, the present invention relates to such mutated or modified polymerases and to kits containing such polymerases. The invention also relates to the use of such mutant or modified polymerases in a number of procedures including DNA sequencing, amplification reactions, nucleic acid synthesis, and polymorphism analysis. Mutant or modified polymerases of particular interest in the invention include Taq DNA polymerase, Tne DNA polymerase, Tma D A polymerase, Pfu DNA polymerase, Tfl DNA polymerase, Tth DNA polymerase, Tbr DNA polymerase, Pwo DNA polymerase, Bst DNA polymerase, Bca DNA polymerase, VENT™ DNA polymerase, DEEP VENT™ DNA polymerase, T7 DNA polymerase, T5 DNA polymerase, DNA polymerase III, Klenow fragment DNA polymerase, Stoffel fragment DNA polymerase, and mutants, fragments or derivatives thereof RNA polymerases of interest include T7, SP6, and T3 RNA polymerases and mutants, variants and derivatives thereof. The present invention relates in particular to mutant Poll type DNA polymerases (preferably thermostable DNA polymerases) wherein one or more mutations have been made in the O-helix which reduces, substantially reduces or eliminates the ability of the enzyme to add one or more non-templated nucleotides to the 3' terminus of a synthesized nucleic acid molecule. The O-helix is defined as RXXXKXXXFXXXYX (SEQ LD NO: 11), wherein X may be any amino acid. The preferred sites for mutation or modification to produce the polymerases of the invention are the R and/or F and/or K and/or Y positions in the O-helix, although other changes (or combinations thereof) within the O-helix may be made to make the desired polymerase. In this preferred aspect of the invention, R and/or F and/or K and/or Y may be replaced with any other amino acid including Aa, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Pro, Ser, Thr, Tip, Tyr and Val. In accordance with the invention, other functional changes (or combinations thereof) may be made to the polymerases having reduced ability to add non-templated nucleotides to the 3' terminus of a synthesized nucleic acid molecule. For example, the polymerase may also be modified to reduce, substantially reduce or eliminate 5' exonuclease activity, and/or 3' exonuclease activity. Thus, the invention relates to mutant or modified DNA polymerases having reduced ability to add non-templated nucleotides which are modified in at least one way selected from the group consisting of (a) to reduce or eliminate the 3 '-5' exonuclease activity of the polymerase; (b) to reduce or eliminate the 5'-3' exonuclease activity ofthe polymerase; Any one or a number of these mutations or modifications (or combinations thereof) may be made to provide the polymerases of the invention. Preferred polymerases of the invention, in addition to having reduced ability to add non- templated 3' nucleotides, also have reduced, substantially reduced or eliminated 3' exonuclease activity. The present invention is also directed to nucleic acid molecules (preferably vectors) containing a gene encoding the mutant or modified polymerases ofthe present invention and to host cells containing such molecules. Any number of hosts may be used to express the gene of interest, including prokaryotic and eukaryotic cells. Preferably, prokaryotic cells are used to express the polymerases of the invention. The preferred prokaryotic host according to the present invention is E. coli. The invention also relates to a method of producing the polymerases ofthe invention, said method comprising: (a) culturing the host cell comprising a gene encoding a polymerase of the invention; (b) expressing said gene; and (c) isolating said polymerase from said host cell. The invention also relates to a method of synthesizing a nucleic acid molecule comprising: (a) mixing one or more nucleic acid templates (e.g. RNA or DNA) with one or more polymerases ofthe invention; and (b) incubating said mixture under conditions sufficient to synthesize nucleic acid molecules complementary to all or a portion of said templates. Such condition may include incubation with one or more deoxy- and/or dideoxyribonucleoside triphosphates. Such deoxy- and dideoxyribonucleoside triphosphates include dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, 7-deaza- dATP, dUTP, ddATP, ddCTP, ddGTP, ddlTP, ddTTP, [α-S]dATP, [α-S]dTTP, [α-S]dGTP, and [α-S]dCTP. The synthesized nucleic acid molecules may in accordance with the invention be cloned into one or more vectors. The invention also relates to a method of sequencing a DNA molecule, comprising: (a) hybridizing a primer to a first DNA molecule; (b) contacting said molecule of step (a) with deoxyribonucleoside triphosphates, one or more DNA polymerases ofthe invention, and one or more terminator nucleotides; (c) incubating the mixture of step (b) under conditions sufficient to synthesize a random population of DNA molecules complementary to said first DNA molecule, wherein said synthesized DNA molecules are shorter in length than said first DNA molecule and wherein said synthesized DNA molecules comprise a terminator nucleotide at their 3' termini; and (d) separating said synthesized DNA molecules by size so that at least a part ofthe nucleotide sequence of said first DNA molecule can be determined. Such terminator nucleotides include but are not limited to dideoxyribonucleoside triphosphates such as ddTTP, ddATP, ddGTP, ddlTP or ddCTP. The invention also relates to a method for amplifying a double stranded DNA molecule, comprising: (a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3 '-termini ofthe first strand of said DNA molecule and said second primer is complementary to a sequence at or near the 3'-termini ofthe second strand of said DNA molecule; (b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of one or more polymerases ofthe invention, under conditions such that a third DNA molecule complementary to said first strand and a fourth DNA molecule complementary to said second strand are synthesized; (c) denaturing said first and third strands, and said second and fourth strands; and (d) repeating steps (a) to (c) one or more times. The amplified double- stranded nucleic acid molecules produced by the method ofthe invention may be cloned into one or more vectors. Thus, the invention relates also to a method of cloning an amplified DNA molecule comprising: (a) amplifying one or more DNA molecules with one or more polymerases ofthe invention; and (b) ligating said amplified DNA molecules in one or more vectors. The invention further relates to a method of cloning a nucleic acid molecule comprising: (a) mixing a nucleic acid template (or one or more templates) with one or more polymerases ofthe invention; (b) incubating said mixture under conditions sufficient to synthesize a nucleic acid molecule complementary to all or a portion of said template, thereby producing a double-stranded nucleic acid molecule (preferably a double-stranded DNA molecule); and (c) ligating said double-stranded nucleic acid molecule into one or more vectors. Preferably, the vectors used for ligating the amplified or synthesized double-stranded nucleic acid molecules have blunt ended termini and may be prepared by digesting a vector with any one or a number of restriction enzymes known in the art which provide blunt end cleavage. Such restriction enzymes include Seal, Smal, Hpal, Hindi, Haelϊl, Alul, and the like. The invention also relates to kits for sequencing, amplifying, synthesizing or cloning of nucleic acid molecules comprising one or more polymerases ofthe invention and one or more other components (or combinations thereof) selected from the group consisting of (a) one or more dideoxyribonucleoside triphosphates; (b) one or more deoxyribonucleoside triphosphates; (c) one or more primers; (d) one or more suitable buffers; and (e) one or more ligases. Other preferred embodiments ofthe present invention will be apparent to one of ordinary skill in light of the following drawings and description of the invention, and ofthe claims. BRIEF DESCRIPTION OF THE FIGURES FIGURE 1 shows the restriction map ofthe approximate DNA fragment which contains the Tne DNA polymerase gene in pSport 1 and pUC19. This figure also shows the region containing the O-helix homologous sequences. FIGURE 2A schematically depicts the construction of plasmids pUC-Tne (3'→5') and pUC-Tne FY. FIGURE 2B schematically depicts the construction of plasmids pTrcTne35 and pTrcTne FY. FIGURE 3 schematically depicts the construction of plasmid pTrcTne35 FY. FIGURE 4 schematically depicts the construction of plasmids P TTQTne5FY and P TTQTne535FY. FIGURE 5 depicts a plasmid containing the Taq DNA polymerase gene. FIGURE 6 depicts an autoradiogram showing ofthe ability of polymerase mutants to add non-templated 3' nucleotides. FIGURE 7 is an autoradiogram ofthe product of PCR amplification ofthe upper and lower alleles ofthe CD4 locus, using primers corresponding to these alleles, demonstrating nontemplated nucleotide addition (n+1) by Taq DNA polymerase but not by Tne DNA polymerase. FIGURE 8 is an autoradiogram ofthe product of PCR amplification ofthe upper and lower alleles ofthe D20S27 locus, using primers corresponding to these alleles, demonstrating nontemplated nucleotide addition (n+1) by Taq DNA polymerase but not by Tne DNA polymerase. FIGURE 9 is a composite of electropherogram gel scans of PCR amplifications at the D15S153 (Figures 9 A and 9B) and D15S127 loci (Figures 9C and 9D), demonstrating nontemplated nucleotide addition (n+1) by Taq DNA polymerase (Figures 9A and 9C) but not by Tne DNA polymerase (Figures 9B and 9D). FIGURE 10A and B are composites of a electropherogram gel scan of PCR amplifications at D16S405 and D16S401 loci. FIGURE 11 is a composite of a electropherogram gel scan of PCR amplifications at D16S401 locus. FIGURE 12A and B are composites of a electropherogram gel scan of PCR amplifications at D15S127 and D15S153 loci. FIGURE 13 is a composite of a electropherogram gel scan of PCR amplifications at D16S401 locus. DETAILED DESCRIPTION OF THE INVENTION Definitions In the description that follows, a number of terms used in recombinant DNA technology are extensively utilized. In order to provide a clearer and consistent understanding ofthe specification and claims, including the scope to be given such terms, the following definitions are provided. Polymorphic. As is understood by one of ordinary skill in the art, a nucleic acid molecule is said to be "polymorphic" if it may exist in more than one form. For example, a nucleic acid molecule is said to be polymorphic if it may have more than one specific nucleotide sequence (such as degenerate nucleic acid molecules or genes that may each encode the same protein). More commonly, a nucleic acid molecule is said to be polymorphic if it displays size differences (i.e., differences in length), particularly when comparisons of nucleic acid molecules from different individuals are made. Of course, other definitions of the term "polymorphic" will be apparent to one of ordinary skill and are also encompassed within this definition. Cloning vector. A plasmid, cosmid or phage DNA or other DNA molecule which is able to replicate autonomously in a host cell, and which is characterized by one or a small number of restriction endonuclease recognition sites at which such DNA sequences may be cut in a determinable fashion without loss of an essential biological function ofthe vector, and into which DNA may be spliced in order to bring about its replication and cloning. The cloning vector may further contain a marker suitable for use in the identification of cells transformed with the cloning vector. Markers, for example, are tetracycline resistance or ampicillin resistance. Recombinant host. Any prokaryotic or eukaryotic microorganism which contains the desired cloned genes in an expression vector, cloning vector or any DNA molecule. The term "recombinant host" is also meant to include those host cells which have been genetically engineered to contain the desired gene on the host chromosome or genome. Host. Any prokaryotic or eukaryotic microorganism that is the recipient of a replicable expression vector, cloning vector or any DNA molecule. The DNA molecule may contain, but is not limited to, a structural gene, a promoter and/or an origin of replication. Promoter. A DNA sequence generally described as the 5' region of a gene, located proximal to the start codon. At the promoter region, transcription of an adjacent gene(s) is initiated. Gene. A DNA sequence that contains information necessary for expression of a polypeptide or protein. It includes the promoter and the structural gene as well as other sequences involved in expression ofthe protein. Structural gene. A DNA sequence that is transcribed into messenger RNA that is then translated into a sequence of amino acids characteristic of a specific polypeptide. Operably linked. As used herein "operably linked" means that the promoter is positioned to control the initiation of expression ofthe polypeptide encoded by the structural gene. Expression. Expression is the process by which a gene produces a polypeptide. It includes transcription ofthe gene into messenger RNA (mRNA) and the translation of such mRNA into polypeptide(s). Substantially Pure. As used herein "substantially pure" means that the desired purified protein is essentially free from contaminating cellular contaminants which are associated with the desired protein in nature. Contaminating cellular components may include, but are not limited to, phosphatases, exonucleases, endonucleases or undesirable DNA polymerase enzymes. Primer. As used herein "primer" refers to a single-stranded oligonucleotide that is extended by covalent bonding of nucleotide monomers during amplification or polymerization of a nucleic acid molecule. Minisatellite primers used for the amplification of minisatellite dimer, trimer, tetramer, etc., sequences are well-known in the art. Template. The term "template" as used herein refers to a double-stranded or single-stranded nucleic acid molecule which is to be amplified, synthesized or sequenced. In the case of a double-stranded DNA molecule, denaturation of its strands to form a first and a second strand is performed before these molecules may be amplified, synthesized or sequenced. A primer, complementary to a portion of a template is hybridized under appropriate conditions and the polymerase ofthe invention may then synthesize a molecule complementary to said template or a portion thereof. The newly synthesized molecule, according to the invention, may be equal or shorter in length than the original template. Mismatch incorporation or strand slippage during the synthesis or extension ofthe newly synthesized molecule may result in one or a number of mismatched base pairs. Thus, the synthesized molecule need not be exactly complementary to the template. Incorporating. The term "incorporating" as used herein means becoming a part of a nucleic acid (e.g., DNA) molecule or primer. Amplification. As used herein "amplification" refers to any in vitro method for increasing the number of copies of a nucleotide sequence with the use of a DNA polymerase. Nucleic acid amplification results in the incorporation of nucleotides into a DNA molecule or primer thereby forming a new DNA molecule complementary to a DNA template. The formed DNA molecule and its template can be used as templates to synthesize additional DNA molecules. As used herein, one amplification reaction may consist of many rounds of DNA replication. DNA amplification reactions include, for example, polymerase chain reactions (PCR). One PCR reaction may consist of 5 to 100 "cycles" of denaturation and synthesis of a DNA molecule. Oligonucleotide. "Oligonucleotide" refers to a synthetic or natural molecule comprising a covalently linked sequence of nucleotides which are joined by a phosphodiester bond between the 3' position ofthe pentose of one nucleotide and the 5' position ofthe pentose ofthe adjacent nucleotide. Nucleotide. As used herein "nucleotide" refers to a base-sugar-phosphate combination. Nucleotides are monomeric units of a nucleic acid sequence (DNA and RNA). The term nucleotide includes deoxyribonucleoside triphosphates such as dATP, dCTP, dITP, dUTP, dGTP, dTTP, or derivatives thereof. Such derivatives include, for example, [αSjdATP, 7-deaza-dGTP and 7-deaza-dATP. The term nucleotide as used herein also refers to dideoxyribonucleoside triphosphates (ddNTPs) and their derivatives. Illustrated examples of dideoxyribonucleoside triphosphates include, but are not limited to, ddATP, ddCTP, ddGTP, ddlTP, and ddTTP. According to the present invention, a "nucleotide" may be unlabeled or detectably labeled by well known techniques. Detectable labels include, for example, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels. Thermostable. As used herein "thermostable" refers to a polymerase which is resistant to inactivation by heat. DNA polymerases synthesize the formation of a DNA molecule complementary to a single-stranded DNA template by extending a primer in the 5'-to-3' direction. This activity for mesophilic DNA polymerases may be inactivated by heat treatment. For example, T5 DNA polymerase activity is totally inactivated by exposing the enzyme to a temperature of 90°C for 30 seconds. As used herein, a thermostable polymerase activity is more resistant to heat inactivation than a mesophilic polymerase. However, a thermostable polymerase does not mean to refer to an enzyme which is totally resistant to heat inactivation and thus heat treatment may reduce the polymerase activity to some extent. A thermostable polymerase typically will also have a higher optimum temperature than mesophilic polymerases. Hybridization. The terms "hybridization" and "hybridizing" refers to the pairing of two complementary single-stranded nucleic acid molecules (RNA and/or DNA) to give a double-stranded molecule. As used herein, two nucleic acid molecules may be hybridized, although the base pairing is not completely complementary. Accordingly, mismatched bases do not prevent hybridization of two nucleic acid molecules provided that appropriate conditions, well known in the art, are used. In the present invention, the term "hybridization" refers particularly to hybridization of an oligonucleotide to a template molecule. 3'-5' Exonuclease Activity. "3'-5' exonuclease activity" is an enzymatic activity well known to the art. This activity is often associated with DNA polymerases, and is thought to be involved in a DNA replication "editing" or correction mechanism. A "DNA polymerase substantially reduced in 3'-5' exonuclease activity" (which may also be represented as "3'exo-") is defined herein as either (1) a mutated DNA polymerase that has about or less than 10%, or preferably about or less than 1%, ofthe 3 -5' exonuclease activity of the corresponding unmutated, wildtype enzyme, or (2) a DNA polymerase having a 3'-5' exonuclease specific activity which is less than about 1 unit/mg protein, or preferably about or less than 0.1 units/mg protein. A unit of activity of 3 '-5' exonuclease is defined as the amount of activity that solubilizes 10 nmoles of substrate ends in 60 min. at 37°C, assayed as described in the "BRL 1989 Catalogue & Reference Guide", page 5, withHΛαl fragments of lambda DNA 3'-end labeled with [ 3 H]dTTP by terminal deoxynucleotidyl transferase (TdT). Protein is measured by the method of Bradford, Anal. Biochem. 72:248 (1976). As a means of comparison, natural, wildtype T5-DNA polymerase (DNAP) or T5-DNAP encoded by pTTQ 19-T5-2 has a specific activity of about 10 units/mg protein while the DNA polymerase encoded by pTTQ19-T5-2(exo-) (U.S. Patent No. 5,270,179) has a specific activity of about 0.0001 units/mg protein, or 0.001% ofthe specific activity ofthe unmodified enzyme, a 10 5 -fold reduction. 5'-3' Exonuclease Activity. "5 -3' exonuclease activity" is also an enzymatic activity well known in the art. This activity is often associated with DNA polymerases, such as E. coli Poll and PolLU. A "DNA polymerase substantially reduced in 5'-3' exonuclease activity" (which may also be represented as "5'exo-") is defined herein as either (1) a mutated DNA polymerase that has about or less than 10%, or preferably about or less than 1%, of the 5'-3' exonuclease activity of the corresponding unmutated, wildtype enzyme, or (2) a DNA polymerase having 5*-3' exonuclease specific activity which is less than about 1 unit/mg protein, or preferably about or less than 0.1 units/mg protein. Both of the 3'-5' and 5 * -3' exonuclease activities can be observed on sequencing gels. Active 5 '-3' exonuclease activity will produce nonspecific ladders in a sequencing gel by removing nucleotides from the 5 '-end of the growing primers. 3'-5' exonuclease activity can be measured by following the degradation of radiolabeled primers in a sequencing gel. Thus, the relative amounts of these activities, e.g. by comparing wildtype and mutant polymerases, can be determined with no more than routine experimentation. Minisatellite DNA. As used herein, the term "minisatellite DNA" refers to a DNA fragment comprising a short stretch of tandemly repetitive nucleotide sequence. In vivo, minisatellite DNA fragments are found interspersed throughout the genomes of most eukaryotic organisms thus far examined. These repeating sequences appear in tandem and often in variable numbers within the genome; thus, the terms "short tandem repeats" ("STRs") or "variable numbers of tandem repeats" ("VNTRs") may be used synonymously when referring to these regions. Minisatellite DNA fragments are typically about 9 bases to about 60 bases in length and are repeated about 20-50 times at a typical locus in a eukaryotic genome. Microsatellite DNA. As used herein, the term "microsatellite DNA" refers to DNA fragments which are typically of a repeat unit size of about 1-6 bases in length. The most prevalent of these microsatellite DNA fragments in the human genome is the dinucleotide repeat (dC-dA) n »(dG-dT) n (where n is the number of repetitions in a given stretch of nucleotides). The terms "STRs" and "VNTRs" may also be used synonymously to denote these structures. Non-templated 3' Terminal Nucleotide Addition. As used herein, the term "non-templated 3' terminal nucleotide addition" or "extranucleotide addition" means the propensity of an enzyme such as a DNA polymerase to incorporate one or more additional nucleotides, which are not found in the template strand at the 3' terminus of a newly synthesized nucleic acid molecule in a synthesis or amplification reaction, such as PCR. As a result of non-templated 3' terminal nucleotide addition, the synthesized or amplification products (i.e., the newly synthesized DNA strand) will be longer by one or more nucleotides than is the template, in such a fashion that if the template is "n" nucleotides in length, the synthesis or amplification products will be "n+1," "n+2," "n+3," etc., nucleotides in length. A "polymerase substantially reduced in the ability to add one or more non-templated nucleotides to the 3' terminus of a nucleic acid molecule" is defined herein as a DNA polymerase, which when it has no 3' exonuclease activity or has substantially reduced 3' exonuclease activity, it will produce a collection of amplification products in which less than about 50%, preferably less than about 30%, more preferably less than about 20%, still more preferably less than about 10%, still more preferably less than about 5%, and most preferably less than about 1% ofthe amplification products contain one or more non-templated nucleotides at their 3' termini compared to amplification products produced by Taq DNA polymerase assayed under the same conditions. Preferably, the conditions used for assaying 3' non-templated nucleotide addition is performed such that less than 100% of the amplification products of Taq DNA polymerase exhibits 3' non- templated nucleotide addition. Included in this definition are those polymerases that satisfy this definition for any primer set used. Thus, if the use of any primer set provides the indicated reduction of 3' non-templated nucleotide addition, the polymerase is said to be substantially reduced in the ability to add one or more non-templated nucleotides to the 3' terminus of a nucleic acid molecule. When referring to polymerases which have been mutated or modified to reduce or eliminate 3' non-templated nucleotide addition, the mutated or modified polymerase is said to be "reduced in the ability to add one or more non-templated nucleotides to the 3' terminus of a nucleic acid molecule" when the polymerase has a lower or reduced or eliminated ability to add non-templated 3' nucleotides compared to the corresponding unmutated, unmodified or wildtype polymerase. For example, when testing the affect of a point mutation in the O-helix of a polymerase on non-templated nucleotide addition, the polymerase unmodified in the same position ofthe O-helix is preferably used for comparison purposes. Such mutated or modified polymerases are said to "substantially reduced in the ability to add one or more non-templated nucleotides to the 3' terminus of a nucleic acid molecule" if the mutated or modified polymerase has less than about 50%, preferably less than about 30%, more preferably less than about 20%, still more preferably less than about 10%, still more preferably less than about 5%, and most preferably less than about 1% ofthe activity for adding non-templated 3' terminal nucleotides compared to the corresponding unmutated, unmodified or wildtype polymerase. Preferably, the conditions used for assaying 3' non-templated nucleotide addition is performed such that less than 100% of the amplification products produced by the unmutated, unmodified or wildtype polymerase control exhibits 3' non-templated nucleotide addition. Included in this definition are those mutant or modified polymerases that satisfy this definition for any primer set tested. The ability of a polymerase to add a non-templated 3' terminal nucleotide to the growing strand may be assessed by a variety of techniques, most preferably by gel electrophoresis ofthe synthesized or amplification products for a direct size comparison and by comparison to markers of known size (see Figures 6-13). Other terms used in the fields of recombinant DNA technology and molecular and cell biology as used herein will be generally understood by one of ordinary skill in the applicable arts. Sources of Polymerases The methods of the present invention rely on the use of polymerases (thermostable or mesophilic DNA or RNA polymerases) reduced, substantially reduced or eliminated in the ability to add one or more non-templated 3' terminal nucleotide to a growing nucleic acid strand. These thermostable DNA polymerases may be obtained from any strain of any thermophilic microorganism, including but not limited to strains of Thermus aquaticus (Taq polymerase; see U.S. Patent Nos. 4,889,818 and 4,965,188), Thermus thermophilus (Tth polymerase), Thermococcus litoralis (Tli or VENT™ polymerase), Pyrococcus fliriosus (Pfi or DEEPVENT™ polymerase), Pyrococcus woosii (Pwo polymerase) and other Pyrococcus species, Bacillus sterothermophilus (Bst polymerase,), Sulfolobus acidocaldarius (Sac polymerase), Thermoplasma acidophilum (Tac polymerase), Bacillus caldophilus (Bca polymerase,), Thermus flavus (Tfl/Tub polymerase), Thermus ruber (Tru polymerase), Thermus brockianus (DYNAZYME™ polymerase), Thermotoga neapolitana (Tne polymerase; see WO 96/10640 and WO96/41014), Thermotoga maritima (Tma polymerase; see U. S. Patent No. 5,374,553) and other species ofthe Thermotoga genus (Tsp polymerase) and Methanobacterium thermoautotrophicum (Mth polymerase). Mesophilic DNA polymerases of interest in the invention include but are not limited to T7 DNA polymerases, T5 DNA polymerase, DNA polymerase III, Klenow fragment DNA polymerase and mutants, fragments or derivatives thereof. RNA polymerases such as T3, T5, SP6 and mutants, variants and derivatives thereof may also be used in accordance with the invention. Polymerases having reduced or substantially reduced ability to add a non- templated 3' nucleotide to a growing nucleic acid strand may be wildtype polymerases, or may be made by mutating such wildtype polymerases by standard techniques (for example, by generating point mutations, insertions, deletions, etc., in the wildtype gene or protein). Polymerases that are reduced or substantially reduced in the ability to add a non-templated 3' nucleotide to a growing strand may be identified by assaying the synthesized products (e.g. PCR products) formed by such enzymes, as is well-known in the art and as generally described below in the Examples. The nucleic acid polymerases used in the present invention may be mesophilic or thermophilic, and are preferably thermophilic. Preferred mesophilic DNA polymerases include T7 DNA polymerase, T5 DNA polymerase, Klenow fragment DNA polymerase, DNA polymerase III and the like. Preferred thermostable DNA polymerases that may be used in the methods ofthe invention include Taq, Tne, Tma, Pfu, Tfl, Tth, Stoffel fragment, VENT™ and DEEPVENT™ DNA polymerases, and mutants, variants and derivatives thereof (U.S. Patent No. 5,436,149; U.S. Patent 4,889,818; U.S. Patent 4,965,188; U.S. Patent 5,079,352; U.S. Patent 5,614,365; U.S. Patent 5,374,553; U.S. Patent 5,270,179; U.S. Patent 5,047,342; U.S. Patent No. 5,512,462; WO 92/06188; WO 92/06200; WO 96/10640; Barnes, W.M., Gene 772:29-35 (1992); Lawyer, F.C., etal, PCRMeth. Appl. 2:275-287 (1993); Flaman, J.-M, etal, Nucl. Acids Res. 22(15):3259-3260 (1994)). For amplification of long nucleic acid molecules (e.g., nucleic acid molecules longer than about 3-5 Kb in length), at least two DNA polymerases (one substantially lacking 3' exonuclease activity and the other having 3' exonuclease activity) are typically used. See U.S. Patent No. 5,436,149; U.S. PatentNo. 5,512,462; Fames, W.M., Ge«e 772:29-35 (1992); and copending U.S. Patent Application No. 08/689,814, filed February 14, 1997, the disclosures of which are incorporated herein in their entireties. Examples of DNA polymerases substantially lacking in 3' exonuclease activity include, but are not limited to, Taq, Jwe(exo ' ), 7mα(exo ' ), Pfu (exo " ), JVo(exo ' ) and Tth DNA polymerases, and mutants, variants and derivatives thereof. Polypeptides having nucleic acid polymerase activity are preferably used in the present methods at a final concentration in solution of about 0.1-200 units per milliliter, about 0.1-50 units per milliliter, about 0.1-40 units per milliliter, about 0.1-3.6 units per milliliter, about 0.1-34 units per milliliter, about 0.1-32 units per milliliter, about 0.1-30 units per milliliter, or about 0.1-20 units per milliliter, and most preferably at a concentration of about 20-40 units per milliliter. Of course, other suitable concentrations of nucleic acid polymerases suitable for use in the invention will be apparent to one or ordinary skill in the art. In a preferred aspect ofthe invention, polymerases of the invention and preferably the mutant or modified polymerases of the invention are made by recombinant techniques. A number of cloned polymerase genes are available or may be obtained using standard recombinant techniques. To clone a gene encoding a polymerase, which may be modified in accordance with the invention, isolated DNA which contains the polymerase gene is used to construct a recombinant library in a vector. Any vector, well known in the art, can be used to clone the DNA polymerase of interest. However, the vector used must be compatible with the host in which the recombinant DNA library will be transformed. Prokaryotic vectors for constructing the plasmid library include plasmids such as those capable of replication in E. coli such as, for example, pBR322, ColE 1 , pSC 101 , pUC-vectors (pUC 18, pUC 19, etc. : In: Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1982); and Sambrook et al, In: Molecular Cloning A Laboratory Manual (2d ed.) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York (1989)). Bacillus plasmids include ρC194, pC221, ρC217, etc. Such plasmids are disclosed by Glyczan, T. In: 7 2e Molecular Biology Bacilli, Academic Press, York (1982), 307-329. Suitable Streptomyces plasmids include pIJlOl (Kendall et al, J. Bacteriol 169:4177-4183 (1987)). Pseudomonas plasmids are reviewed by John et al, (Rad. Insec. Dis. 8:693-104 (1986)), and Igaki, (Jpn. J. Bacteriol. 33:129-142 (1978)). Broad-host range plasmids or cosmids, such as pCP13 (Darzins and Chakrabarbary, J. Bacteriol 759:9-18, 1984) can also be used for the present invention. The preferred vectors for cloning the genes ofthe present invention are prokaryotic vectors. Preferably, pCP13 and pUC vectors are used to clone the genes ofthe present invention. The preferred host for cloning the polymerase genes of interest is a prokaryotic host. The most preferred prokaryotic host is E. coli. However, the desired polymerase genes of the present invention may be cloned in other prokaryotic hosts including, but not limited to, Escherichia, Bacillus, Streptomyces, Pseudomonas, Salmonella, Serratia, and Proteus. Bacterial hosts of particular interest include E. coli DH10B, which may be obtained from Life Technologies, Inc. (LTI) (Rockville, MD). Eukaryotic hosts for cloning and expression ofthe polymerases of interest include yeast, fungi, and mammalian cells. Expression ofthe desired polymerase in such eukaryotic cells may require the use of eukaryotic regulatory regions which include eukaryotic promoters. Cloning and expressing the polymerase gene in eukaryotic cells may be accomplished by well known techniques using well known eukaryotic vector systems. Once a DNA library has been constructed in a particular vector, an appropriate host is transformed by well known techniques. Transformed colonies are preferably plated at a density of approximately 200-300 colonies per petri dish. For thermostable polymerase selection, colonies are then screened for the expression of a heat stable DNA polymerase by transferring transformed E. coli colonies to nitrocellulose membranes. After the transferred cells are grown on nitrocellulose (approximately 12 hours), the cells are lysed by standard techniques, and the membranes are then treated at 95 °C for 5 minutes to inactivate the endogenous E. coli enzyme. Other temperatures may be used to inactivate the host polymerases depending on the host used and the temperature stability ofthe polymerase to be cloned. Stable polymerase activity is then detected by assaying for the presence of polymerase activity using well known techniques (see, e.g., Sagner et al. , Gene 97 : 119- 123 ( 1991 ), which is hereby incorporated by reference in its entirety). The gene encoding a polymerase ofthe present invention can be cloned using the procedure described by Sanger et al, supra. Other techniques for selecting cloned polymerases in accordance with the present invention will be well-known to those of ordinary skill in the art. Modifications or Mutations of Polymerases In accordance with the invention, the nucleotide binding domain ofthe polymerase of interest is modified or mutated in such a way as to produce a mutated or modified polymerase having reduced, substantially reduced or eliminated activity for adding non-templated 3' nucleotides. The O-helix region typically defines the nucleotide binding domain of DNA polymerases. The O-helix may be defined as RXXXKXXXFXXXYX (SEQ LD NO: 11), wherein X may be any amino acid. One or more mutations or combinations of mutations may be made in the O-helix of any polymerase in order to reduce or eliminate nontemplated 3' nucleotide addition in accordance with the invention. Such mutations include point mutation, frame-shift mutations, deletions and insertions. Preferably, one or more point mutations, resulting in one or more amino acid substitutions, are used to produce polymerases having such activity. Such mutations may be made by a number of methods that will be familiar to one of ordinary skill, including but not limited to site-directed mutagenesis. In a preferred aspect ofthe invention, one or more mutations at positions R, K, F, and/or Y in the polymerase O-helix may be made to produced a polymerase having the desired activity. Most preferably, one or more mutations at position R and/or F and/or K and/or Y within the O-helix results in polymerases having reduced, substantially reduced or eliminated activity for adding non-templated 3' nucleotides. In the preferred aspect, amino acid substitutions are made at position R and/or F and/or K and/or Y (or combinations thereof). Thus, R (Arg) and/or F (Phe) and/or K (Lys) may be substituted with any other amino acid including Aa, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, and Val. Preferably, R (Arg) is substituted with amino acids Lys, Tyr, Leu, His, Gin, Met, or Asn. F (Phe) is preferably substituted with amino acids Tyr, Aa, Leu, Thr, and Ser. K (Lys) is preferably substituted with amino acids Arg, Tyr, Leu, His, Gin, Met or Asn, and more preferably with Arg or His. Y (Tyr) is preferably substituted with amino acids Lys, Arg, Aa, Thr, Phe, Leu, His, Gin, Met, or Asn. Positions corresponding to R, K, F and Y for RNA polymerases may also be determined by comparing nucleotide and/or amino acid sequences with those of DNA polymerases, to determine homologies therebetween. Corresponding mutations or modification may then be made to produce the desired result in any RNA polymerase. The O-helix has been identified and defined for a number of polymerases and may be readily identified for other polymerases by one with skill in the art. Thus, given the defined O-helix region and the methods and assays described herein, one with skill in the art can make one or a number of modifications which would result in polymerases having reduced, substantially reduced or eliminated activity for adding non-templated 3' nucleotides. Accordingly, the invention relates to methods for producing such polymerases having modifications in the O-helix domain resulting in reduction, substantial reduction or elimination of activity for adding non-templated 3' nucleotides, methods for producing nucleic acid molecules encoding such polymerases, and polymerases and nucleic acid molecules produced by such methods. The following table illustrates identified O-helix regions for known polymerases. Thus, in accordance with a preferred aspect of the invention, corresponding mutations in the R and/or F and/or K positions ofthe O-helix can be made for the following enzymes based on the tables below. The mutation position of Arg 705 for Bca is based on the sequence information in GenBank. It should be noted, however, that according to the sequence described by Vemori et al. J. Biochem. (Japan) 773:401 -410 ( 1993 ), the position of Arg in Bca is 703. Additional Modifications or Mutations of Polymerases In accordance with the invention, in addition to the mutations or modifications described above, one or more additional mutations or modifications (or combinations thereof) may be made to the polymerases of interest. Mutations or modifications of particular interest include those modifications of mutations which (1) reduce or eliminate 3' to 5' exonuclease activity; and (2) reduce or eliminate 5' to 3' exonuclease activity. If the DNA polymerase has 3'-to-5' exonuclease activity, this activity may be reduced, substantially reduced, or eliminated by mutating the polymerase gene. Such mutations include point mutations, frame shift mutations, deletions and insertions. Preferably, the region ofthe gene encoding the 3'-to-5' exonuclease activity is mutated or deleted using techniques well known in the art (Sambrook et al, (1989) in: Molecular Cloning, A Laboratory Manual (2nd Ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY). The 3'-to-5' exonuclease activity can be reduced or impaired by creating site specific mutants within the 3'- 5' exonuclease domain. See infra. In a specific embodiment ofthe invention Asp 323 of Tne DNA polymerase is changed to any amino acid, preferably to Aa 323 to substantially reduce 3'→5' exonuclease activity. In another specific embodiment ofthe invention, Asp 323 of Tma may be changed to any other amino acid, preferably to Aa to substantially reduce 3 ,→ 5' exonuclease activity. The following represents a domain of interest for a number of polymerases for preparing 3'->5' exonuclease mutants. Tne 318 PSFALDLETSS 328 (SEQ LD NO: 18) Pol l 350 PVFAFDTETDS 360 (SEQ LD NO: 19) T5 159 GPVAFDSETSA 169 (SEQ LD NO:20) T7 1 MrVSDLEANA lO (SEQ LD NO:21) Mutations, such as insertions, deletions and substitutions within the above domain can result in substantially reduced 3'→5' exonuclease activity. By way of example, Asp 355 (Poll), Asp 164 (T5), and Asp 5 (T7) may be substituted with any amino acid to substantially reduce 3'→5' exonuclease activity. For example, Asp at these positions may be substituted with Aa. The 5'→3' exonuclease activity of the polymerases can be reduced, substantially reduced or eliminated by mutating the polymerase gene or by deleting the 5' to 3' exonuclease domain. Such mutations include point mutations, frame shift mutations, deletions, and insertions. Preferably, the region of the gene encoding the 5'- 3' exonuclease activity is deleted using techniques well known in the art. In embodiments of this invention, any one of six conserved amino acids that are associated with the 5'→3' exonuclease activity can be mutated. Examples of these conserved amino acids with respect to Tne DNA polymerase include Asp 8 , Glu 112 , Asp 114 , Asp 115 , Asp 137 , and Asp 139 . Other possible sites for mutation are Gly 102 , Gly 187 and Gly 195 . Corresponding amino acid to target for other polymerases to reduce or eliminate 5'→3' exonuclease activity as follows: E. coli poll: Asp 13 , Glu 113 , Asp 115 , Asp 116 , Asp 138 , and Asp 140 ' Taq pol: Asp 18 , Glu 117 , Asp 119 , Asp 120 , Asp 142 , and Asp 144 - Tma pol: Asp 8 , Glu 112 , Asp 114 , Asp 115 , Asp 137 , and Asp 139 ' Amino acid residues of Taq DNA polymerase are as numbered in U.S. 5,079,352. Amino acid residues of Thermotoga maritima (Tma) DNA polymerase are numbered as in U.S. Patent No. 5,374,553. Examples of other amino acids which may be targeted for other polymerases to reduce 5'→3' exonuclease activity include: Enzyme or source Mutation positions Streptococcus pneumoniae Asp 10 , Glu 114 , Asp 116 , Asp" 7 , Asp"*, Asp ,141 Thermus flavus Asp 17 , Glu" 6 , Asp" 8 , Asp 119 , Asp 141 , Asp ,143 Thermus thermophilus Asp 18 , Glu" 8 . Asp 120 , Asp 121 , Asp 1 , Asp ,145 Deinococcus radiodurans Asp 18 . Glu" 7 , Asp" 9 , Asp 12 ", Asp" 2 , Asp Bacillus caldotenax Asp 9 , Glu 109 , Asp 111 , Asp" 2 , Asp 134 , Asp ,136 Coordinates of 5. pneumoniae, T. flavus, D. radiodurans, B. caldotenax were obtained from Gutman and Minton. Coordinates of T. thermophilus were obtained from International Patent No. WO 92/06200. Typically, the mutant polymerases of the invention can be affected by substitution of amino acids typically which have different properties. For example, an acidic amino acid such as Asp may be changed to a basic, neutral or polar but uncharged amino acid such as Lys, Arg, His (basic); Aa, Val, Leu, He, Pro, Met, Phe, Tip (neutral); or Gly, Ser, Thr, Cys, Tyr, Asn or Gin (polar but uncharged). Glu may be changed to Asp, Aa, Val Leu, He, Pro, Met, Phe, Tip, Gly, Ser, Thr, Cys, Tyr, Asn or Gin. Preferably, oligonucleotide directed mutagenesis is used to create the mutant polymerases which allows for all possible classes of base pair changes at any determined site along the encoding DNA molecule. In general, this technique involves annealing a oligonucleotide complementary (except for one or more mismatches) to a single stranded nucleotide sequence coding for the DNA polymerase of interest. The mismatched oligonucleotide is then extended by DNA polymerase, generating a double stranded DNA molecule which contains the desired change in the sequence on one strand. The changes in sequence can of course result in the deletion, substitution, or insertion of an amino acid. The double stranded polynucleotide can then be inserted into an appropriate expression vector, and a mutant polypeptide can thus be produced. The above-described oligonucleotide directed mutagenesis can of course be carried out via PCR. Enhancing Expression of Polymerases To optimize expression of the polymerases of the present invention, inducible or constitutive promoters are well known and may be used to express high levels of a polymerase structural gene in a recombinant host. Similarly, high copy number vectors, well known in the art, may be used to achieve high levels of expression. Vectors having an inducible high copy number may also be useful to enhance expression ofthe polymerases ofthe invention in a recombinant host. To express the desired structural gene in a prokaryotic cell (such as, E. coli, B. subtilis, Pseudomonas, etc.), it is necessary to operably link the desired structural gene to a functional prokaryotic promoter. However, the natural promoter of the polymerase gene may function in prokaryotic hosts allowing expression of the polymerase gene. Thus, the natural promoter or other promoters may be used to express the polymerase gene. Such other promoters may be used to enhance expression and may either be constitutive or regulatable (i.e., inducible or derepressible) promoters. Examples of constitutive promoters include the int promoter of bacteriophage λ, and the bla promoter of the β-lactamase gene of pBR322. Examples of inducible prokaryotic promoters include the major right and left promoters of bacteriophage λ (P R and P L ), trp, recA lacZ, lacl, tet, gal, trc, and tac promoters of E. coli. The B. subtilis promoters include α-amylase (Ulmanen etal, J. Bacteriol 162:176-182 (1985)) and Bacillus bacteriophage promoters (Gryczan, T., In: The Molecular Biology Of Bacilli, Academic Press, New York (1982)). Streptomyces promoters are described by Ward et al, Mol. Gen. Genet. 203:468478 (1986)). Prokaryotic promoters are also reviewed by Glick, J. Ind. Microbiol. 1:277-282 (1987); Cenatiempto, Y. , Biochimie 68 : 505-516 ( 1986); and Gottesman, Ann. Rev. Genet. 18:415-442 ( 1984). Expression in a prokaryotic cell also requires the presence of a ribosomal binding site upstream ofthe gene-encoding sequence. Such ribosomal binding sites are disclosed, for example, by Gold et al, Ann. Rev. Microbiol. 35:365404 (1981). To enhance the expression of polymerases ofthe invention in a eukaryotic cell, well known eukaryotic promoters and hosts may be used. Preferably, however, enhanced expression ofthe polymerases is accomplished in a prokaryotic host. The preferred prokaryotic host for overexpressing the polymerases ofthe invention is E. coli. Isolation and Purification of Polymerases The enzyme(s) of the present invention is preferably produced by fermentation of the recombinant host containing and expressing the desired polymerase gene. However, the polymerases of the present invention may be isolated from any strain which produces the polymerase ofthe present invention. Fragments of the polymerase are also included in the present invention. Such fragments include proteolytic fragments and fragments having polymerase activity. Any nutrient that can be assimilated by a host containing the polymerase gene may be added to the culture medium. Optimal culture conditions should be selected case by case according to the strain used and the composition of the culture medium. Antibiotics may also be added to the growth media to insure maintenance of vector DNA containing the desired gene to be expressed. Media formulations have been described in DSM or ATCC Catalogs and Sambrook et al, In: Molecular Cloning, a Laboratory Manual (2nd ed.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (1989). Host cells producing the polymerases of this invention can be separated from liquid culture, for example, by centrifugation. In general, the collected microbial cells are dispersed in a suitable buffer, and then broken down by ultrasonic treatment or by other well known procedures to allow extraction ofthe enzymes by the buffer solution. After removal of cell debris by ultracentrifugation or centrifugation, the polymerase can be purified by standard protein purification techniques such as extraction, precipitation, chromatography, affinity chromatography, electrophoresis or the like. Assays to detect the presence ofthe polymerase during purification are well known in the art and can be used during conventional biochemical purification methods to determine the presence of these enzymes. Thermotoga Polymerases Thermotoga polymerases for use in the present invention are obtained from any strain of Thermotoga species, more preferably from a strain of Thermotoga neapolitana (WO 96/10640 or WO96/41014) or Thermotoga maritima (U.S. Patent No. 5,374,553). Enzymes suitable for use in the present invention from these more preferred sources are the wildtype DNA polymerases (Tne from T neapolitana, Tma from T. maritima), or mutants or derivatives thereof. The present invention provides isolated nucleic acid molecules encoding preferred mutant Tne DNA polymerases, mutant Tne DNA polymerases encoded by such isolated nucleic acid molecules, and specific mutant Tne DNA polymerase proteins. Most preferred are the wildtype Tne DNA polymerase (SEQ LD NOs:l,2), the wildtype Tma DNA polymerase (U.S. Patent No. 5,374,553), and the following mutants of Tne DNA polymerase: Tne N'Δ219, D323A (SEQ LD NO:3); Tne N'Δ283, D323A (SEQ LD NO:4); Tne NΔ192, D323A (SEQ LD NO:5); r«eD137A D323A(SEQ LDNO:6); J«e D8A D323A (SEQ ID NO:7); Tne G195D, D323A (SEQ LD NO: 8); Tne G37D, D323A (SEQ LD NO:9); Tne N'Δ283 (SEQ LD NO: 10); Tne D137A D323A R722K; Tne D137A D323A R722Y; Tne D137A D323A R722L; Tne D137A D323A R722H; 7«e D137A D323 R722Q; 7>» D137A, D323A F730Y; J«e D137 D323A K726R; Tne D137A D323A K726H; Tne D137A D323A R722K, F730Y 7«e D137A D323A R722K, K726R; Tne D137A D323A R722K, K726H Tne D137A D323A R722H, F730Y; Tne D137A D323A R722H, K726R; Tne D137A D323A R722H, K726H; 7>ιe D137A D323A R722Q, F730Y Tne D137A D323A R722Q, K726R; Tne D137A, D323A R722Q, K726H: Tne D137A D323A R722N, F730Y; Tne D137A D323A R722N, K726R J«e D137 D323 R722N, K726H; J«e D137A D323 F730S; 7weN*Δ283, D323 A R722K H/Q/N/Y/L; Tne N'Δ219, D323 A R722K; Tne N'Δ219, D323A F730Y; 7«eN'Δ219, D323A K726R; J«e Δ219, D323A K726H; 7weD137A D323A F730S, R722K/Y/Q/N/H/L, K726R/H; Tne D137A D323A F730T, R722K/Y/Q/N/H/L, K726R/H; Tne D137A D323A F730T; Tne F730S; Tne F730A; Tne K726R; Tne K726H; and Tne D137A D323A R722N. It will of course be understood by the skilled artisan that the designations of the above- described mutant polymerases indicate the position ofthe amino acid residue in the wildtype amino acid sequence (SEQ LD NO:2) that is being mutated, as well as to what residue the amino acid is being mutated. Thus, for example, "D 137A" indicates that the Asp (D) residue at position 137 in SEQ LD NO:2 has been mutated to an Aa (A) residue, and, for example, "R722K/Y/Q/N/H/L" indicates that the Arg (R) residue at position 722 in SEQ LD NO:2 has been mutated to a Lys (K), Tyr (Y), Gin (Q), Asn (N), His (H) or Leu (L) residue. Mutant polymeraes having one or more mutations or modifications corresponding to the Tne mutants ofthe invnetion are also contemplated by the invention. The following chart indicates the nucleic acid sequences ofthe nucleic acid molecules encoding the above-described mutant Tne DNA polymerases (SEQ LD NOs:3-10), each with reference to the wildtype Tne DNA polymerase (SEQ LD NO:l): Using these same approaches, the sequence guidance provided herein, and knowledge of appropriate nucleotide substitutions to be made to SEQ LD NO:l, one of ordinary skill can readily produce other nucleic acid molecules encoding mutant polymerases, such as those described in detail above, having the desired activity. In addition, other nucleic acid molecules which comprise a sequence substantially different from those described above but which, due to the degeneracy ofthe genetic code, still encode a mutant Tne DNA polymerase having an amino acid sequence set forth above, are also encompassed by the present invention. Since the genetic code is well known in the art, it is routine for one of ordinary skill in the art to produce such mutants and degenerate variants without undue experimentation. Each of these mutant Tne DNA polymerases are reduced or substantially reduced in the ability to add a non-templated 3' terminal nucleotide to the growing strand. These mutant Tne DNA polymerase proteins may be prepared by recombinant DNA techniques routine to one of ordinary skill. Preferably, such mutant Tne polymerases are prepared by inserting an isolated DNA molecule having a nucleotide sequence as described above for each individual mutant into a recombinant vector, inserting the vector into a host cell, preferably an Escherichia coli cell, and culturing the host cell under conditions favoring the production ofthe mutant Tne DNA polymerase. The mutant Tne polymerase is then isolated from the host cell according to standard protein purification techniques. Further guidance for the preparation and isolation of mutant DNA polymerases from thermostable microorganisms can be found, for example, in U. S . Patent No. 5,374,553, in co-pending U.S. Patent Application No. 08/689,818 of Deb K. Chatterjee and A. John Hughes, entitled "Cloned DNA Polymerases from Thermotoga and Mutants Therof," filed September 6, 1996, and in co-pending U.S. Patent Application No. 08/689,807 of Deb K. Chatterjee, entitled "Cloned DNA Polymerases from Thermotoga and Mutants Therof," filed September 6, 1996, the disclosures of all of which are incorporated herein in their entirety. In the methods ofthe present invention, Thermotoga DNA polymerases substantially reduced in 3'-5' exonuclease activity (such as a Tne mutant having an amino acid sequence as set forth in any one of SEQ ID NOs:3-9), or Thermotoga DNA polymerases not substantially reduced in 3'-5' exonuclease activity (such as Tne DNA polymerase (SEQ LD NOs: 1,2), Tma DNA polymerase (U.S. Patent No. 5,374,553), or the Tne mutant 7«eN'Δ283 (SEQ LD NO: 10)), may be used with similar results, since both types of Thermotoga DNA polymerase are substantially reduced in the ability to add a nontemplated 3' terminal nucleotide to a DNA template. Other thermostable DNA polymerases substantially reduced in 3'-5' exonuclease activity, such as Taq, VENT™(exo-), DEEPVENT™(exo-), Dtok(exo-) and THERMOLASE™ Tbr, are not preferred for use in the present methods as they will add non-templated nucleotides to the 3' termini of the amplification products as described below. However, such thermostable polymerase can be made which have reduced, substantially reduced or eliminated activity to add 3' non-template nucleotides by mutating or modifying the polymerase in accordance with the invention. The preferred Thermotoga polymerases of the invention contain such mutations or modifications in their O-helix. The recombinant host comprising the gene encoding Tne DNA polymerase, E. coli DH10B(pUC-Tne), was deposited on September 30, 1994, with the Collection, Agricultural Research Culture Collection (NRRL), 1815 North University Street, Peoria, Illinois 61604 USA as Deposit No. NRRL B-21238. The gene encoding Tma DNA polymerase has also been cloned and sequenced (U.S. Patent No. 5,374,553, which is expressly incorporated by reference herein in its entirety). Methods for preparing mutants and derivatives of these Tne and Tma polymerases are well-known in the art, and are specifically described in co-pending U.S. Patent Application No. 08/689,818 of Deb K. Chatterjee and A. John Hughes, entitled "Cloned DNA Polymerases from Thermotoga and Mutants Therof," filed September 6, 1996, and co-pending U.S. Patent Application No. 08/689,807 of Deb K. Chatterjee, entitled "Cloned DNA Polymerases from Thermotoga and Mutants Therof, " filed September 6, 1996, the disclosures of which are incorporated herein in their entirety. Advantages of Thermostable Polymerases The use of thermostable polymerases (e.g. Thermotoga polymerases) or mutants or derivatives thereof in the methods of the present invention provide several distinct advantages. These advantages are particularly apparent in the application of the present methods to analysis and typing of minisatellite, microsatellite and STR DNA regions. With respect to traditional thermolabile DNA polymerases used in DNA amplification and sequencing, such as T4, T7 or E. coli Klenow fragment polymerases, thermostable polymerases such as Thermotoga DNA polymerases maintain their enzymatic activity in the multiple high-temperature cycles used in PCR and analogous automated amplification methodologies. It is therefore unnecessary to add fresh enzyme at the beginning of each amplification cycle when using thermostable polymerases, as must be done when thermolabile enzymes are used. With respect to other thermostable enzymes, it has been unexpectedly discovered in the present invention (as described in more detail in the Examples below) that the use of Tne or Tma DNA polymerase mutants or derivatives thereof, does not result in the incorporation of non-templated 3' nucleotides into the newly synthesized DNA strands during DNA amplification reactions. This non-templated incorporation is a common problem when using certain other commonly employed thermostable enzymes, such as Taq, VENT™(exo-), DEEPVENT™(exo-), Dtok(exo-) and THERMOLASE™ Tbr. It has also been unexpectedly discovered that mutants of these polymerases can be made to reduce or eliminate addition of non-templated 3' nucleotides. In particular, such mutations are preferably made within the O-helix of such polymerases. Thus, the use of Tne or Tma DNA polymerases or mutants or derivatives thereof (or other mutant polymerases produced according to the invention) in amplifying and typing DNA sequences, particularly hypervariable DNA sequences such as minisatellite, microsatellite or STR regions, will allow a faithful amplification and resolution of polymorphisms in these regions. This faithful resolution is not possible using other thermostable polymerases due to their propensity for non-templated incorporation. Thus, these enzymes are suitable for use in automated amplification systems such as PCR. Sources of DNA Suitable sources of DNA including a variety of cells, tissues, organs or organisms, may be obtained through any number of commercial sources (including American Type Culture Collection (ATCC), Rockville, Maryland; Jackson Laboratories, Bar Harbor, Maine; Cell Systems, Inc., Kirkland, Washington; Advanced Tissue Sciences, La Jolla, California). Cells that may be used as starting materials for genomic DNA preparation are preferably eukaryotic (including fungi or yeasts, plants, protozoans and other parasites, and animals including humans and other mammals). Athough any mammalian cell may be used for preparation of DNA preferred are blood cells (erythrocytes and leukocytes), endothelial cells, epithelial cells, neuronal cells (from the central or peripheral nervous systems), muscle cells (including myocytes and myoblasts from skeletal, smooth or cardiac muscle), connective tissue cells (including fibroblasts, adipocytes, chondrocytes, chondroblasts, osteocytes and osteoblasts) and other stromal cells (e.g., macrophages, dendritic cells, Schwann cells), although other cells, including the progenitors, precursors and stem cells that give rise to the above-described somatic cells, are equally suitable. Aso suitable for use in the preparation of DNA are mammalian tissues or organs such as those derived from brain, kidney, liver, pancreas, blood, bone marrow, muscle, nervous, skin, genitourinary, circulatory, lymphoid, gastrointestinal and connective tissue sources, as well as those derived from a mammalian (including human) embryo or fetus. These cells, tissues and organs may be normal, or they may be pathological such as those involved in infectious diseases (caused by bacteria, fungi or yeast, viruses (including ADDS) or parasites), in genetic or biochemical pathologies (e.g. , cystic fibrosis, hemophilia, Azheimer's disease, schizophrenia, muscular dystrophy or multiple sclerosis), or in cancerous processes. More specifically, in one aspect ofthe invention, the relationship between a first individual and a second individual may be determined by analyzing and typing a particular polymorphic DNA fragment, such as a minisatellite or microsatellite DNA sequence. In such a method, the amplified fragments for each individual are compared to determine similarities or dissimilarities. Such an analysis is accomplished, for example, by comparing the size of the amplified fragments from each individual, or by comparing the sequence of the amplified fragments from each individual. In another aspect of the invention, genetic identity can be determined. Such identity testing is important, for example, in paternity testing, forensic analysis, etc. In this aspect ofthe invention, a sample containing DNA (e.g., a crime scene sample or a sample from an individual) is analyzed and compared to a sample from one or more individuals. In one such aspect ofthe invention, one sample of DNA may be derived from a first individual and another sample may be derived from a second individual whose relationship to the first individual is unknown; comparison of these samples from the first and second individuals by the methods of the invention may then facilitate a determination ofthe genetic identity or relationship between the first and second individual. In a particularly preferred such aspect, the first DNA sample may be a known sample derived from a known individual and the second DNA sample may be an unknown sample derived, for example, from crime scene material. In an additional aspect ofthe invention, one sample of DNA may be derived from a first individual and another sample may be derived from a second individual who is related to the first individual; comparison of these samples from the first and second individuals by the methods of the invention may then facilitate a determination ofthe genetic kinship ofthe first and second individuals by allowing examination of the Mendelian inheritance, for example, of a polymorphic, minisatellite, microsatellite or STR DNA fragment. In another aspect of the invention, DNA fragments important as genetic markers for encoding a gene of interest can be identified and isolated. For example, by comparing samples from different sources, DNA fragments which may be important in causing diseases such as infectious diseases (of bacterial, fungal, parasitic or viral etiology), cancers or genetic diseases, can be identified and characterized. In this aspect of the invention a DNA sample from normal cells or tissue is compared to a DNA sample from diseased cells or tissue. Upon comparison according to the invention, one or more unique polymorphic fragments present in one DNA sample and not present in the other DNA sample can be identified and isolated. Identification of such unique polymorphic fragments allows for identification of sequences associated with, or involved in, causing the diseased state. Once the starting cells, tissues, organs or other samples are obtained, DNA may be prepared therefrom by methods that are well-known in the art (See, e.g., Maniatis, T., et al, Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, pp. 9.16-9.23 (1989); Kaufman, P.B., et al, Handbook of Molecular and Cellular Methods in Biology and Medicine, Boca Raton, Florida: CRC Press, pp. 1-26 (1995)). The DNA samples thus prepared may then be used to identify, analyze and type polymorphic DNA fragments, including minisatellite, microsatellite and STR DNA fragments, by amplification, preferably by PCR amplification, as modified by the methods of the present invention. General methods for amplification and analysis of DNA fragments are well-known to one of ordinary skill in the art (see, e.g., U.S. Pat. Nos. 4,683,195; 4,683,202; and 4,800,159; Innis, M.A, et al., eds., PCR Protocols: A Guide to Methods and Applications, San Diego, California: Academic Press, Inc. (1990); Griffin, H.G., and Griffin, A.M., eds., PCR Technology: Current Innovations, Boca Raton, Florida: CRC Press (1994)). Typically, these methods comprise contacting the DNA sample with a thermostable DNA polymerase in the presence of one or more primer sequences, amplifying the DNA sample to generate a collection of amplified polymorphic, minisatellite, microsatellite or STR DNA fragments, preferably by PCR or equivalent automated amplification technique, separating the amplified DNA fragments by size, preferably by gel electrophoresis, and analyzing the gels for the presence of polymorphic, minisatellite, microsatellite or STR DNA fragments by direct comparison of the pattern of fragments generated from a first sample of DNA to those from a second sample of DNA or by a more indirect comparison using known size markers. As noted above, amplification protocols used heretofore for analyzing and typing polymorphic DNA fragments, particularly minisatellite, microsatellite or STR DNA sequences, use certain thermostable DNA polymerases such as Taq (U.S. Patent Nos. 4,683,195; 4,683,202; and 4,800,159). However, as discussed in detail above, these approaches yield amplification products in which one or more non-templated nucleotides is added to the 3' termini ofthe products by the polymerases, thus leading to heterogeneity in the amplification products, and ambiguity concerning the correct size ofthe amplification products. This problem is overcome in the present invention by contacting the DNA sample in the amplification reaction mixtures with one or more DNA polymerases of the invention which are reduced, substantially reduced or eliminated in the ability to add a nontemplated 3' terminal nucleotide to the growing strand. Preferably, such DNA polymerases are Thermotoga DNA polymerases, more preferably a Thermotoga DNA polymerase substantially reduced in 3'-5' exonuclease activity, still more preferably a Tne polymerase (SEQ LD NOs: 1,2), a Tma polymerase (U.S. Patent No. 5,374,553), or a mutant or derivative thereof, and most preferably one of the following mutants of 7>?e polymerase: Tne NΔ219, D323A (SEQ D NO:3); Tne N'Δ283, D323A (SEQ LD NO:4); Tne NΔ192, D323A (SEQ LD NO:5); Tne D137A D323A (SEQ ID NO:6); Tne D8A, D323A (SEQ LD NO:7); Tne G195D, D323 A (SEQ LD NO:8); Tne G37D, D323A (SEQ LD NO:9); Tne N'Δ283 (SEQ LD NO: 10); Tne D137A, D323A R722K; Tne D137A D323A R722Y; Tne D137A D323A R722L; 7«eD137A D323A R722H; JneD137A D323A R722Q; JneD137A D323A, F730Y; Tne D137A D323A K726R; Tne D137A D323A K726H; Tne D137A, D323A R722K, F730Y; Tne D137A D323A R722K, K726R; Tne D137A, D323A R722K, K726H; Tne D137A D323A R722H, F730Y; Tne D137A, D323A R722H, K726R; Tne D137A, D323A R722H, K726H; Tne D137A D323A R722Q, F730Y; Tne D137A D323A R722Q, K726R; Tne D137A, D323A R722Q, K726H; Tne D137A D323A R722N, F730Y; Tne D137A, D323A, R722N, K726R; Tne D137A D323A, R722N, K726H; Tne D137A D323 F730S; 7weN'Δ283, D323A R722K/H/Q/N/Y/L; 7«eN'Δ219, D323 R722K; 7«eN'Δ219, D323 F730Y; J«eN'Δ219, D323 A K726R; 7«eN'Δ219, D323A 726H; r«eD137AD323AF730S,R722K7Y/Q/N/H/L,K726R/H; Tne D137A D323A F730T, R722K7Y/Q/N/H/L, K726R/H; Tne O131A, D323A F730T; Tne F730S; 7«e F730A; Tne K726R; Tne K726H; and Tne O131A, D323A R722N. It will be understood, however, that other thermostable DNA polymerases or mutants thereof, any of which are reduced, substantially reduced, or eliminated in the ability to add a non-templated 3' terminal nucleotide to the growing strand, may be used in the methods of the present invention equivalently. The DNA polymerases are used in the methods ofthe present invention at a concentration of about 0.0001 units/ml to about 10 units/ml, preferably at a concentration of about 0.001 units/ml to about 5 units/ml, more preferably at a concentration of about 0.004 units/ml to about 1 unit/ml, and most preferably at a concentration of about 0.04 units/ml. Thus, the methods of the present invention produce a population of amplified DNA fragments, most preferably of polymorphic or microsatellite DNA fragments, which comprise substantially no non-templated 3' terminal nucleotides. By "substantially no non-templated 3' terminal nucleotides" is meant that the population of amplified DNA fragments demonstrates about 0- 50%), about 0-30%, about 0-20%, preferably about 0-10%, more preferably about 0-5%), still more preferably about 0-1% and most preferably about 0%, of DNA molecules containing non-templated 3' nucleotides compared to amplified DNA fragments produced by the polymerase control. When testing the ability of a DNA polymerase to add 3' non-templated nucleotides, the polymerase, when it has substantially reduced or eliminated 3' exonuclease activity, is compared to Taq DNA polymerase (see above). When testing polymerases which have been modified or mutated to reduce or eliminate 3' non-templated nucleotide addition, the mutated or modified polymerase is compared to the corresponding wildtype, unmodified or unmutated polymerase (see above). Following amplification by the methods of the present invention, the amplified DNA fragments may be analyzed to identify or type a polymorphic, minisatellite, microsatellite or STR DNA fragment. This step is usually accomplished by separation ofthe amplified DNA fragments by size, a procedure which permits the determination ofthe presence of unique polymorphic fragments in one or more of the DNA samples. The fragments may be separated by any physical or biochemical means including gel electrophoresis, capillary electrophoresis, chromatography (including sizing, affinity and immunochromatography), density gradient centrifugation and immunoadsorption. For carrying out the present invention, separation of DNA fragments by gel electrophoresis is particularly preferred, as it provides a rapid and highly reproducible means of sensitive separation of a multitude of DNA fragments, and permits direct, simultaneous comparison ofthe fragments in several samples of DNA or samples of DNA from a first and a second individual. Gel electrophoresis is typically performed on agarose or polyacrylamide sequencing gels according to standard protocols, preferably using gels containing polyacrylamide at concentrations of 3-12% and most preferably at about 8%, and containing urea at a concentration of about 4-12M, most preferably about 8M. Samples are loaded onto the gels, usually with samples containing amplified DNA fragments prepared from different sources of genomic DNA being loaded into adjacent lanes ofthe gel to facilitate subsequent comparison. Reference markers of known sizes may be used to facilitate the comparison of samples. Following electrophoretic separation, DNA fragments may be visualized and identified by a variety of techniques that are routine to those of ordinary skill in the art, such as autoradiography. One can then examine the autoradiographic films either for differences in polymorphic fragment patterns ("typing") or for the presence of one or more unique bands in one lane ofthe gel ("identifying"); the presence of a band in one lane (corresponding to a single sample, cell or tissue type) that is not observed in other lanes indicates that the DNA fragment comprising that unique band is source-specific and thus a potential polymorphic DNA fragment. A variety of DNA fragments comprising polymorphic, minisatellite, microsatellite or STR DNA fragments can thus be identified using the methods of the present invention by comparing the pattern of bands on the films depicting various samples. Importantly, using the present methods the amplification products ofthe polymorphic DNA fragments will be faithful copies ofthe template (allele) material — i.e., they will not exhibit undesired additional nucleotides at their 3' termini via non-templated addition of nucleotides by the polymerases. One can extend this approach, in another preferred embodiment, to isolate and characterize these fragments or any DNA fragment amplified without the non- templated addition of a 3' terminal nucleotide. In this embodiment, one or more of the unique DNA fragments are removed from the gel which was used for identification (see above), according to standard techniques such as electroelution or physical excision. The isolated unique DNA fragments may then be inserted into standard nucleotide vectors, including expression vectors, suitable for transfection or transformation of a variety of prokaryotic (bacterial) or eukaryotic (yeast, plant or animal including human and other mammalian) cells. In particular, the present invention provides methods of cloning such isolated unique DNA fragments, or any PCR-amplified DNA fragment, by blunt-end cloning. As described above, Taq DNA polymerase adds a non-templated nucleotide, typically a deoxyadenosine ("A"), to the 3' terminus ofthe amplified DNA fragment. Thus, T g-catalyzed PCR generates a collection of DNA fragments with 3' A overhangs. To clone such Jα^-amplified fragments, two approaches are commonly used: either the 3' A overhang is removed by treating the amplified fragment with, for example, T4 DNA polymerase (a technique sometimes called "3' polishing"), or a special cloning vector with a 3' T overhang (a "TA cloning vector") is used. Of course, such approaches are more time-consuming and expensive than if direct insertion ofthe amplified fragment were done. Such a direct approach is possible using the methods ofthe invention, which generates little or no 3' A overhangs (and thus, blunt ends) on the amplified DNA fragments. The DNA fragments, amplified according to the methods ofthe invention, may thus be directly inserted into corresponding blunt-ended vectors according to standard techniques (for example, using T4 DNA ligase). Thus, the present invention provides a method of blunt-end cloning of a DNA fragment that obviates the use of TA cloning vectors or 3' polishing. To identify the presence of minisatellite DNA fragments, the polymorphic DNA fragments that are identified and isolated by the methods of the present invention may be further characterized, for example by sequencing (i.e., determining the nucleotide sequence ofthe polymorphic fragments), by methods described above and others that are standard in the art (see, e.g. , U. S . Patent Nos. 4,962,022 and 5,498,523, which are directed to methods of DNA sequencing). Kits The invention also provides kits for use in the identification, analysis and typing of a polymorphic DNA fragment, particularly a minisatellite or STR DNA fragment, according to the present methods. Kits according to the present invention may comprise a carrying means being compartmentalized to receive in close confinement therein one or more containers such as vials, tubes, bottles and the like. Each of such containers may comprise components or a mixture of components needed to perform DNA amplification or analysis. Such kits may comprise of one or more thermostable DNA polymerases reduced, substantially reduced or eliminated in the ability to add a non-templated 3' nucleotide to a growing DNA strand. Preferably the container contains a Thermotoga DNA polymerase or a mutant or a derivative thereof, particularly those described in full detail above. The kit may also contain one or more DNA primer molecules, one or more deoxyribonucleoside triphosphates needed to synthesize a DNA molecule complementary to a DNA template, and/or a buffer suitable for amplification of a nucleic acid molecule (or combinations threof). A kit for DNA analysis may include one or more ofthe above components, and may further include containers which contain reagents necessary for separation and analysis of DNA fragments, such as polyacrylamide, agarose, urea, detergents and the like. Of course, it is also possible to combine one or more of these reagents in a single tube. A detailed description of such formulations at working concentrations is described in co-pending U.S. Application No. 08/689,815 of Ayoub Rashtchian and Joseph Solus, entitled "Stable Compositions for Nucleic Acid Amplification and Sequencing" filed on August 14, 1996, the disclosure of which is incorporated by reference herein in its entirety. The invention also relates to kits for detectably labeling molecules, sequencing, amplifying and synthesizing molecules by well known techniques. See U.S. Patent Nos. 4,962,020, 5,173,41 1, 4,795,699, 5,498,523, 5,405,776 and 5,244,797. Such kits may comprise a carrying means being compartmentalized to receive in close confinement one or more container means such as vials, test tubes and the like. Each of such container means comprises components or a mixture of components needed to perform nucleic acid synthesis, sequencing, labeling, or amplification. A kit for sequencing DNA may comprise a number of container means. Such a kit may comprise one or more ofthe polymerases ofthe invention, one or a number of types of nucleotides needed to synthesize a DNA molecule complementary to DNA template, one or a number of different types of terminators (such as dideoxynucleoside triphosphates), a pyrophosphatase, one or a number of primers and/or a suitable sequencing buffer (or combinations of such components). A kit used for amplifying or synthesizing of nucleic acids will comprise, one or more polymerases ofthe invention, and one or a number of nucleotides or mixtures of nucleotides. Various primers may be included in a kit as well as a suitable amplification or synthesis buffers. When desired, the kit ofthe present invention may also include container means which comprise detectably labeled nucleotides which may be used during the synthesis or sequencing of a nucleic acid molecule. One of a number of labels may be used to detect such nucleotides. Illustrative labels include, but are not limited to, radioactive isotopes, fluorescent labels, chemiluminescent labels, bioluminescent labels and enzyme labels. Use of the Methods and Kits The polymeraes, methods and kits embodied in the present invention will have general utility in any application utilizing nucleic acid amplification methodologies, particularly those directed to the analysis and typing of polymorphic or minisatellite DNA fragments, and most particularly those directed to the analysis and typing of minisatellite, microsatellite and STR DNA fragments. Amplification techniques in which the present methods may be used include PCR (U.S. Patent Nos. 4,683,195 and 4,683,202), Strand Displacement Amplification (SDA; U.S. Patent No. 5,455,166; EP 0 684 315), and Nucleic Acid Sequence- Based Amplification (NASBA; U.S. Patent No. 5,409,818; EP 0 329 822). Nucleic acid analysis and typing techniques which may employ the present compositions include nucleic acid sequencing methods such as those disclosed in U.S. Patent Nos. 4,962,022 and 5,498,523, as well as more complex PCR-based nucleic acid fingerprinting techniques such as Random Amplified Polymorphic DNA (RAPD) analysis (Williams, J.G.K., et al, Nucl Acids Res. 18(22):653 \- 6535, 1990), Arbitrarily Primed PCR (AP-PCR; Welsh, J., and McClelland, M., Nucl. Acids Res. 18(24):1213-12\8, 1990), DNA Amplification Fingerprinting (DAF; Caetano-Anolles et al, Bio/Technology 9:553-557, 1991), and microsatellite PCR or Directed Amplification of Minisatellite-region DNA (DAMD; Heath, D.D., et al, Nucl. Acids Res. 21(24): 5782-5785, 1993). In particular, the polymerases, methods and kits of the present invention will be useful in the fields of medical genetics, therapeutics and diagnostics, forensics (particularly identity and paternity testing), and agricultural (e.g., plant breeding) and other biological sciences, in any procedure utilizing DNA polymerases for analysis and typing of polymorphic, minisatellite, microsatellite or STR DNA fragments. Particularly suitable for diagnosis by the methods of the present invention are genetic diseases such as cystic fibrosis, hemophilia, Azheimer's disease, schizophrenia, muscular dystrophy or multiple sclerosis. Together, these abilities will assist medical professionals and patients in diagnostic and prognostic determinations as well as in the development of treatment and prevention regimens for these and other disorders. It will also be apparent to one of ordinary skill in the art that the present methods may be used to screen animal tissues to be subsequently used in medical procedures such as tissue or organ transplants, blood transfusions, zygote implantations and artificial inseminations. In such procedures, pre-screening ofthe subject tissues for the presence of particular polymorphic DNA fragments may improve the success of tissue or organ transplants (by decreasing the likelihood of rejection due to donor-recipient genetic incompatibility) and of zygote implantations (by eliminating the use of genetically defective zygotes). Similarly, use of these methods will reduce the chances of transmission of infectious diseases (e.g., hepatitis and A DS) in medical procedures that are often prone to such transmission, such as blood transfusions and artificial insemination. Finally, use of the present invention for identification of unique polymorphic, minisatellite, microsatelliet and STR DNA fragments will assist in forensic science in such applications as crime-scene analysis of blood, tissue and body secretions containing small amounts of DNA as well as in paternity testing. It will be readily apparent to those skilled in the relevant arts that other suitable modifications and adaptations to the methods and applications described herein are obvious and may be made without departing from the scope of the invention or any embodiment thereof. Having now described the present invention in detail, the same will be more clearly understood by reference to the following examples, which are included herewith for purposes of illustration only and are not intended to be limiting ofthe invention. xExample 1: Bacterial Strains And Growth Conditions Thermotoga neapolitana DSM No. 5068 was grown under anaerobic conditions as described in the DSM catalog (addition of resazurin, Na^, and sulfur granules while sparging the media with nitrogen) at 85°C in an oil bath from 12 to 24 hours. The cells were harvested by filtering the broth through Whatman #1 filter paper. The supernatant was collected in an ice bath and then centrifuged in a refrigerated centrifuge at 8,000 rpms for twenty minutes. The cell paste was stored at -70°C prior to total genomic DNA isolation. E. coli strains were grown in 2X LB broth base (Lennox L broth base: GLBCO/BRL) medium. Transformed cells were incubated in SOC (2% tryptone, 0.5% yeast extract, yeast 10 mM NaCl, 2.5 mM KC1, 20mM glucose, lOmM MgCl 2 , and lOmM MgSO 4 per liter) before plating. When appropriate antibiotic supplements were 20 mg/1 tetracycline and 100 mg/1 ampicillin. E. coli strain DH10B (Lorow et al, Focus 12:19-20 (1990)) was used as host strain. Competent DH10B may be obtained from Life Technologies, Inc. (LTI) (Rockville, MD). xExample 2: DNA Isolation Thermotoga neapolitana chromosomal DNA was isolated from l.lg of cells by suspending the cells in 2.5 ml TNE (50mM Tris-HCl, pH 8.0, 50mM NaCl, lOmM EDTA) and treated with 1% SDS for 10 minutes at 37°C. DNA was extracted with phenol by gently rocking the lysed cells overnight at 4°C. The next day, the lysed cells were extracted with chloroform:isoamyl alcohol. The resulting chromosomal DNA was further purified by centrifugation in a CsCl density gradient. Chromosomal DNA isolated from the density gradient was extracted three times with isopropanol and dialyzed overnight against a buffer containing 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA (TE). xExample 3: Construction of Genomic Libraries The chromosomal DNA isolated in Example 2 was used to construct a genomic library in the plasmid pCP13. Briefly, 10 tubes each containing lOμg of Thermotoga neapolitana chromosomal DNA was digested with 0.01 to 10 units of SauϊϊlM for 1 hour at 37°C. A portion ofthe digested DNA was tested in an agarose (1.2%) gel to determine the extent of digestion. Samples with less than 50% digestion were pooled, ethanol precipitated and dissolved in TE. 6.5 μg of partially digested chromosomal DNA was ligated into 1.5 μg of pCP13 cosmid which had been digested with BamHI restriction endonuclease and dephosphorylated with calf intestinal alkaline phosphatase. Ligation of the partially digested Thermotoga DNA and BamHI cleaved pCP13 was carried out with T4 DNA ligase at 22°C for 16 hours. After ligation, about lμg of ligated DNA was packaged using λ-packaging extract (obtained from Life Technologies, Inc., Rockville, MD). DH10B cells (Life Tech. Inc.) were then infected with 100 μl of the packaged material. The infected cells were plated on tetracycline containing plates. Serial dilutions were made so that approximately 200 to 300 tetracycline resistant colonies were obtained per plate. xExample 4: Screeningfor Clones Expressing Thermotoga neapolitana DNA Polymerase Identification ofthe Thermotoga neapolitana DNA polymerase gene ofthe invention was cloned using the method of Sagner et al, Gene 97: 119-123 (1991) which reference is herein incorporated in its entirety. Briefly, the E. coli tetracycline resistant colonies from Example 3 were transferred to nitrocellulose membranes and allowed to grow for 12 hours. The cells were then lysed with the fumes of chloroform:toluene (1:1) for 20 minutes and dried for 10 minutes at room temperature. The membranes were then treated at 95°C for 5 minutes to inactivate the endogenous E. coli enzymes. Surviving DNA polymerase activity was detected by submerging the membranes in 15 ml of polymerase reaction mix (50 mM Tris-HCl (pH 8.8), 1 mM MgCl 2 , 3 mM β-mercaptoethanol, 10 μM dCTP, dGTP, dTTP, and 15 μCi of 3,000 Ci mmol [α 32 P]dATP) for 30 minutes at 65°C. Using autoradiography, three colonies were identified that expressed a Thermotoga neapolitana DNA polymerase. The cells were grown in liquid culture and the protein extract was made by sonication. The presence of the cloned thermostable polymerase was confirmed by treatment at 90°C followed by measurement of DNA polymerase activity at 72°C by incorporation of radioactive deoxyribonucleoside triphosphates into acid insoluble DNA. One ofthe clones, expressing Tne DNA polymerase, contained a plasmid designated pCP13-32 and was used for further study. Example 5: Subcloning of Tne DNA polymerase Since the pCP13-32 clone expressing the Tne DNA polymerase gene contains about 25 kb of T neapolitana DNA subcloning a smaller fragment ofthe 7>?e polymerase gene was attempted. The molecular weight of the Tne DNA polymerase purified from E. co/z/pCP13-32 was about 700 kd. Therefore, a 2.5-3.0 kb DNA fragment will be sufficient to code for full-length polymerase. A second round of Sau3A partial digestion similar to Example 3 was done using pCP13-32 DNA. In this case, a 3.5 kb region was cut out from the agarose gel, purified by Gene Clean (BIO 101, La Jolla, CA) and ligated into plasmid p Sport 1 (Life Technologies, Inc.) which had been linearized with BamHI and dephosphorylated with calf intestinal alkaline phosphatase. After ligation, DH10B was transformed and colonies were tested for DNA polymerase activity as described in Example 1. Several clones were identified that expressed Tne DNA polymerase. One of the clones (pSport-Jwe) containing about 3 kb insert was further characterized. A restriction map ofthe DNA fragment is shown in Fig. 1. Further, a 2.7 Kb Hindllϊ-Sstl fragment was subcloned into pUC19 to generate pUC19-7«e. E. coli/τp\JC19-Tne also produced Tne DNA polymerase. E. coli DH10B (pUC19-7«e) was deposited on September 30, 1994 with the Collection, Agricultural Research Culture Collection (NRRL), 1815 Peoria, IL 61604 as Deposit No. NRRL B-21338. The nucleotide and amino acid sequence of Tne polymerase is described in U.S. application serial nos. 08/706,702 and 08/706,706 filed September 9, 1996, both of which are incorporated by reference herein. Example 6: xPurification ofThermotoga neapolitana DNA Polymerase from E. coli Twelve grams of E. coli cells expressing cloned Tne DNA polymerase (DH1 OB/p Sport- Tne) were lysed by sonication (four thirty-second bursts with a medium tip at the setting of nine with a Heat Systems Ultrasonics Inc., model 375 sonicator) in 20 ml of ice cold extraction buffer (50 mM Tris HCI (pH 7.4), 8% glycerol, 5 mM mercaptoethanol, 10 mM NaCl, 1 mM EDTA 0.5 mM PMSF). The sonicated extract was heated at 80°C for 15 min. and then cooled in ice for 5 min. 50 mM KC1 and PEI (0.4%) was added to remove nucleic acids. The extract was centrifuged for clarification. Ammonium sulfate was added to 60%, the pellet was collected by centrifugation and resuspended in 10 ml of column buffer (25 mM Tris-HCl (pH 7.4), 8% glycerol, 0.5% EDTA 5mM 2-mercaptoethanol, 10 mM KC1). A Blue-Sepharose (Pharmacia) column, or preferably a Toso heparin (Tosohaas) column, was washed with 7 column volumes of column buffer and eluted with a 15 column volume gradient of buffer from 10mM to 2 MKCl. Fractions containing polymerase activity were pooled. The fractions were dialyzed against 20 volumes of column buffer. The pooled fractions were applied to a Toso650Q column (Tosohaas). The column was washed to baseline OD 2g0 and elution effected with a linear 10 column volume gradient of 25 mM Tris (pH 7.4), 8% glycerol, 0.5 mM EDTA 0 mM KC1, 5 mM β-mercaptoethanol to the same buffer plus 650 mM KC1. Active fractions were pooled. xExample 7: Construction ofThermotoga neapolitana 3 '-to-5 'Exonuclease Mutant The amino acid sequence of portions of the Tne DNA polymerase was compared with other known DNA polymerases such as E. coli DNA polymerase 1, Taq DNA polymerase, T5 DNA polymerase, and T7 DNA polymerase to localize the regions of 3'-to-5' exonuclease activity, and the dNTP binding domains within the DNA polymerase. One ofthe 3'-to-5' exonuclease domains was determined based on the comparison ofthe amino acid sequences of various DNA polymerases (Blanco, L., et al. Gene 112: 139-144 (1992); Braithwaite and Ito, Nucleic Acids Res. 21 : 787-802 ( 1993)) is as follows: Tne 318 PSFALDLETSS 328 (SEQ LD NO: 18) Pol l 350 PVFAFDTETDS 360 (SEQ LD NO:19) T5 159 GPVAFDSETSA 169 (SEQ LD NO:20) T7 1 MTVSDLEANA 10 (SEQ LD NO:21) As a first step to make the Tne DNA polymerase devoid of 3' ~ >5' exonuclease activity, a 2kb Sph fragment from pSport-Tne was cloned into M13mpl9 (LTI, Rockville, MD). The recombinant clone was selected in E. coli DH5αF'IQ (LTI, Rockville, MD). One ofthe clones with the proper insert was used to isolate uracilated single-stranded DNA by infecting E. coli C J236 (Biorad, California) with the phage particle obtained from E. coli DH5αF'IQ. An oligonucleotide, GA CGT TTC AAG CGC TAG GGC AAA AGA (SEQ ID NO:22) was used to perform site directed mutagenesis. This site-directed mutagenesis converted Asp 323 (indicated as * above) to Aa 323 . An Eco47III restriction site was created as part of this mutagenesis to facilitate screening ofthe mutant following mutagenesis. The mutagenesis was performed using a protocol as described in the Biorad manual (1987) except T7 DNA polymerase was used instead of T4 DNA polymerase (USB, Cleveland, OH). The mutant clones were screened for the Ecø47III restriction site that was created in the mutagenic oligonucleotide. One ofthe mutants having the created Eco47III restriction site was used for further study. The mutation Asp 323 to Aa 323 was confirmed by DNA sequencing. To incorporate the 3 '→ 5 ' exonuclease mutation in an expression vector, the mutant phage was digested with Sphl and HindHl. A 2 kb fragment containing the mutation was isolated. This fragment was cloned in pUC-Tne to replace the wild type fragment. See Figure 2 A. The desired clone, pUC-Tne (3'- 5'), was isolated. The presence ofthe mutant sequence was confirmed by the presence of the unique Eco4711l site. The plasmid was then digested with SstI and Hindll. The entire mutant polymerase gene (2.6 kb) was purified and cloned into SstI and Hindlll digested pTrc99 expression vector (Pharmacia, Sweden). The clones were selected in DH10B (LTI, Rockville, MD). The resulting plasmid was designated pTrcTne35. See Figure 2B. This clone produced active heat stable DNA polymerase. xExample 8: Phenylalanine to Tyrosine Mutant The polymerase active site including the dNTP binding domain is usually present at the carboxyl terminal region ofthe polymerase. The sequence ofthe Tne polymerase gene suggests that the amino acids that presumably contact and interact with the dNTPs are present within the 694 bases starting at the internal BamHI site. See Figure 1. This conclusion is based on homology with a prototype polymerase E. coli DNA polymerase I. See Polisky et al., J. Biol Chem. 265:14579-14591 (1990). A comparison was made of the O-helix for various polymerases: Tne 722 RRVGKMVNFSIIYG 735 (SEQ LD NO 12) Pol l 754 RRSAKAINFGLLYG 767 (SEQ LD NO 13) T5 562 RQAAKAITFGLLYG 575 (SEQ LD NO 14) T7 518 RDNAKTFIYGFLYG 531 (SEQ D NO 15) Taq 659 RRAAKTLNFGVLYG 672 (SEQ LD NO 16) In order to change Phe 730 ofthe Tne polymerase to a Tyr 730 site directed mutagenesis was performed using the oligonucleotide GTA TAT TAT AGA GTA GTT AAC CAT CTT TCC A (SEQ LD NO:23). As part of this oligonucleotide directed mutagenesis, a Hpal restriction site was created in order to screen mutants easily. The same uracilated single-stranded DNA and mutagenesis procedure described in Example 7 were used for this mutagenesis. Following mutagenesis, the mutants were screened for the Hpal site. Mutants with the desired Hpal site were used for further study. The mutation was confirmed by DNA sequencing. The Phe 730 to Tyr 730 mutation was incorporated into pUC- 7>?e by replacing the wild type Sphl -Hindlll fragment with the mutant fragment obtained from the mutant phage DNA. The presence of the desired clone, pUC-TneFY, was confirmed by the presence of the unique Hpal site, see Figure 2 A. The entire mutant polymerase gene was subcloned into pTrc99 as an Sstl-Hindlll fragment as described above in DH 1 OB . The resulting plasmid was designated pTrcTneF Y. (Figure 2B). The clone produced active heat stable polymerase. xExample 9: 3'→5' Exonuclease and Phe 730 →Tyr 730 Double Mutants In order to introduce the 3'→5' exonuclease mutation and the Phe 730 →-Tyr 730 mutation in the same expression vector, pTrc99, it was necessary to first reconstitute both mutations in the pUC-Tne clone. See Figure 3. Both the pUC-Tne (3'→5') and the pUC-TneFY were digested with BamHI. The digested pUC-Tne (3'- 5') was dephosphorylated to avoid recirculation in the following ligations. The resulting fragments were purified on a 1% agarose gel. The largest BamHI fragment (4.4 kb) was purified from pUC-Tne (3'→5') digested DNA and the smallest BamHI fragment (0.8 kb) containing thePhe 730 - Tyr 730 mutation was purified and ligated to generate pUC-Tne35FY. The proper orientation and the presence of both mutations in the same plasmid was confirmed by Eco47III, Hpal, and Sphϊ-Hind∑ll restriction digests. See Figure 3. The entire polymerase containing both mutations was subcloned as a Sstϊ- Hindiπ fragment in pTrc99 to generate ρTrcTne35FY in DH10B. The clone produced active heat stable polymerase. xExample lO: 3 '→5' .Exonuclease, 5'→3' xExonuclease, and Phe 730 →Tyr 730 Triple Mutants In most of the known polymerases, the 5'-to-3' exonuclease activity is present at the amino terminal region ofthe polymerase (Ollis, D.L., et al. , Nature 313, 762-766, 1985; Freemonι, P.S., etal, Proteins 1, 66-73, 1986; Joyce, CM., Curr. Opin. Struct. Biol. 1: 123-129 (1991). There are some conserved amino acids that are implicated to be responsible for 5'-to-3' exonuclease activity (Gutman and Minton, Nucl. Acids Res. 21, 4406-4407, 1993). See supra. It is known that 5'-to-3' exonuclease domain is dispensable. The best known example is the Klenow fragment of E. coli Pol I. The Klenow fragment is a natural proteolytic fragment devoid of 5'-to-3' exonuclease activity (Joyce, CM., et al, J. Biol Chem. 257, 1958-1964, 1990). In order to generate an equivalent mutant for Tne DNA polymerase devoid of 5'-to-3' exonuclease activity, the presence of a unique Sphl site present 680 bases from the SstI site was exploited. pUC-Tne35FY was digested with Hindlll, filled-in with Klenow fragment to generate a blunt-end, and digested with Sphl. The 1.9 kb fragment was cloned into an expression vector pTTQ 19 (Stark, M.J.R., Gene 51, 255-267, 1987) at the Sphl-Smal sites and was introduced into DH10B . This cloning strategy generated an in-frame polymerase clone with an initiation codon for methionine from the vector. The resulting clone is devoid of 219 amino terminal amino acids of Tne DNA polymerase. This clone is designated as pTTQTne535FY (Fig. 4). The clone produced active heat stable polymerase. No exonuclease activity could be detected in the mutant polymerase as evidenced by lack of presence of unusual sequence ladders in the sequencing reaction. This particular mutant polymerase is highly suitable for DNA sequencing. xExample 11: 5'→3 Exonuclease Deletion and Phe 730 →Tyr 730 Substitution Mutant In order to generate the 5'-to-3' exonuclease deletion mutant ofthe Tne DNA polymerase Phe 730 →Tyr 73() mutant, the 1.8 kb Sphl-Spel fragment of pTTQTne535FY was replaced with the identical fragment of pUC-Tne FY. See Fig. 4. A resulting clone, pTTQTne5FY, produced active heat stable DNA polymerase. As measured by the rate of degradation of a labeled primer, this mutant has a modulated, low but detectable, 5'-to-3' exonuclease activity compared to wild type Tne DNA polymerase. M13/pUC Forward 23-Base Sequencing Primer™, obtainable from LTI, Rockville, MD, was labeled at the 5' end with [P 32 ] ATP and T4 kinase, also obtainable from LTI, Rockville, MD, as described by the manufacturer. The reaction mixtures contained 20 units of either wildtype or mutant Tne DNA polymerase, 0.25 pmol of labeled primer, 20 mM tricine, pH 8.7, 85 mM potassium acetate, 1.2 mM magnesium acetate, and 8% glycerol. Incubation was carried out at 70°C At various time points, 10 μl aliquots were removed to 5 μl cycle sequencing stop solution and were resolved in a 6 % polyacrylamide sequencing gel followed by andoradiography. While the wildtype polymerase degraded the primer in 5 to 15 minutes, it took the mutant polymerase more than 60 minutes for the same amount of degradation of the primer. xExample 12: Purification ofthe Mutant Polymerases The purification of the mutant polymerases was done essentially as described Example 6, supra, with minor modifications. Specifically, 5 to 10 grams of cells expressing cloned mutant Tne DNA polymerase were lysed by sonication with a Heat Systems Ultrasonic, Inc. Model 375 machine in a sonication buffer comprising 50 mM Tris-HCl (pH 7.4); 8% glycerol; 5 mM 2-mercaptoethanol, 10 mM NaCl, 1 mM EDTA and 0.5 mM PMSF. The sonication sample was heated at 75°C for 15 minutes. Following heat treatment, 200 mM NaCl and 0.4% PEI was added to remove nucleic acids. The extract was centrifuged for clarification. Ammonium sulfate was added to 48%, the pellet was resuspended in a column buffer consisting of 25 mM Tris-HCl (pH 7.4); 8% glycerol; 0.5% EDTA; 5 mM 2-mercaptoethanol; 10 mM KC1 and loaded on a heparin agarose (LTI) column. The column was washed with 10 column volumes using the loading buffer and eluted with a 10 column volume buffer gradient from 10 mM to 1 M KC1. Fractions containing polymerase activity were pooled and dialyzed in column buffer as above with the pH adjusted to 7.8. The dialyzed pool of fractions were loaded onto a MonoQ (Pharmacia) column. The column was washed and eluted as described above for the heparin column. The active fractions are pooled and a unit assay was performed. The unit assay reaction mixture contained 25 mM TAPS (pH 9.3), 2 mM MgCl 2 , 50 mM KC1, 1 mM DTT, 0.2 mM dNTPs, 500 μg/ml DNAse I treated salmon sperm DNA 21 mCi ml [ P 32 ] dCTP and various amounts of polymerase in a final volume of 50 μl. After 10 minutes incubation at 70°C, 10 μl of 0.5 M EDTA was added to the tube. TCA perceptible counts were measured in GF/C filters using 40 μl ofthe reaction mixture. xExample 13: Generation of S'-to-3' exonuclease mutant of full length Tne DNA polymerase 1. Identification of Two Amino Acids Responsible for 5'-to-3' Exonuclease Activity Tne DNA polymerase contains three enzymatic activities similar to E. coli DNA polymeraseI: 5'-to-3'DNA polymerase activity, 3'-to-5' exonuclease activity and 5'-to-3' exonuclease activity. This example is directed to the elimination ofthe 5'-to-3' exonuclease activity in full length 7>?e DNA polymerase. Gutman and Minton (Nucleic Acids Res. 1993, 27, 4406-4407) identified six (A-F) conserved 5'-to-3' exonuclease domains containing a total of 10 carboxylates in various DNA polymerases in the poll family. Seven out of 10 carboxylates (in domains A D and E) have been implicated to be involved in divalent metal ions binding as judged from the crystal structure (Kim et al. Nature, 1995, 376, 612-616) of Taq DNA polymerase. However, there was no clear demonstration that these carboxylates are actually involved 5'-to-3' exonuclease activity. In order to find out the biochemical characteristics of some of these carboxylates, two of the aspartic acids in domains A and E were chosen for mutagenesis. The following aspartic acids in these two domains were identified: Tne DNA polymerase: 5 FLFD 8 GT 10 (domain A) (SEQ LD NO:24) Taq DNA polymerase: 15 LLVD 18 GH 20 (SEQ LD NO:25) and Tne DNA polymerase: 132 SLITGD 137 KDML141 (domain E) (SEQ LD NO:26) Taq DNA polymerase: 137 RLLTAD 142 KDLY146 (SEQ ID NO:27) 2. Isolation of Single Stranded DNA for Mutagenesis Single stranded DNA was isolated from pSportTne (see infra). pSportTne was introduced into DH5αFTQ (LTI, Rockville, MD) by transformation. A single colony was grown in 2 ml Circle Grow (Bio 101, CA) medium with ampicillin at 37°C for 16 hrs. A 10 ml fresh media was inoculated with 0.1 ml ofthe culture and grown at 37°C until the A590 reached approximately 0.5. At that time, 0.1 ml of M13KO7 helper phage (1X10 11 pfu/ml, LTI) was added to the culture. The infected culture was grown for 75 min. Kanamycin was then added at 50 μg/ml, and the culture was grown overnight ( 16 hrs.). The culture was spun down. 9 ml ofthe supernatant was treated with 50 μg each of RNaseA and DNasel in the presence of 10 mM MgCl 2 for 30 min. at room temperature. To this mixture, 0.25 volume of a cocktail of 3M ammonium acetate plus 20% polyethylene glycol was added and incubated for 20 min. on ice to precipitate phage. The phage was recovered by centrifugation. The phage pellet was dissolved in 200 μl of TE (10 mM Tris-HCl (pH 8) and 1 mM EDTA). The phage solution was extracted twice with equal volume of buffer saturated phenol (LTI, Rockville, MD), twice with equal volume of phenol:chloroform:isoamyl alcohol mixture (25:24: 1, LTI, Rockville, MD) and finally, twice with chloroform: isoamyl alcohol (24: 1). To the aqueous layer, 0.1 volume of 7.5 M ammonium acetate and 2.5 volume of ethanol were added and incubated for 15 min. at room temperature to precipitate single stranded DNA. The DNA was recovered by centrifugation and suspended in 200 μl TE. 3. Mutagenesis of D 8 and D 137 Two oligos were designed to mutagenize D 8 and D 137 to alanine. The oligos are: 5' GTAGGCCAGGGCTGTGCCGGCAAAGAGAAATAGTC 3' (D8A) (SEQ LD NO:28) and 5' GAAGCATATCCTTGGCGCCGGTTAT TATGAAAATC 3' (D137A) (SEQ D NO:29). In the D8A oligo a NgoATV (bold underlined) and in the oligo D137A a Kasl (bold underlined) site was created for easy identification of clones following mutagenesis. 200 pmol of each oligo was kinased according to the Muta-gene protocol (Bio-Rad, CA) using 5 units of T4 Kinase (LTI, Rockville, MD). 200 ng of single stranded DNA was annealed with 2 pmol of oligo according to the Muta-gene protocol. The reaction volume was 10 μl. Following the annealing step, complementary DNA synthesis and ligation was carried out using 5 units of wildtype T7 DNA polymerase (USB, Ohio) and 0.5 unit T4 ligase (LTI). 1 μl ofthe reaction was used to transform a MutS E. coli (obtainable from Dr. Paul Modrich at the Duke University, NC) and selected in agar plates containing ampicillin. A control annealing and synthesis reaction was carried out without addition of any oligo to determine the background. There were 50-60 fold more colonies in the transformation plates with the oligos than without any oligo. Six colonies from each mutagenic oligo directed synthesis were grown and checked for respective restriction site (Ngo AIV oτKasϊ). For D8 A (Ngo AIV), 4 out of 6 generated two fragments (3 kb and 4.1 kb). Since pSportTne has an N o AIV site near the fl intergenic region, the new NgoAIV site within the Tne DΝA polymerase produced the expected fragments. The plasmid was designated as pSportTneNgoAIV. For D137A (Kasϊ), 5 out of 6 clones produced two expected fragments of 1.1 kb and 6 kb in size. Since pSportTne has another Kasl site, the newly created Kas site generated these two expected fragments. The plasmid was designated as pSportTneKasI. Both D8A and D137A mutations were confirmed by DΝA sequencing. 4. Reconstruction of the Mutant Polymerase into Expression Vector During the course of expression of Tne DΝA polymerase or mutant 7we DΝA polymerase, a variety of clones were constructed. One such clone was designated as pTTQ Tne SeqSl. This plasmid was constructed as follows: first, similar to above mutagenesis technique glycine 195 was changed to an aspartic acid in pSportTne. A mutation in the corresponding amino acid in E. coli DΝA polymerasel (polA214, domain F) was found to have lost the 5 '-to-3' exonuclease activity (Gutman and Minton, see above). An Sspl site was created in the mutant polymerase. Second, a 650 bp Sstl-Sphϊ fragment containing the Gl 95D mutation was subcloned in pUCTne35FY (see infra) to replace the wild type fragment. This plasmid was called pUCTne3022. Finally, the entire mutant Tne DNA polymerase was subcloned from pUCTne3022 into pTTQ18 as Sstl-Hindlϊl fragment to generate pTTQTneSeqS 1. To introduce the mutation D8A or D 137A in this expression vector, the 650 bp Sstl-Sphl was replaced with the same Sstl- Sphl fragment from pSportTneNgoAIV or pSportTneKasI. The plasmids were designated as ρTTQTneNgo(D8A) and pTTQTneKas(D137A), respectively. 5. Confirmation of the Mutations by DNA Sequencing DNA sequencing of both mutant polymerases confirmed the presence of the restriction site NgoAIV as well as the mutation D8 A; and Kasl site as well as the mutation D 137 A. Aso confirmed by DΝA sequencing was the presence of the mutation D323A and theEco47LII restriction site in the 3'-to-5' exonuclease region. In addition, confirmed by DΝA sequencing was the F730Y mutation and the Hpal restriction site in the O-helix region ofthe mutant Tne DΝA polymerase. 6. 5*-to-3* exonuclease Activity of the Mutant Tne DΝA Polymerases The full length mutant DΝA polymerase was purified as described above The 5'-to-3' exonuclease activity was determined as described in the LTI catalog. Briefly, 1 pmol of labeled ( 32 P) Hαelll digested λ DΝA (LTI) was used for the assay. The buffer composition is: 25 mM Tris-HCl (pH 8.3), 5 mM MgCl 2 , 50 mM ΝaCl, 0.01% gelatin. The reaction was initiated by the addition of 0, 2, 4, 6 and 10 units of either wild type or mutant Tne DΝA polymerase in a 50 μl reaction. The reaction mix was incubated for 1 hr at 72°C A 10 μl aliquot was subjected to PEI-cellulose thin layer chromatography and the label released was quantitated by liquid scintillation. In this assay, both D8A and D137A mutants showed less than 0.01% label release compared to the wild type Tne DΝA polymerase. The result demonstrates that in both D8A and D137A mutants the 5'-to-3' exonuclease activity has been considerably diminished. Thus, it has been confirmed that these two aspartates are involved with the 5'-to-3' exonuclease activity. Example 14: Generation of double mutants, R722K/F730Y, R722Q/F730Y, R722H/F730Y and R722N/F730Y of Tne DNA polymerase For all mutations, the PCR method was used. A common 5'-oligo, CAC CAG ACG GGTACC GCC ACT GGC AGG TTG (SEQ LD NO:30), was used. This oligo contains a Kpnl site (shown above in bold italics). The template used for PCR was pTTQTneSeqS 1 (Example 13) which already contains the F730Y mutation in the Tne polymerase gene. For the R722K/F730 Y mutation, the oligo used was TAT AGA GTA GTT AAC CAT CTT TCC AAC CCG TTT CAT TTC TTC GAA CAC (SEQ LD NO:31). For the R722Q/F730Y mutation, the oligo used was TAT AGA GTA GTT AA C CAT CTT TCC AAC CCG TTG CAT TTC TTC GAA CAC (SEQ LD NO:32). For the R722N/F730Y mutation, the oligo used was TAT AGA GTA GTT AAC CAT CTT TCC AAC CCG GTT CAT TTC TTC GAA CAC (SEQ LD NO:33) and for the R722H/F730Y the oligo used was TAT AGA GTA GTT AAC CAT CTT TCC AAC CCG ATG CAT TTC TTC GAA CAC (SEQ LD NO:34). Each of these oligos contains a Hpal site (bold italics). The underlined codons were the mutated codons for arginine at the position 722 for respective amino acids. The PCR generated a 318 bp product containing a Kpnl and a Hpal site. The PCR products were digested with Kpnl and Hpal and cloned into pUC-TneFY digested with Kpnl and Hpal to replace the original fragment to generate pUC19TneFY-R722K, pUC19TneFY-R722Q, pUC19TneFY-R722H and pUC19TneFY-R722N. Finally, the Kpnl-Hindlll fragment (~800bp) of ρTTQTneKasI(D137A) was replaced by the -800 bp Kpnl- Hindlll fragment from these plasmids to generate pTnel l (R722K/F730Y), pTnelO (R722Q/F730Y), pTnel3 (R722H/F730Y) and pTne9 (R722N/F739Y), respectively. The mutations were confirmed by DNA sequencing. Example 15: Generation of Tne DNA Polymerase mutants F730A andF730S F730A was constructed using PCR. The forward oligo was AAG ATG GTT AAC GCG TCI ATA ATA TAC GG (SEQ LD NO:35) which contains a Hpal site and a Mlul site (bold italics). The reverse oligo was CAA GAG GCA CAG AGA GTT TCA CC (SEQ LD NO:36) which anneals downstream of Spel present in the Tne polymerase gene . The template used for PCR was pTTQTne Kasl (D137A). The 482bp PCR product was digested with Hpal and Spel and cloned into pUC-TneFY thereby replacing the amino acid tyrosine at position 730 with alanine. This construct was called pUC-Tne FA. F730S was constructed by site directed mutagenesis. The oligo was GTA TAT TAT AGA GGA GTT AAC CAT CTT TCC (SEQ LD NO:37) where aHpal site was created (bold italics). The single stranded DNA used was isolated from pSport-Tne that contains the double mutation D137A and D323 A. This construct was designated pTne 47. The Tne polymerase gene was then cloned as an SstI and Hindlll fragment into the plasmid pUC 19 and the resulting clone was designated pTnelOl. Example 16: Generation of Tne DNA polymerase with a Hpal site in front of the amino acid phenylalanine at position 730. A construct of Tne polymerase was made using PCR where a Hpal restriction enzyme site was introduced into the gene in front of the amino acid phenylalanine at position 730. The forward oligonucleotide was AAG ATG GTT AACTTC TCT ATA ATA TAC GG (SEQ ID NO:38) which contains aHpal site (shown above in bold italics) and the reverse oligo was the same as in Example 15 above. The template used for PCR was pTne33 which contains the Tne polymerase gene with D137A and D323A mutations cloned in pUC19. The 482bp PCR product was digested with Hpal and Spel and was used to replace the corresponding fragment in pTnelOl (see example 15). The construct was sequenced to verify that the amino acid at position 730 was indeed phenylalanine and the plasmid was numbered pTnelOό. Examplel7: Generationof double mutants R722Y/F730A and R722L/F730A ofthe Tne DNA polymerase. For both the mutations PCR method was used. The common 5' oligo was the same as in Example 14. For R722Y/F730A mutation the oligo used was TAT AGA GTA GTT AAC CAT CTT TCC AAC CCG GTA CAT GTC TTC GTT CAC (SEQ LD NO:39). For R722L/F730A mutation the oligo used was TAT AGA GTA GTT AAC CAT CTT TCC AAC CCG CAA CAT GT C TTC GTT CAC (SEQ LD NO:40). Each of these oligos contain a Hpal site (shown above in bold italics). The underlined codons were the mutated codons for arginine at the position 722 for respective amino acids. An Aflϊϊl site was also created (shown above in bold italics next to the underlined codon) in order to confirm the mutation. The PCR generated a 318 bp product containing a Kpnl and a Hpal site. The PCR products were digested with Kpnl and Hpal and cloned into pUC- TneFA (see example 15). The constructs were named as pUCTneYA and pUCTneLA. Example 18: Generation of Tne DNA Polymerase mutants R722Y andR722L. The plasmid pTne 106 (see example 16) was digested with Hpal and Kpnl and the 318 bp fragment was replaced with the corresponding fragment from pUCTneYA or pUCTneLA (see Example 17) to generate the mutants R722Y or R722L. In these constructs the amino acid at position 730 is the same as wild type Tne (phenylalanine). The constructs were sequenced to confirm the R722Y and the R722L mutations. The Tne DNA polymerase gene was then cloned as a Sstl/H/ ' wdlll fragment into the plasmid p Sport 1. Example 19: Generation of Tne DNA Polymerase mutants R722K, R722Q andR722H. The construct pTne 106 (see example 16) was digested with Hpal and Kpnl and the 318 bp fragment was replaced with the corresponding fragment from the construct pUC19TneFY-R722K, pUC19TneFY-R722H or pTnelO (see Example 14), to generate the mutants R722K, R722H and R722Q. The constructs were sequenced to confirm the mutations. The Tne DNA polymerase gene was then subcloned into the vector pSportl as a SstVHindlϊl fragment. xExample 20: Purification ofthe mutant Tne DNA Polymerases The purification ofthe mutants of Tne DNA polymerase was carried out based on the method described above with minor modifications. Two to three grams of cells expressing cloned mutant Tne DNA polymerase were resuspended in 15-20 ml of sonication buffer (50 mM Tris-HCl , pH 8.0, 10% glycerol, 5mM 2-mercaptoethanol, 50 mM NaCl, 1 mM EDTA and 0.5 mM PMSF and sonicated with a 550 Sonic Dismembrator (Fisher Scientific). The sonicated sample was heated at 82°C for 20 min and then cooled in ice-water for 5 min. In the sample, 20 mM NaCl and 0.2% PEI were added and centrifuged at 13,000 rmp for 10 min. Ammonium sulfate (305g/L) was added to the supernatant. The pellet was collected by centrifugation and resuspended in 4 ml of MonoQ column buffer (50 mM Tris-HCl, pH 8.0, 10% glycerol, 5 mM 2-mercapto ethanol, 50mM NaCl, and 1 mM EDTA). The sample was dialyzed against one litter of MonoQ buffer overnight. Following the centrifugation at 13,000 rpm to remove any insoluble materials, the sample was loaded onto a MonoQ column (HR5/5, Pharmacia). The column was washed with MonoQ column buffer to baseline of OD 2g0 and then eluted with a linear gradient of 50-300 mM NaCl in 20 ml MonoQ column buffer. The fractions were analyzed by 8% SDS-PAGE and the 7>2e DNA polymerase activity determined as described earlier. The fractions containing active and pure Tne DNA polymerase were pooled. Example 21: Generation of Taq DNA Polymerase Mutants R659K, R659H andR659Y A 2.5 kb portion ofthe gene encoding Taq DNA polymerase (Figure 5) was cloned as a Hind M-Xba I fragment into M13mpl9. Site directed mutagenesis was performed using the BioRad mutagene kit (BioRad California) using the following oligonucleotides: CTTGGCCGCCCG 4rGCATCAGGGGGTC (SEQ LD NO:41) for the R659H mutation where an Nsil site was created (see bold italics); CTTGGCCGCCCGCTrC4ra4GGGGGTCCAC (SEQ LD NO:42) for the R659K mutation where a BspHl site was created (see bold italics); and CTTGGCCGCCC7G7 C4TCAGGGGGTC (SEQ LD NO:43) for the R659Y mutation where a BsrGl site was created (see bold italics). For each mutation, six clones were screened by analyzing the M13RF DNA for the expected restriction sites. Mutations were confirmed by DNA sequencing. DNA shown to contain the mutation by the presence ofthe expected restriction site was digested with Ngo AIV and Xba I and the approximately 1600 base pair fragment was used to replace corresponding fragment in the wildtype Taq DNA polymerase gene. These constructs were made in a plasmid containing Taq polymerase gene under the control of Tac promoter (pTTQ Taq) to generate pTTQ Taq (R659K), pTTQ Taq (R659H) and pTTQ Taq (R659Y). These plasmids were transformed into E. coli DH10B (LTI). Example 22: Construction of Tne polymerase mutants containing F730S and F730T Single stranded DNA was isolated from pSportTne (Tne35) containing D137A and D323 A mutations as described in the section 2 of example 13. These D 137 and D323 A mutations rendered Tne DNA polymerase devoid of 5 '-exonuclease and 3'-to-5'-exonuclease activities, respectively. Thus, Tne 35 is devoid of both exonuclease activities. The site-directed mutagenesis was done following the protocol decribed in section 3 of Example 13. The oligos used were 5' GTA TAT TAT AGA GGA GTT AAC CAT CTT TCC 3' (SEQ D NO:37) for F730S and 5' GTA TAT TAT AGA GGT GTT AAC CAT CTT TCC 3' (SEQ LD NO:44) for F730T. Each of these two oligos contain a diagonistic Hpal site for screening of mutants in the MutS strain. The mutant plasmids were transferred to DH10B strains. The mutations were finally confirmed by DNA sequencing. The mutant polymerases were purified by the procedure as described in Example 20. Example 23: Determination of the Activity of Non-templated One Base Addition for Tne and Taq DNA Polymerase by Primer Extension Assay The following 34-mer primer was 32 P labeled at the 5' end with [γ- 32 P] ATP and T4 polynucleotide kinase by standard protocol (Molecular Cloning, A Laboratory Manual, Cold Spring Harbor, NY): 5'-GGGAGACCGGAATTCTCCTTCATTAATTCCTATA-3' (SEQ LDNO:45) The unincorporated ATP was removed by a BioRad P6 column(1.0 ml). The labeled primer was annealed to the following homogenous (purified) 48-mer template: 5'-TGGAGACCCTGGAACTATAGGAATTAATGAAGGAGAATTCCGGT CTCCC-3' (SEQ LD NO:46). Wildtype or mutant DNA polymerases (0.125-1.0 unit) were incubated at 72° C for 2 min in 20 mM Tris-HCl (pH8.3), 1.5 mM MgCl 2 , 50 mM KC1, 1.0 mM DTT, 200 uM of dCTP, dGTP, TTP, dATP, and 0.02 pmol ofthe annealed primer-template. After addition of sequencing stop buffer and heated at 90°C for 2 min, the mixture was loaded onto 10% polyacrylamide-7 M urea. Following the electrophoresis, the gel was dried and the reaction products were analyzed by autoradiography. The non-templated one base addition products shown in Figure 6 were quantified by a Phosphorlmager (Molecular Dynamics). Tne DNA polymerases % of N+l 1 D137A 18.5 2 D137A D323A 78.5 3 D137A D323A R722K 0.7 4 D137A D323A R722Y 0.7 5 D137A D323A R722L 5.7 6 D137A D323A R722H 1.2 7 D137A D323A R722Q 1.4 8 D137A D323A F730Y 61.3 9 D137A D323A R722 K F730Y 6.8 10 D137A D323A R722H F730Y 2.1 11 D137A D323A R722Q F730Y 6.1 12 D137A D323A R722N F730Y 15.9 13 D137A D323A F730S 8.3 14 D137A D323A F730T 24.2 Taq DNA Polymerases % of N+l 1 W.T. 37 2 R659K 1.4 3 R659Y 0.9 4 R659H 0.5 5 F667Y 39.1 Example 24: Comparison of DNA Synthesis by Taq and Tne To examine its propensity to add a nontemplated nucleotides to the 3' termini of PCR products, Tne DNA polymerase (5 'exo " , 3 'exo " ) was compared side-by-side with Taq DNA polymerase in amplifications of short tandem repeats at 23 different marker loci (see Table 1). Reactions comprising 20 mM TRIS- HC1, pH 8.4, 50 mM KC1, 1.5 mM MgCl 2 , 200 mM each dNTP, 200 nM [ 32 P] c -dATP, 200 nM each of the upper and lower primers, 25 ng of human DNA 0.1%) nonionic detergent and 1 unit of DNA polymerase (in a volume of 25 ml) were assembled on ice. Published sequences for upper and lower primers for each locus, as shown in Table 1, were used for all amplifications. Reactions were loaded into a Perkin Elmer model 9600 thermocycler preheated to 94°C and PCR was done using standard cycling conditions ( 1 minute pre-denaturation at 94°C; 30 cycles of 30 seconds at 94°C, 30 seconds at 55°C, and 1 minute at 72°C; 1 minute post-extension at 72°C; overnight soak at 4°C). A portion of each reaction was mixed with an equal volume of 95% formamide containing dyes to indicate the progress of electrophoresis. Samples were heated to 90°C for 2 min, and 5 ml of each was loaded on a 6% denaturing polyacrylamide gel. Sequencing ladders were loaded to provide size markers, and electrophoresis was performed at 70 watts. After electrophoresis the gel was transferred to filter paper and dried. Autoradiography and phosphoimage analysis was performed to visualize the PCR products and estimate the percentage of product which contained the added nucleotide by direct comparison of bands produced by each enzyme. Examples of the side-by-side comparisons of amplification products produced by Taq DNA polymerase and Tne DNA polymerase are shown in Figure 7 for the CD4 locus and in Figure 8 for the D20S27 locus. At both of these loci, a significant portion ofthe Taq PCR product contained an extra nontemplated nucleotide (n+1), while Tne polymerase demonstrated no apparent nontemplated nucleotide incorporation for either the CD4 locus (Figure 7) or the D20S27 locus (Figure 8). Complete results for the 23 marker loci examined are summarized in Table 2. In PCRs using Taq DNA polymerase, a portion ofthe amplification product contained an extra non-templated nucleotide (n+1) at every locus examined. In PCRs using Tne DNA polymerase, however, no detectable portion ofthe product at any ofthe loci examined contained an additional nontemplated nucleotide. These results indicate that Tne DNA polymerase, in contrast to Taq DNA polymerase, is substantially reduced in the ability to add a nontemplated 3' terminal nucleotide to the growing strand. Since the Tne DNA polymerase used in these amplifications was a 3'exo- mutant (t.e., it was substantially reduced in 3' exonuclease activity), these results are consistent with the notion that the Tne polymerase was unable to add the extra nucleotide to the product rather than adding the nucleotide and then removing it via a 3' exonuclease activity. Table 1. Primers Used in Example 24. Table 2. Non-templated 3* Terminal Nucleotide Addition by Taq and Tne DNA Polymerases at 23 Microsatellite DNA Loci. Example 25: Comparison of DNA Synthesis by Tne and Other Thermostable Enzymes To further evaluate the differences in the propensities of Tne and other thermostable DNA polymerases to add non-templated 3' terminal nucleotides to PCR products, side-by-side amplifications were performed using a single marker locus D1S103 and a variety of thermostable enzymes, including 3' exonuclease deficient (3'exo-) enzymes, and 3' exonuclease competent (3'exo+) enzymes. PCR amplifications, electrophoresis and analysis were performed as described for Example 24, using 200 nM of D1S 103 -specific upper and lower primers. Results for the amplifications using 3 'exo- DNA polymerases are shown in Table 3. With the exception of 7we(3'exo-), all ofthe 3'exo- DNA polymerases examined exhibited a propensity to add a non-templated 3' terminal nucleotide (n+1) to the PCR product. For Taq and Tbr DNA polymerases, up to 100% of the PCR products contained an additional non-templated 3' terminal nucleotide, while Vent, Deep Vent, and Dtok 3 'exo- mutants polymerases added this nontemplated nucleotide to 25-100% of the PCR products. In contrast, the 3'exo- mutant of Tne DNA polymerase was substantially reduced in the ability to add a nontemplated 3' terminal nucleotide to the DNA molecule; none of the PCR products from reactions using Tne(3'exo-) had an additional non-templated nucleotide at their 3' termini. Results from amplifications using 3'exo+ DNA polymerases are shown in Table 4. Five polymerases were examined as well as two commercially available enzyme mixes (mixtures of a primary 3 'exo- polymerase and a secondary 3'exo+ polymerase). At this locus, the 3'exo+ DNA polymerases (Tne, Tma, Pfu, Pwo and 9°North) yielded product which did not contain an extra non-templated nucleotide. The enzyme mixtures (Elongase and Expand HiFi) yielded a mixture of products with and without an additional non-templated nucleotide. Together, these results indicate that Tne polymerases, whether 3 'exo- or 3'exo+, are substantially reduced in the ability to add a nontemplated 3' terminal nucleotide to the DNA molecule. Moreover, of the preferred 3'exo- polymerases, only 7we(3'exo-) was substantially reduced in this activity, indicating its favorableness in PCR applications where non-templated nucleotide addition to the amplification product is undesirable. Table 3. Non-templated 3' Terminal Nucleotide Addition by 3'exo- DNA Polymerases. Table 4. Non-templated 3' Terminal Nucleotide Addition by 3'exo+ DNA Polymerases. xExample 26: Comparison of DNA Synthesis by Tne Mutants To examine the utility of Tne DNA polymerase and various mutants thereof in amplification of microsatellite DNA sequences, the experiments described in Example 25 were repeated with 11 different Tne DNA polymerase mutants. Of these mutants, 3 were 5'exo+, while the remainder were 5'exo- either due to N-terminal deletions of the protein, or to point mutations in the 5' exonuclease domain ofthe polymerase. As shown in Table 5, use ofthe 5 'exo- Tne mutants resulted in productive amplifications, yielding PCR products with no non-templated 3' terminal nucleotide additions. Results were identical for all seven J«e(3'exo-/5'exo-) polymerase mutants, as well as for the single 7«e(3'exo+/5 , exo-) mutant tested. Results with 5'exo+ Tne mutants were inconclusive under the conditions tested. These results indicate that the mutants of Tne DNA polymerase tested in the present studies are substantially reduced in the ability to add nontemplated 3' terminal nucleotides to the growing strand, particularly a DNA template comprising a microsatellite DNA sequence or an STR. Table 5. Non-templated 3' Terminal Nucleotide Addition by Tne DNA Polymerase Mutants Example 27: Fluorescent Analysis of DNA Synthesis by Tne and Taq DNA Polymerases In an alternative analysis approach, the propensities of Taq DNA polymerase and Tne DNA polymerase to add non-templated nucleotides to the PCR products were compared using fluorescent detection. The polymerases were compared in side-by-side amplifications utilizing a commonly used commercially available marker panel (ABI Prism Linkage Mapping Set Panel 21 ), examining ten different loci. Reaction mixtures (15 ml) containing 1.5 mM MgCl 2 , 250 mM of each deoxynucleoside triphosphate, 333 nM of each primer, 50 ng of human DNA and 0.6 units of Taq or Tne DNA polymerase were assembled on ice. Reactions were loaded into aPerkin Elmer model 9600 thermocycler preheated to 95°C, and PCR was performed using recommended cycling conditions (5 minutes pre- denaturation at 95°C; 10 cycles of 15 seconds at 95°C, 15 seconds at 55°C, and 60 seconds at 72°C; and 20 cycles of 15 seconds at 89°C, 15 seconds at 55°C, and 60 seconds at 72°C). Two sets of extension reactions were conducted for each locus, one with a 10 minute post-extension incubation at 72°C followed by an overnight soak and storage at 4°C (conditions which favor nontemplated 3' nucleotide addition), the other with no post-extension incubation followed by immediate storage at -20°C (conditions which inhibit nontemplated 3' nucleotide addition). A portion of each reaction was diluted, mixed with loading cocktail, heat denatured and loaded on an 8% polyacrylamide sequencing gel. The ABI 373 Stretch Automated Sequencer was run for 5-6 hours at 15W in order to obtain single base resolution, and data were analyzed using GeneScan software. Areas of the peaks recognized by the software were used to estimate the percentage of nontemplated 3' nucleotide addition ("n+1 ") for each locus by the two polymerases under the two different extension conditions. The total area under the allelic peaks was used to compare the yields of specific PCR product obtained in Tne and Taq amplifications, and yields produced by Tne polymerase were expressed for each locus as a percentage of those produced by Taq polymerase. Table 6 summarizes the results obtained. Table 6. Comparison of DNA Amplification by Taq and Tne DNA Polymerases by Fluorescent Detection The results shown in Table 6 confirm that under conditions favoring ("10' final ext") or inhibiting ("no final ext") 3' nontemplated nucleotide addition, Tne DNA polymerase produced PCR products that were 95-100% free from nontemplated nucleotide addition ("n") for each locus examined. Taq DNA polymerase, however, demonstrated significant addition of nontemplated nucleotides under inhibiting conditions in most loci tested, while under permissive conditions well over half, and in some cases all, ofthe PCR product produced by Taq DNA polymerase demonstrated an additional nontemplated 3' nucleotide. Furthermore, under most conditions the amount of PCR product yielded by Tne DNA polymerase was at least as high as that of Taq DNA polymerase, and for some loci was 3- to 4-fold higher. Figure 9 shows two examples of electropherogram gel scans, aligned by PCR product size, comparing the PCR products obtained with Taq and Tne polymerases with a 10-minute final extension. For the D15S153 locus, Taq exhibited non-templated nucleotide addition to 40% ofthe PCR product (Figure 39), while Tne exhibited no such addition of non-templated nucleotides (Figure 9B). Similar results were obtained with the D15S127 locus: 53% ofthe TaqVCR products demonstrated non-templated nucleotide addition (Figure 9C), while none ofthe Tne PCR products demonstrated non-templated nucleotide addition (Figure 9D). These results demonstrate the difficulty in identifying alleles in a heterogeneous pattern as generated by Taq amplification, compared to the more homogeneous, simple pattern generated by amplification with Tne. Together with Examples 24-26, these results indicate that Tne DNA polymerase and the mutants thereof tested in the present studies are substantially reduced in the ability to add a nontemplated 3' terminal nucleotide to DNA templates, particularly DNA templates comprising microsatellite DNA sequences or STRs. Conversely, Taq DNA polymerase demonstrates significant addition of nontemplated 3' nucleotides to PCR products. xExample 28: Comparison of Taq and Tne To examine the ability of a truncated form of Tne DNA polymerase (NA283, 5'exo-, 10% 3'exo activity) to add a nucleotide to the end ofthe PCR product, the enzyme was compared side-by-side with wild type Taq DNA polymerase in amplifications of short tandem repeats at 5 different marker loci. A portion of ABI Prism Linkage Mapping Set Panel 21 was used for the primer sets for the loci. 15 ul reactions (20 mM Tris-HCl, pH 8.4, 50 mM KC1, 1.5 mM MgCl 2 , 200 uM each dNTP, 333 nM each primer, 60 ng human DNA, 0.1% nonionic detergent, 0.6 U DNA polymerase) were assembled on ice. Reactions were loaded into a Perkin Elmer model 9600 thermocycler preheated to 95 °C and PCR was done using recommended cycling conditions (5 min. pre-denaturation at 95°C; 10 cycles of 15 sec at 95°C, 15 sec at 55 °C, and 60 sec at 72 °C; 20 cycles of 15 sec at 89 °C, 15 sec at 55 °C, and 60 sec at 72°C; lOmin final extension at 72°C). A portion of each reaction was diluted, mixed with loading cocktail, heat denatured and loaded on a 8% sequencing gel. The ABI 373 Stretch Automated Sequencer was run for 5-6hr at 15W in order to obtain lbase resolution. Data was analyzed using GeneScan software. Areas of the peaks recognized by the software were used to estimate the percent of extranucleotide addition. Table 7 summarizes the results obtained. Examples of the electropherogram data is shown in Figure 10. Table 7: Percent extranucleotide addition exhibited by Taq and Tne DNA polymerases at specific loci. Locus Taq(% n +1) Tne< ;% n+l) D16S405 46 0 D16S401 100 45 D16S520 63 0 D15S131 51 0 D16S411 53 0 xExample 29: Comparison of Tne Mutants In order to evaluate the effect of amino acid substitutions in Tne DNA polymerase in regard to extra nucleotide addition, different mutations at position F730 in the untruncated polymerase were compared in side-by-side amplifications with Taq( ύd type) and a truncated J«e(N'Δ219, D323A F730Y) utilizing a portion of ABI Prism Linkage Mapping Set Panel 21. Six loci were examined. 15 ul reactions (20 mM Tris-HCl, pH 8.4, 50 mM KC1, 1.5 mM MgCl 2 , 200 uM each dNTP, 333 nM each primer, 50-60 ng human DNA 0.1% nonionic detergent, 0.15-0.6 U DNA polymerase) were assembled on ice. Reactions were loaded into a Perkin Elmer model 9600 thermocycler preheated to 95 °C and PCR was done using recommended cycling conditions (5 min. pre-denaturation at 95°C; 10 cycles of 15 sec at 95°C, 15 sec at 55 °C, and 60 sec at 72 °C; 20 cycles of 15 sec at 89 °C, 15 sec at 55 °C, and 60 sec at 72°C; lOmin final extension at 72°C). A portion of each reaction was diluted, mixed with loading cocktail, heat denatured and loaded on a 8% sequencing gel. The ABI 373 Stretch Automated Sequencer was run for 5-6hr at 15W in order to obtain lbase resolution. Data was analyzed using GeneScan software. Areas of the peaks recognized by the software were used to estimate the percent of extranucleotide addition. Table 8 summarizes the results obtained. An example ofthe electropherogram data is shown in Figure 11. Table 8: Percent extranucleotide addition exhibited by mutant Tne DNA polymerases at specific loci mutant: locus: D16S405 D16S401 D15S131 D15S127 D16S511 D15S Taq (wild type) 46% 100% 51% 100% 100% 100% Tne-1 ι (NΔ219, D323 F730Y) 0% 0% 0% 0% 0% 0% Tne-35 (D137A, D323A) 0% 52% 0% 0% 0% 0% Tne- 18 (D137A D323A F730Y) 0% 2% 0% 0% 0% 0% Tne- 13 (D137A D323A R722FL 0% 0% 0% 0% 0% 0% F730Y) Tne- 14 (D137A, D323A F730A) nd 0% 0% nd nd nd Tne-47 (D137 D323A, F730S) 0% 0% 0% 0% 0% 0% Tne-48 (D137A D323A F730T) 0% 0% 0% 0% 0% 0% Example 30: Comparison of Tne and Taq Mutants In order to evaluate the effect of amino acid substitution at position F667 in Taq DNA polymerase(equivalent to F730 in Tne DNA polymerase) in regard to extra nucleotide addition, a commercially available mutant of Taq DNA polymerase (Taq FS) (N'Δ3, G46D, F667Y) was compared in side-by-side amplifications with Taq DNA polymerase(wild type) and Tne-1 DNA polymerase(N'Δ219, D323A F730Y). Three loci were examined (a portion of ABI Prism Linkage Mapping Set Panel 21). 15 ul reactions (20 mM Tris-HCl, pH 8.4, 50 mM KC1, 1.5 mM MgCl 2 , 200 uM each dNTP, 333 nM each primer, 60 ng human DNA 0.1% nonionic detergent, 0.6 U DNA polymerase) were assembled on ice. Reactions were loaded into a Perkin Elmer model 9600 thermocycler preheated to 95 °C and PCR was done using recommended cycling conditions (5 min. pre-denaturation at 95°C; 10 cycles of 15 sec at 95 °C, 15 sec at 55 °C, and 60 sec at 72 °C; 20 cycles of 15 sec at 89 °C, 15 sec at 55 °C, and 60 sec at 72 °C; lOmin final extension at 72 °C). A portion of each reaction was diluted, mixed with loading cocktail, heat denatured and loaded on a 8% sequencing gel. The ABI 373 Stretch Automated Sequencer was run for 5-6hr at 15W in order to obtain lbase resolution. Data was analyzed using GeneScan software. Areas of the peaks recognized by the software were used to estimate the percent of extranucleotide addition. Table 9 summarizes the results obtained. Examples of the electropherogram data are shown in Figure 12. Table 9: Percent extranucleotide addition exhibited by Taq and Tne DNA polymerases at specific loci. xExample 31: Comparison of Tne Mutants In order to evaluate the effect of amino acid substitutions at position R722 in Tne DNA polymerase in regard to extranucleotide addition, different mutations in the polymerase were compared in side-by-side amplifications utilizing a portion of ABI Prism Linkage Mapping Set Panel 21. Six loci were examined. 15 ul reactions (20 mM Tris-HCl, pH 8.4, 50 mM KCl, 1.5 mM MgCl 2 , 200 uM each dNTP, 333 nM each primer, 50-60 ng human D 0- 1% nonionic detergent, 0.2- 0.6 U DNA polymerase) were assembled on ice. Reactions were loaded into a Perkin Elmer model 9600 thermocycler preheated to 95 °C and PCR was done using recommended cycling conditions (5 min. pre-denaturation at 95°C; 10 cycles of 15 sec at 95 °C, 15 sec at 55 °C, and 60 sec at 72 °C; 20 cycles of 15 sec at 89 °C, 15 sec at 55 °C, and 60 sec at 72 °C; lOmin final extension at 72 °C). A portion of each reaction was diluted, mixed with loading cocktail, heat denatured and loaded on a 8% sequencing gel. The ABI 373 Stretch Automated Sequencer was run for 5-6hr at 15W in order to obtain lbase resolution. Data was analyzed using GeneScan software. Heights of the n and n+1 peaks recognized by the software were used to estimate the percent of extranucleotide addition. Table 10 summarizes the results obtained. An example ofthe electropherogram data is shown in Figure 13. Table 10: Percent extranucleotide addition exhibited by mutant Tne DNA polymerases at specific loci. mutant: locus: D16S405 D16S401 D15S131 D15S127 D16S511 D15S153 Tne-35 (D137A D323A) 0% 54% 0% 0% 0% 0% Tne- 109 (D137A D323A R722Y) 0% 0% 0% 0% 0% 0% Tne-l lO (D137A D323A, R722L) 0% 0% 0% 0% 0% 0% Tne-114 (D137A D323 A R722K) 0% 0% 0% 0% 0% 0% Tne- 115 (D 137 A, D323 A, R722Q) 0% 0% 0% 0% 0% 0% Tne-116 (D137A, D323A R722H) 0% 0% 0% 0% 0% 0% Example 32: Generation of Tne DNA Polymerase Mutant K726R The mutation of the Tne polymerase was done by essentially the same procedure as described above in Example 13. The single-stranded DNA was isolated from pSport-Tne containing D137A and D323A mutations. The oligonucleotide used for the mutagenesis was 5'-GAA GTT CAC CAT CCG GCC GAC CCG TCG CAT TTC 3' (SEQ LD NO:93). An XmalU. site (bold italics in the above sequence) was introduced into the oligonucleotide for easy screening ofthe mutants. The mutation was confirmed by DNA sequencing. The clone was named pTnel29 (D137A D323A K726R). Example 33: Determination of the Activity of Non-templated One Base Addition for Tne DNA Polymerase and its Mutant D137A, D323A, K726R, by Primer Extension Assay The mutant Tne DNA polymerase (Tne D137A, D323A K726R) prepared in Example 32 was purified as described in Example 20. The assay for non-templated one base addition was conducted as described in Example 23. The results were as follows: Tne DNA Polymerase % of Product With N+l D137A D323A 78.4 D137A D323A R722H 1.7 D137A, D323A K726R 0.9 These results demonstrate that mutation ofthe lysine residue at position 726 of Tne, particularly to arginine, substantially reduces the activity of the polymerase in adding non-templated bases. Having now fully described the present invention in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious to one of ordinary skill in the art that the same can be performed by modifying or changing the invention within a wide and equivalent range of conditions, formulations and other parameters without affecting the scope ofthe invention or any specific embodiment thereof, and that such modifications or changes are intended to be encompassed within the scope ofthe appended claims. Al publications, patents and patent applications mentioned in this specification are indicative ofthe level of skill of those skilled in the art to which this invention pertains, and are herein incorporated by reference to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: Life Technologies, Inc. (B) STREET: 9800 Medical Center Drive (C) CITY: Rockville (D) STATE: Maryland (E) COUNTRY: USA (F) POSTAL CODE (ZIP) : 20850 (ii) TITLE OF INVENTION: Polymerases for Analyzing or Typing Polymorphic Nucleic Acid Fragments and Uses Thereof (iii) NUMBER OF SEQUENCES: 93 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0, Version #1.30 (EPO) (v) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (To be assigned) (B) FILING DATE: (Herewith) (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US (To be assigned) (B) FILING DATE: OG-JAN-1998 (vi) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 60/037,393 (B) FILING DATE: 07-FEB-1997 (2) INFORMATION FOR SEQ ID NO:l: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2682 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : both (D) TOPOLOGY: both (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:l: ATGGCGAGAC TATTTCTCTT TGATGGCACA GCCCTGGCCT ACAGGGCATA TTACGCCCTC 60 GACAGATCCC TTTCCACATC CACAGGAATT CCAACGAACG CCGTCTATGG CGTTGCCAGG 120 ATGCTCGTTA AATTCATTAA GGAACACATT ATACCCGAAA AGGACTACGC GGCTGTGGCC 180 TTCGACAAGA AGGCAGCGAC GTTCAGACAC AAACTGCTCG TAAGCGACAA GGCGCAAAGG 240 CCAAAGACTC CGGCTCTTCT AGTTCAGCAG CTACCTTACA TCAAGCGGCT GATAGAAGCT 300 CTTGGTTTCA AAGTGCTGGA GCTGGAGGGA TACGAAGCAG ACGATATCAT CGCCACGCTT 360 GCAGTCAGGG CTGCACGTTT TTTGATGAGA TTTTCATTAA TAACCGGTGA CAAGGATATG 420 CTTCAACTTG TAAACGAGAA GATAAAGGTC TGGAGAATCG TCAAGGGGAT ATCGGATCTT 480 GAGCTTTACG ATTCGAAAAA GGTGAAAGAA AGATACGGTG TGGAACCACA TCAGATACCG 540 GATCTTCTAG CACTGACGGG AGACGACATA GACAACATTC CCGGTGTAAC GGGAATAGGT 600 GAAAAGACCG CTGTACAGCT TCTCGGCAAG TATAGAAATC TTGAATACAT TCTGGAGCAT 660 GCCCGTGAAC TCCCCCAGAG AGTGAGAAAG GCTCTCTTGA GAGACAGGGA AGTTGCCATC 720 CTCAGTAAAA AACTTGCAAC TCTGGTGACG AACGCACCTG TTGAAGTGGA CTGGGAAGAG 780 ATGAAATACA GAGGATACGA CAAGAGAAAA CTACTTCCGA TATTGAAAGA ACTGGAGTTT 840 GCTTCCATCA TGAAGGAACT TCAACTGTAC GAAGAAGCAG AACCCACCGG ATACGAAATC 900 GTGAAGGATC ATAAGACCTT CGAAGATCTC ATCGAAAAGC TGAAGGAGGT TCCATCTTTT 960 GCCCTGGACC TTGAAACGTC CTCCCTTGAC CCGTTCAACT GTGAGATAGT CGGCATCTCC 1020 GTGTCGTTCA AACCGAAAAC AGCTTATTAC ATTCCACTTC ATCACAGAAA CGCCCAGAAT 1080 CTTGATGAAA CACTGGTGCT GTCGAAGTTG AAAGAGATCC TCGAAGACCC GTCTTCGAAG 1140 ATTGTGGGTC AGAACCTGAA GTACGACTAC AAGGTTCTTA TGGTAAAGGG TATATCGCCA 1200 GTTTATCCGC ATTTTGACAC GATGATAGCT GCATATTTGC TGGAGCCAAA CGAGAAAAAA 1260 TTCAATCTCG AAGATCTGTC TTTGAAATTT CTCGGATACA AAATGACGTC TTATCAGGAA 1320 CTGATGTCGT TTTCCTCACC ACTTTTTGGT TTCAGCTTTG CGGATGTTCC GGTAGACAAG 1380 GCTGCGAACT ACTCCTGCGA GGATGCAGAC ATCACTTATA GGCTCTACAA GATACTCAGC 1440 ATGAAGCTCC ATGAAGCGGA ACTTGAGAAC GTCTTCTACA GGATAGAGAT GCCGTTGGTG 1500 AACGTTCTTG CACGCATGGA ATTGAACGGG GTGTATGTGG ACACAGAATT CCTGAAAAAG 1560 CTCTCGGAGG AGTACGGCAA AAAGCTCGAG GAACTGGCCG AAAAAATCTA CCAGATAGCA 1620 GGTGAGCCCT TCAACATCAA TTCTCCAAAA CAGGTTTCAA AGATCCTTTT TGAGAAGCTG 1680 GGAATAAAAC CCCGTGGAAA AACGACAAAA ACAGGAGAGT ACTCTACCAG GATAGAGGTG 1740 TTGGAAGAGA TAGCGAATGA GCACGAGATA GTACCCCTCA TTCTCGAGTA CAGAAAGATC 1800 CAGAAACTGA AATCGACCTA CATAGACACC CTTCCGAAAC TTGTGAACCC GAAAACCGGA 1860 AGAATTCATG CATCTTTCCA CCAGACGGGT ACCGCCACTG GCAGGTTGAG TAGCAGTGAT 1920 CCAAATCTTC AGAATCTTCC GACAAAGAGC GAAGAGGGAA AAGAAATTAG AAAAGCGATT 1980 GTGCCCCAGG ATCCAGACTG GTGGATCGTC AGTGCGGATT ATTCCCAAAT AGAACTCAGA 2040 ATCCTCGCTC ATCTCAGTGG TGATGAGAAC CTTGTGAAGG CCTTCGAGGA GGGCATCGAT 2100 GTGCACACCT TGACTGCCTC CAGGATCTAC AACGTAAAGC CAGAAGAAGT GAACGAAGAA 2160 ATGCGACGGG TTGGAAAGAT GGTGAACTTC TCTATAATAT ACGGTGTCAC ACCGTACGGT 2220 CTTTCTGTGA GACTTGGAAT ACCGGTTAAA GAAGCAGAAA AGATGATTAT CAGCTATTTC 2280 ACACTGTATC CAAAGGTGCG AAGCTACATC CAGCAGGTTG TTGCAGAGGC AAAAGAGAAG 2340 GGCTACGTCA GGACTCTCTT TGGAAGAAAA AGAGATATTC CCCAGCTCAT GGCAAGGGAC 2400 AAGAACACCC AGTCCGAAGG CGAAAGAATC GCAATAAACA CCCCCATTCA GGGAACGGCG 2460 GCAGATATAA TAAAATTGGC TATGATAGAT ATAGACGAGG AGCTGAGAAA AAGAAACATG 2520 AAATCCAGAA TGATCATTCA GGTTCATGAC GAACTGGTCT TCGAGGTTCC CGATGAGGAA 2580 AAAGAAGAAC TAGTTGATCT GGTGAAGAAC AAAATGACAA ATGTGGTGAA ACTCTCTGTG 2640 CCTCTTGAGG TTGACATAAG CATCGGAAAA AGCTGGTCTT GA 2682 (2) INFORMATION FOR SEQ ID NO:2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 893 amino acids (B) TYPE: amino acid (C) STRANDEDNESS : not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2: Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala 1 5 10 15 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly lie Pro Thr 20 25 30 Asn Ala Val Tyr Gly Val Ala Arg Met Leu Val Lys Phe lie Lys Glu 35 40 45 His lie lie Pro Glu Lys Asp Tyr Ala Ala Val Ala Phe Asp Lys Lys 50 55 60 Ala Ala Thr Phe Arg His Lys Leu Leu Val Ser Asp Lys Ala Gin Arg 65 70 75 80 Pro Lys Thr Pro Ala Leu Leu Val Gin Gin Leu Pro Tyr lie Lys Arg 85 90 95 Leu lie Glu Ala Leu Gly Phe Lys Val Leu Glu Leu Glu Gly Tyr Glu 100 105 110 Ala Asp Asp lie lie Ala Thr Leu Ala Val Arg Ala Ala Arg Phe Leu 115 120 125 Met Arg Phe Ser Leu lie Thr Gly Asp Lys Asp Met Leu Gin Leu Val 130 135 140 Asn Glu Lys lie Lys Val Trp Arg lie Val Lys Gly lie Ser Asp Leu 145 150 155 160 Glu Leu Tyr Asp Ser Lys Lys Val Lys Glu Arg Tyr Gly Val Glu Pro 165 170 175 His Gin lie Pro Asp Leu Leu Ala Leu Thr Gly Asp Asp lie Asp Asn 180 185 190 lie Pro Gly Val Thr Gly lie Gly Glu Lys Thr Ala Val Gin Leu Leu 195 200 205 Gly Lys Tyr Arg Asn Leu Glu Tyr lie Leu Glu His Ala Arg Glu Leu 210 215 220 Pro Gin Arg Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Val Ala lie 225 230 235 240 Leu Ser Lys Lys Leu Ala Thr Leu Val Thr Asn Ala Pro Val Glu Val 245 ' 250 255 Asp Trp Glu Glu Met Lys Tyr Arg Gly Tyr Asp Lys Arg Lys Leu Leu 260 265 270 Pro He Leu Lys Glu Leu Glu Phe Ala Ser He Met Lys Glu Leu Gin 275 280 285 Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu He Val Lys Asp His 290 295 300 Lys Thr Phe Glu Asp Leu He Glu Lys Leu Lys Glu Val Pro Ser Phe 305 310 315 320 Ala Leu Asp Leu Glu Thr Ser Ser Leu Asp Pro Phe Asn Cys Glu He 325 330 335 Val Gly He Ser Val Ser Phe Lys Pro Lys Thr Ala Tyr Tyr He Pro 340 345 350 Leu His His Arg Asn Ala Gin Asn Leu Asp Glu Thr Leu Val Leu Ser 355 360 365 Lys Leu Lys Glu He Leu Glu Asp Pro Ser Ser Lys He Val Gly Gin 370 375 380 Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val Lys Gly He Ser Pro 385 390 395 400 Val Tyr Pro His Phe Asp Thr Met He Ala Ala Tyr Leu Leu Glu Pro 405 410 415 Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser Leu Lys Phe Leu Gly 420 425 430 Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser Phe Ser Ser Pro Leu 435 440 445 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Asp Lys Ala Ala Asn Tyr 450 455 460 Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu Tyr Lys He Leu Ser 465 470 475 480 Met Lys Leu His Glu Ala Glu Leu Glu Asn Val Phe Tyr Arg He Glu 485 490 495 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr 500 505 510 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys 515 520 525 Leu Glu Glu Leu Ala Glu Lys He Tyr Gin He Ala Gly Glu Pro Phe 530 535 540 Asn He Asn Ser Pro Lys Gin Val Ser Lys He Leu Phe Glu Lys Leu 545 550 555 560 Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Glu Tyr Ser Thr 565 570 575 Arg He Glu Val Leu Glu Glu He Ala Asn Glu His Glu He Val Pro 580 585 590 Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu Lys Ser Thr Tyr He 595 600 605 Asp Thr Leu Pro Lys Leu Val Asn Pro Lys Thr Gly Arg He His Ala 610 615 620 Ser Phe His Gin Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 625 630 635 640 Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu He 645 650 655 Arg Lys Ala He Val Pro Gin Asp Pro Asp Trp Trp He Val Ser Ala 660 665 670 Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala His Leu Ser Gly Asp 675 680 685 Glu Asn Leu Val Lys Ala Phe Glu Glu Gly He Asp Val His Thr Leu 690 695 700 Thr Ala Ser Arg He Tyr Asn Val Lys Pro Glu Glu Val Asn Glu Glu 705 710 715 720 Met Arg Arg Val Gly Lys Met Val Asn Phe Ser He He Tyr Gly Val 725 730 735 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly He Pro Val Lys Glu Ala 740 745 750 Glu Lys Met He He Ser Tyr Phe Thr Leu Tyr Pro Lys Val Arg Ser 755 760 765 Tyr He Gin Gin Val Val Ala Glu Ala Lys Glu Lys Gly Tyr Val Arg 770 775 780 Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin Leu Met Ala Arg Asp 785 790 795 800 Lys Asn Thr Gin Ser Glu Gly Glu Arg He Ala He Asn Thr Pro He 805 810 815 Gin Gly Thr Ala Ala Asp He He Lys Leu Ala Met He Asp He Asp 820 825 830 Glu Glu Leu Arg Lys Arg Asn Met Lys Ser Arg Met He He Gin Val 835 840 845 His Asp Glu Leu Val Phe Glu Val Pro Asp Glu Glu Lys Glu Glu Leu 850 855 860 Val Asp Leu Val Lys Asn Lys Met Thr Asn Val Val Lys Leu Ser Val 865 870 875 880 Pro Leu Glu Val Asp He Ser He Gly Lys Ser Trp Ser 885 890 (2) INFORMATION FOR SEQ ID NO:3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 677 amino acids (B) TYPE : amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: Met Ser Leu His Ala Arg Glu Leu Pro Gin Arg Val Arg Lys Ala Leu 1 5 10 15 Leu Arg Asp Arg Glu Val Ala He Leu Ser Lys Lys Leu Ala Thr Leu 20 25 30 Val Thr Asn Ala Pro Val Glu Val Asp Trp Glu Glu Met Lys Tyr Arg 35 40 45 Gly Tyr Asp Lys Arg Lys Leu Leu Pro He Leu Lys Glu Leu Glu Phe 50 55 60 Ala Ser He Met Lys Glu Leu Gin Leu Tyr Glu Glu Ala Glu Pro Thr 65 70 75 80 Gly Tyr Glu He Val Lys Asp His Lys Thr Phe Glu Asp Leu He Glu 85 90 95 Lys Leu Lys Glu Val Pro Ser Phe Ala Leu Ala Leu Glu Thr Ser Ser 100 105 110 Leu Asp Pro Phe Asn Cys Glu He Val Gly He Ser Val Ser Phe Lys 115 120 125 Pro Lys Thr Ala Tyr Tyr He Pro Leu His His Arg Asn Ala Gin Asn 130 135 140 Leu Asp Glu Thr Leu Val Leu Ser Lys Leu Lys Glu He Leu Glu Asp 145 150 155 160 Pro Ser Ser Lys He Val Gly Gin Asn Leu Lys Tyr Asp Tyr Lys Val 165 170 175 Leu Met Val Lys Gly He Ser Pro Val Tyr Pro His Phe Asp Thr Met 180 185 190 He Ala Ala Tyr Leu Leu Glu Pro Asn Glu Lys Lys Phe Asn Leu Glu 195 200 205 Asp Leu Ser Leu Lys Phe Leu Gly Tyr Lys Met Thr Ser Tyr Gin Glu 210 215 220 Leu Met Ser Phe Ser Ser Pro Leu Phe Gly Phe Ser Phe Ala Asp Val 225 230 235 240 Pro Val Asp Lys Ala Ala Asn Tyr Ser Cys Glu Asp Ala Asp He Thr 245 250 255 Tyr Arg Leu Tyr Lys He Leu Ser Met Lys Leu His Glu Ala Glu Leu 260 265 270 Glu Asn Val Phe Tyr Arg He Glu Met Pro Leu Val Asn Val Leu Ala 275 280 285 Arg Met Glu Leu Asn Gly Val Tyr Val Asp Thr Glu Phe Leu Lys Lys 290 295 300 Leu Ser Glu Glu Tyr Gly Lys Lys Leu Glu Glu Leu Ala Glu Lys He 305 310 315 320 Tyr Gin He Ala Gly Glu Pro Phe Asn He Asn Ser Pro Lys Gin Val 325 330 335 Ser Lys He Leu Phe Glu Lys Leu Gly He Lys Pro Arg Gly Lys Thr 340 345 350 Thr Lys Thr Gly Glu Tyr Ser Thr Arg He Glu Val Leu Glu Glu He 355 360 365 Ala Asn Glu His Glu He Val Pro Leu He Leu Glu Tyr Arg Lys He 370 375 380 Gin Lys Leu Lys Ser Thr Tyr He Asp Thr Leu Pro Lys Leu Val Asn 385 390 395 400 Pro Lys Thr Gly Arg He His Ala Ser Phe His Gin Thr Gly Thr Ala 405 410 415 Thr Gly Arg Leu Ser Ser Ser Asp Pro Asn Leu Gin Asn Leu Pro Thr 420 425 430 Lys Ser Glu Glu Gly Lys Glu He Arg Lys Ala He Val Pro Gin Asp 435 440 445 Pro Asp Trp Trp He Val Ser Ala Asp Tyr Ser Gin He Glu Leu Arg 450 455 460 He Leu Ala His Leu Ser Gly Asp Glu Asn Leu Val Lys Ala Phe Glu 465 470 475 480 Glu Gly He Asp Val His Thr Leu Thr Ala Ser Arg He Tyr Asn Val 485 490 495 Lys Pro Glu Glu Val Asn Glu Glu Met Arg Arg Val Gly Lys Met Val 500 505 510 Asn Phe Ser He He Tyr Gly Val Thr Pro Tyr Gly Leu Ser Val Arg 515 520 525 Leu Gly He Pro Val Lys Glu Ala Glu Lys Met He He Ser Tyr Phe 530 535 540 Thr Leu Tyr Pro Lys Val Arg Ser Tyr He Gin Gin Val Val Ala Glu 545 550 555 560 Ala Lys Glu Lys Gly Tyr Val Arg Thr Leu Phe Gly Arg Lys Arg Asp 565 570 575 He Pro Gin Leu Met Ala Arg Asp Lys Asn Thr Gin Ser Glu Gly Glu 580 585 590 Arg He Ala He Asn Thr Pro He Gin Gly Thr Ala Ala Asp He He 595 600 605 Lys Leu Ala Met He Asp He Asp Glu Glu Leu Arg Lys Arg Asn Met 610 615 620 Lys Ser Arg Met He He Gin Val His Asp Glu Leu Val Phe Glu Val 625 630 635 640 Pro Asp Glu Glu Lys Glu Glu Leu Val Asp Leu Val Lys Asn Lys Met 645 650 655 Thr Asn Val Val Lys Leu Ser Val Pro Leu Glu Val Asp He Ser He 660 665 670 Gly Lys Ser Trp Ser 675 (2) INFORMATION FOR SEQ ID NO:4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 610 amino acids (B) TYPE : amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4: Met Lys Glu Leu Gin Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu 1 5 10 15 He Val Lys Asp His Lys Thr Phe Glu Asp Leu He Glu Lys Leu Lys 20 25 30 Glu Val Pro Ser Phe Ala Leu Ala Leu Glu Thr Ser Ser Leu Asp Pro 35 40 45 Phe Asn Cys Glu He Val Gly He Ser Val Ser Phe Lys Pro Lys Thr 50 55 60 Ala Tyr Tyr He Pro Leu His His Arg Asn Ala Gin Asn Leu Asp Glu 65 70 75 80 Thr Leu Val Leu Ser Lys Leu Lys Glu He Leu Glu Asp Pro Ser Ser 85 90 95 Lys He Val Gly Gin Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val 100 105 110 Lys Gly He Ser Pro Val Tyr Pro His Phe Asp Thr Met He Ala Ala 115 120 125 Tyr Leu Leu Glu Pro Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser 130 135 140 Leu Lys Phe Leu Gly Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser 145 150 155 160 Phe Ser Ser Pro Leu Phe Gly Phe Ser Phe Ala Asp Val Pro Val Asp 165 170 175 Lys Ala Ala Asn Tyr Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu 180 185 190 Tyr Lys He Leu Ser Met Lys Leu His Glu Ala Glu Leu Glu Asn Val 195 200 205 Phe Tyr Arg He Glu Met Pro Leu Val Asn Val Leu Ala Arg Met Glu 210 215 220 Leu Asn Gly Val Tyr Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu 225 230 235 240 Glu Tyr Gly Lys Lys Leu Glu Glu Leu Ala Glu Lys He Tyr Gin He 245 250 255 Ala Gly Glu Pro Phe Asn He Asn Ser Pro Lys Gin Val Ser Lys He 260 265. 270 Leu Phe Glu Lys Leu Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr 275 280 285 Gly Glu Tyr Ser Thr Arg He Glu Val Leu Glu Glu He Ala Asn Glu 290 295 300 His Glu He Val Pro Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu 305 310 315 320 Lys Ser Thr Tyr He Asp Thr Leu Pro Lys Leu Val Asn Pro Lys Thr 325 330 335 Gly Arg He His Ala Ser Phe His Gin Thr Gly Thr Ala Thr Gly Arg 340 345 350 Leu Ser Ser Ser Asp Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu 355 360 365 Glu Gly Lys Glu He Arg Lys Ala He Val Pro Gin Asp Pro Asp Trp 370 375 380 Trp He Val Ser Ala Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala 385 390 395 400 His Leu Ser Gly Asp Glu Asn Leu Val Lys Ala Phe Glu Glu Gly He 405 410 415 Asp Val His Thr Leu Thr Ala Ser Arg He Tyr Asn Val Lys Pro Glu 420 425 430 Glu Val Asn Glu Glu Met Arg Arg Val Gly Lys Met Val Asn Phe Ser 435 440 445 He He Tyr Gly Val Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly He 450 455 460 Pro Val Lys Glu Ala Glu Lys Met He He Ser Tyr Phe Thr Leu Tyr 465 470 475 480 Pro Lys Val Arg Ser Tyr He Gin Gin Val Val Ala Glu Ala Lys Glu 485 490 495 Lys Gly Tyr Val Arg Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin 500 505 510 Leu Met Ala Arg Asp Lys Asn Thr Gin Ser Glu Gly Glu Arg He Ala 515 520 525 He Asn Thr Pro He Gin Gly Thr Ala Ala Asp He He Lys Leu Ala 530 535 540 Met He Asp He Asp Glu Glu Leu Arg Lys Arg Asn Met Lys Ser Arg 545 550 555 560 Met He He Gin Val His Asp Glu Leu Val Phe Glu Val Pro Asp Glu 565 570 575 Glu Lys Glu Glu Leu Val Asp Leu Val Lys Asn Lys Met Thr Asn Val 580 585 590 Val Lys Leu Ser Val Pro Leu Glu Val Asp He Ser He Gly Lys Ser 595 600 605 Trp Ser 610 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 708 amino acids (B) TYPE : amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: Met Asn Ser Ser Ser Val Pro He Pro Gly Val Thr Gly He Gly Glu 1 5 10 15 Lys Thr Ala Val Gin Leu Leu Gly Lys Tyr Arg Asn Leu Glu Tyr He 20 25 30 Leu Glu His Ala Arg Glu Leu Pro Gin Arg Val Arg Lys Ala Leu Leu 35 40 45 Arg Asp Arg Glu Val Ala He Leu Ser Lys Lys Leu Ala Thr Leu Val 50 55 60 Thr Asn Ala Pro Val Glu Val Asp Trp Glu Glu Met Lys Tyr Arg Gly 65 70 75 80 Tyr Asp Lys Arg Lys Leu Leu Pro He Leu Lys Glu Leu Glu Phe Ala 85 90 95 Ser He Met Lys Glu Leu Gin Leu Tyr Glu Glu Ala Glu Pro Thr Gly 100 105 110 Tyr Glu He Val Lys Asp His Lys Thr Phe Glu Asp Leu He Glu Lys 115 120 125 Leu Lys Glu Val Pro Ser Phe Ala Leu Ala Leu Glu Thr Ser Ser Leu 130 135 140 Asp Pro Phe Asn Cys Glu He Val Gly He Ser Val Ser Phe Lys Pro 145 150 155 160 Lys Thr Ala Tyr Tyr He Pro Leu His His Arg Asn Ala Gin Asn Leu 165 170 175 Asp Glu Thr Leu Val Leu Ser Lys Leu Lys Glu He Leu Glu Asp Pro 180 185 190 Ser Ser Lys He Val Gly Gin Asn Leu Lys Tyr Asp Tyr Lys Val Leu 195 200 205 Met Val Lys Gly He Ser Pro Val Tyr Pro His Phe Asp Thr Met He 210 215 220 Ala Ala Tyr Leu Leu Glu Pro Asn Glu Lys Lys Phe Asn Leu Glu Asp 225 230 235 240 Leu Ser Leu Lys Phe Leu Gly Tyr Lys Met Thr Ser Tyr Gin Glu Leu 245 250 255 Met Ser Phe Ser Ser Pro Leu Phe Gly Phe Ser Phe Ala Asp Val Pro 260 265 270 Val Asp Lys Ala Ala Asn Tyr Ser Cys Glu Asp Ala Asp He Thr Tyr 275 280 285 Arg Leu Tyr Lys He Leu Ser Met Lys Leu His Glu Ala Glu Leu Glu 290 295 300 Asn Val Phe Tyr Arg He Glu Met Pro Leu Val Asn Val Leu Ala Arg 305 310 315 320 Met Glu Leu Asn Gly Val Tyr Val Asp Thr Glu Phe Leu Lys Lys Leu 325 330 335 Ser Glu Glu Tyr Gly Lys Lys Leu Glu Glu Leu Ala Glu Lys He Tyr 340 345 350 Gin He Ala Gly Glu Pro Phe Asn He Asn Ser Pro Lys Gin Val Ser 355 360 365 Lys He Leu Phe Glu Lys Leu Gly He Lys Pro Arg Gly Lys Thr Thr 370 375 380 Lys Thr Gly Glu Tyr Ser Thr Arg He Glu Val Leu Glu Glu He Ala 385 390 395 400 Asn Glu His Glu He Val Pro Leu He Leu Glu Tyr Arg Lys He Gin 405 410 415 Lys Leu Lys Ser Thr Tyr He Asp Thr Leu Pro Lys Leu Val Asn Pro 420 425 430 Lys Thr Gly Arg He His Ala Ser Phe His Gin Thr Gly Thr Ala Thr 435 440 445 Gly Arg Leu Ser Ser Ser Asp Pro Asn Leu Gin Asn Leu Pro Thr Lys 450 455 460 Ser Glu Glu Gly Lys Glu He Arg Lys Ala He Val Pro Gin Asp Pro 465 470 475 480 Asp Trp Trp He Val Ser Ala Asp Tyr Ser Gin He Glu Leu Arg He 485 490 495 Leu Ala His Leu Ser Gly Asp Glu Asn Leu Val Lys Ala Phe Glu Glu 500 505 510 Gly He Asp Val His Thr Leu Thr Ala Ser Arg He Tyr Asn Val Lys 515 520 525 Pro Glu Glu Val Asn Glu Glu Met Arg Arg Val Gly Lys Met Val Asn 530 535 540 Phe Ser He He Tyr Gly Val Thr Pro Tyr Gly Leu Ser Val Arg Leu 545 550 555 560 Gly He Pro Val Lys Glu Ala Glu Lys Met He He Ser Tyr Phe Thr 565 570 575 Leu Tyr Pro Lys Val Arg Ser Tyr He Gin Gin Val Val Ala Glu Ala 580 585 590 Lys Glu Lys Gly Tyr Val Arg Thr Leu Phe Gly Arg Lys Arg Asp He 595 600 605 Pro Gin Leu Met Ala Arg Asp Lys Asn Thr Gin Ser Glu Gly Glu Arg 610 615 620 He Ala He Asn Thr Pro He Gin Gly Thr Ala Ala Asp He He Lys 625 630 635 640 Leu Ala Met He Asp He Asp Glu Glu Leu Arg Lys Arg Asn Met Lys 645 650 655 Ser Arg Met He He Gin Val His Asp Glu Leu Val Phe Glu Val Pro 660 665 670 Asp Glu Glu Lys Glu Glu Leu Val Asp Leu Val Lys Asn Lys Met Thr 675 680 685 Asn Val Val Lys Leu Ser Val Pro Leu Glu Val Asp He Ser He Gly 690 695 700 Lys Ser Trp Ser 705 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 893 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala 1 5 10 15 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly He Pro Thr 20 25 30 Asn Ala Val Tyr Gly Val Ala Arg Met Leu Val Lys Phe He Lys Glu 35 40 45 His He He Pro Glu Lys Asp Tyr Ala Ala Val Ala Phe Asp Lys Lys 50 55 60 Ala Ala Thr Phe Arg His Lys Leu Leu Val Ser Asp Lys Ala Gin Arg 65 70 75 80 Pro Lys Thr Pro Ala Leu Leu Val Gin Gin Leu Pro Tyr He Lys Arg 85 90 95 Leu He Glu Ala Leu Gly Phe Lys Val Leu Glu Leu Glu Gly Tyr Glu 100 105 110 Ala Asp Asp He He Ala Thr Leu Ala Val Arg Ala Ala Arg Phe Leu 115 120 125 Met Arg Phe Ser Leu He Thr Gly Ala Lys Asp Met Leu Gin Leu Val 130 135 140 Asn Glu Lys He Lys Val Trp Arg He Val Lys Gly He Ser Asp Leu 145 150 155 160 Glu Leu Tyr Asp Ser Lys Lys Val Lys Glu Arg Tyr Gly Val Glu Pro 165 170 175 His Gin He Pro Asp Leu Leu Ala Leu Thr Gly Asp Asp He Asp Asn 180 185 190 He Pro Gly Val Thr Gly He Gly Glu Lys Thr Ala Val Gin Leu Leu 195 200 205 Gly Lys Tyr Arg Asn Leu Glu Tyr He Leu Glu His Ala Arg Glu Leu 210 215 220 Pro Gin Arg Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Val Ala He 225 230 235 240 Leu Ser Lys Lys Leu Ala Thr Leu Val Thr Asn Ala Pro Val Glu Val 245 250 255 Asp Trp Glu Glu Met Lys Tyr Arg Gly Tyr Asp Lys Arg Lys Leu Leu 260 265 270 Pro He Leu Lys Glu Leu Glu Phe Ala Ser He Met Lys Glu Leu Gin 275 280 285 Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu He Val Lys Asp His 290 295 300 Lys Thr Phe Glu Asp Leu He Glu Lys Leu Lys Glu Val Pro Ser Phe 305 310 315 320 Ala Leu Ala Leu Glu Thr Ser Ser Leu Asp Pro Phe Asn Cys Glu He 325 330 335 Val Gly He Ser Val Ser Phe Lys Pro Lys Thr Ala Tyr Tyr He Pro 340 345 350 Leu His His Arg Asn Ala Gin Asn Leu Asp Glu Thr Leu Val Leu Ser 355 360 365 Lys Leu Lys Glu He Leu Glu Asp Pro Ser Ser Lys He Val Gly Gin 370 375 380 Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val Lys Gly He Ser Pro 385 390 395 400 Val Tyr Pro His Phe Asp Thr Met He Ala Ala Tyr Leu Leu Glu Pro 405 410 415 Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser Leu Lys Phe Leu Gly 420 425 430 Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser Phe Ser Ser Pro Leu 435 440 445 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Asp Lys Ala Ala Asn Tyr 450 455 460 Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu Tyr Lys He Leu Ser 465 470 475 480 Met Lys Leu His Glu Ala Glu Leu Glu Asn Val Phe Tyr Arg He Glu 485 490 495 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr 500 505 510 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys 515 520 525 Leu Glu Glu Leu Ala Glu Lys He Tyr Gin He Ala Gly Glu Pro Phe 530 535 540 Asn He Asn Ser Pro Lys Gin Val Ser Lys He Leu Phe Glu Lys Leu 545 550 555 560 Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Glu Tyr Ser Thr 565 570 575 Arg He Glu Val Leu Glu Glu He Ala Asn Glu His Glu He Val Pro 580 585 590 Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu Lys Ser Thr Tyr He 595 600 605 Asp Thr Leu Pro Lys Leu Val Asn Pro Lys Thr Gly Arg He His Ala 610 615 620 Ser Phe His Gin Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 625 630 635 640 Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu He 645 650 655 Arg Lys Ala He Val Pro Gin Asp Pro Asp Trp Trp He Val Ser Ala 660 665 670 Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala His Leu Ser Gly Asp 675 680 685 Glu Asn Leu Val Lys Ala Phe Glu Glu Gly He Asp Val His Thr Leu 690 695 700 Thr Ala Ser Arg He Tyr Asn Val Lys Pro Glu Glu Val Asn Glu Glu 705 710 715 720 Met Arg Arg Val Gly Lys Met Val Asn Phe Ser He He Tyr Gly Val 725 730 735 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly He Pro Val Lys Glu Ala 740 745 750 Glu Lys Met He He Ser Tyr Phe Thr Leu Tyr Pro Lys Val Arg Ser 755 760 765 Tyr He Gin Gin Val Val Ala Glu Ala Lys Glu Lys Gly Tyr Val Arg 770 775 780 Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin Leu Met Ala Arg Asp 785 790 795 800 Lys Asn Thr Gin Ser Glu Gly Glu Arg He Ala He Asn Thr Pro He 805 810 815 Gin Gly Thr Ala Ala Asp He He Lys Leu Ala Met He Asp He Asp 820 825 830 Glu Glu Leu Arg Lys Arg Asn Met Lys Ser Arg Met He He Gin Val 835 840 845 His Asp Glu Leu Val Phe Glu Val Pro Asp Glu Glu Lys Glu Glu Leu 850 855 860 Val Asp Leu Val Lys Asn Lys Met Thr Asn Val Val Lys Leu Ser Val 865 870 875 880 Pro Leu Glu Val Asp He Ser He Gly Lys Ser Trp Ser 885 890 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 893 amino acids (B) TYPE : amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ϋ) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Met Ala Arg Leu Phe Leu Phe Ala Gly Thr Ala Leu Ala Tyr Arg Ala 1 5 10 15 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly He Pro Thr 20 25 30 Asn Ala Val Tyr Gly Val Ala Arg Met Leu Val Lys Phe He Lys Glu 35 40 45 His He He Pro Glu Lys Asp Tyr Ala Ala Val Ala Phe Asp Lys Lys 50 55 60 Ala Ala Thr Phe Arg His Lys Leu Leu Val Ser Asp Lys Ala Gin Arg 65 70 75 80 Pro Lys Thr Pro Ala Leu Leu Val Gin Gin Leu Pro Tyr He Lys Arg 85 90 95 Leu He Glu Ala Leu Gly Phe Lys Val Leu Glu Leu Glu Gly Tyr Glu 100 105 110 Ala Asp Asp He He Ala Thr Leu Ala Val Arg Ala Ala Arg Phe Leu 115 120 125 Met Arg Phe Ser Leu He Thr Gly Asp Lys Asp Met Leu Gin Leu Val 130 135 140 Asn Glu Lys He Lys Val Trp Arg He Val Lys Gly He Ser Asp Leu 145 150 155 160 Glu Leu Tyr Asp Ser Lys Lys Val Lys Glu Arg Tyr Gly Val Glu Pro 165 170 175 His Gin He Pro Asp Leu Leu Ala Leu Thr Gly Asp Asp He Asp Asn 180 185 190 He Pro Gly Val Thr Gly He Gly Glu Lys Thr Ala Val Gin Leu Leu 195 200 205 Gly Lys Tyr Arg Asn Leu Glu Tyr He Leu Glu His Ala Arg Glu Leu 210 215 220 Pro Gin Arg Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Val Ala He 225 230 235 240 Leu Ser Lys Lys Leu Ala Thr Leu Val Thr Asn Ala Pro Val Glu Val 245 250 255 Asp Trp Glu Glu Met Lys Tyr Arg Gly Tyr Asp Lys Arg Lys Leu Leu 260 265 270 Pro He Leu Lys Glu Leu Glu Phe Ala Ser He Met Lys Glu Leu Gin 275 280 285 Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu He Val Lys Asp His 290 295 300 Lys Thr Phe Glu Asp Leu He Glu Lys Leu Lys Glu Val Pro Ser Phe 305 310 315 320 Ala Leu Ala Leu Glu Thr Ser Ser Leu Asp Pro Phe Asn Cys Glu He 325 330 335 Val Gly He Ser Val Ser Phe Lys Pro Lys Thr Ala Tyr Tyr He Pro 340 345 350 Leu His His Arg Asn Ala Gin Asn Leu Asp Glu Thr Leu Val Leu Ser 355 360 365 Lys Leu Lys Glu He Leu Glu Asp Pro Ser Ser Lys He Val Gly Gin 370 375 380 Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val Lys Gly He Ser Pro 385 390 395 400 Val Tyr Pro His Phe Asp Thr Met He Ala Ala Tyr Leu Leu Glu Pro 405 410 415 Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser Leu Lys Phe Leu Gly 420 425 430 Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser Phe Ser Ser Pro Leu 435 440 445 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Asp Lys Ala Ala Asn Tyr 450 455 460 Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu Tyr Lys He Leu Ser 465 470 475 480 Met Lys Leu His Glu Ala Glu Leu Glu Asn Val Phe Tyr Arg He Glu 485 490 495 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr 500 505 510 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys 515 520 525 Leu Glu Glu Leu Ala Glu Lys He Tyr Gin He Ala Gly Glu Pro Phe 530 535 540 Asn He Asn Ser Pro Lys Gin Val Ser Lys He Leu Phe Glu Lys Leu 545 550 555 560 Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Glu Tyr Ser Thr 565 570 575 Arg He Glu Val Leu Glu Glu He Ala Asn Glu His Glu He Val Pro 580 585 590 Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu Lys Ser Thr Tyr He 595 600 605 Asp Thr Leu Pro Lys Leu Val Asn Pro Lys Thr Gly Arg He His Ala 610 615 620 Ser Phe His Gin Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 625 630 635 640 Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu He 645 650 655 Arg Lys Ala He Val Pro Gin Asp Pro Asp Trp Trp He Val Ser Ala 660 665 670 Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala His Leu Ser Gly Asp 675 680 685 Glu Asn Leu Val Lys Ala Phe Glu Glu Gly He Asp Val His Thr Leu 690 695 700 Thr Ala Ser Arg He Tyr Asn Val Lys Pro Glu Glu Val Asn Glu Glu 705 710 715 720 Met Arg Arg Val Gly Lys Met Val Asn Phe Ser He He Tyr Gly Val 725 730 735 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly He Pro Val Lys Glu Ala 740 745 750 Glu Lys Met He He Ser Tyr Phe Thr Leu Tyr Pro Lys Val Arg Ser 755 760 765 Tyr He Gin Gin Val Val Ala Glu Ala Lys Glu Lys Gly Tyr Val Arg 770 775 780 Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin Leu Met Ala Arg Asp 785 790 795 800 Lys Asn Thr Gin Ser Glu Gly Glu Arg He Ala He Asn Thr Pro He 805 810 815 Gin Gly Thr Ala Ala Asp He He Lys Leu Ala Met He Asp He Asp 820 825 830 Glu Glu Leu Arg Lys Arg Asn Met Lys Ser Arg Met He He Gin Val 835 840 845 His Asp Glu Leu Val Phe Glu Val Pro Asp Glu Glu Lys Glu Glu Leu 850 855 860 Val Asp Leu Val Lys Asn Lys Met Thr Asn Val Val Lys Leu Ser Val 865 870 875 880 Pro Leu Glu Val Asp He Ser He Gly Lys Ser Trp Ser 885 890 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 893 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala 1 5 10 15 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly He Pro Thr 20 25 30 Asn Ala Val Tyr Gly Val Ala Arg Met Leu Val Lys Phe He Lys Glu 35 40 45 His He He Pro Glu Lys Asp Tyr Ala Ala Val Ala Phe Asp Lys Lys 50 55 60 Ala Ala Thr Phe Arg His Lys Leu Leu Val Ser Asp Lys Ala Gin Arg 65 70 75 80 Pro Lys Thr Pro Ala Leu Leu Val Gin Gin Leu Pro Tyr He Lys Arg 85 90 95 Leu He Glu Ala Leu Gly Phe Lys Val Leu Glu Leu Glu Gly Tyr Glu 100 105 110 Ala Asp Asp He He Ala Thr Leu Ala Val Arg Ala Ala Arg Phe Leu 115 120 125 Met Arg Phe Ser Leu He Thr Gly Asp Lys Asp Met Leu Gin Leu Val 130 135 140 Asn Glu Lys He Lys Val Trp Arg He Val Lys Gly He Ser Asp Leu 145 150 155 160 Glu Leu Tyr Asp Ser Lys Lys Val Lys Glu Arg Tyr Gly Val Glu Pro 165 170 175 His Gin He Pro Asp Leu Leu Ala Leu Thr Gly Asp Asp He Asp Asn 180 185 190 He Pro Asp Val Thr Gly He Gly Glu Lys Thr Ala Val Gin Leu Leu 195 200 205 Gly Lys Tyr Arg Asn Leu Glu Tyr He Leu Glu His Ala Arg Glu Leu 210 215 220 Pro Gin Arg Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Val Ala He 225 230 235 240 Leu Ser Lys Lys Leu Ala Thr Leu Val Thr Asn Ala Pro Val Glu Val 245 250 255 Asp Trp Glu Glu Met Lys Tyr Arg Gly Tyr Asp Lys Arg Lys Leu Leu 260 265 270 Pro He Leu Lys Glu Leu Glu Phe Ala Ser He Met Lys Glu Leu Gin 275 280 285 Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu He Val Lys Asp His 290 295 300 Lys Thr Phe Glu Asp Leu He Glu Lys Leu Lys Glu Val Pro Ser Phe 305 310 315 320 Ala Leu Ala Leu Glu Thr Ser Ser Leu Asp Pro Phe Asn Cys Glu He 325 330 335 Val Gly He Ser Val Ser Phe Lys Pro Lys Thr Ala Tyr Tyr He Pro 340 345 350 Leu His His Arg Asn Ala Gin Asn Leu Asp Glu Thr Leu Val Leu Ser 355 360 365 Lys Leu Lys Glu He Leu Glu Asp Pro Ser Ser Lys He Val Gly Gin 370 375 380 Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val Lys Gly He Ser Pro 385 390 395 400 Val Tyr Pro His Phe Asp Thr Met He Ala Ala Tyr Leu Leu Glu Pro 405 410 415 Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser Leu Lys Phe Leu Gly 420 425 430 Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser Phe Ser Ser Pro Leu 435 440 445 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Asp Lys Ala Ala Asn Tyr 450 455 460 Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu Tyr Lys He Leu Ser 465 470 475 480 Met Lys Leu His Glu Ala Glu Leu Glu Asn Val Phe Tyr Arg He Glu 485 490 495 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr 500 505 510 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys 515 520 525 Leu Glu Glu Leu Ala Glu Lys He Tyr Gin He Ala Gly Glu Pro Phe 530 535 540 Asn He Asn Ser Pro Lys Gin Val Ser Lys He Leu Phe Glu Lys Leu 545 550 555 560 Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Glu Tyr Ser Thr 565 570 575 Arg lie. Glu Val Leu Glu Glu He Ala Asn Glu His Glu He Val Pro 580 585 590 Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu Lys Ser Thr Tyr He 595 600 605 Asp Thr Leu Pro Lys Leu Val Asn Pro Lys Thr Gly Arg He His Ala 610 615 620 Ser Phe His Gin Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 625 630 635 640 Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu He 645 650 655 Arg Lys Ala He Val Pro Gin Asp Pro Asp Trp Trp He Val Ser Ala 660 665 670 Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala His Leu Ser Gly Asp 675 680 685 Glu Asn Leu Val Lys Ala Phe Glu Glu Gly He Asp Val His Thr Leu 690 695 700 Thr Ala Ser Arg He Tyr Asn Val Lys Pro Glu Glu Val Asn Glu Glu 705 710 715 720 Met Arg Arg Val Gly Lys Met Val Asn Phe Ser He He Tyr Gly Val 725 730 735 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly He Pro Val Lys Glu Ala 740 745 750 Glu Lys Met He He Ser Tyr Phe Thr Leu Tyr Pro Lys Val Arg Ser 755 760 765 Tyr He Gin Gin Val Val Ala Glu Ala Lys Glu Lys Gly Tyr Val Arg 770 775 780 Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin Leu Met Ala Arg Asp 785 790 795 800 Lys Asn Thr Gin Ser Glu Gly Glu Arg He Ala He Asn Thr Pro He 805 810 815 Gin Gly Thr Ala Ala Asp He He Lys Leu Ala Met He Asp He Asp 820 825 830 Glu Glu Leu Arg Lys Arg Asn Met Lys Ser Arg Met He He Gin Val 835 840 845 His Asp Glu Leu Val Phe Glu Val Pro Asp Glu Glu Lys Glu Glu Leu 850 855 860 Val Asp Leu Val Lys Asn Lys Met Thr Asn Val Val Lys Leu Ser Val 865 870 875 880 Pro Leu Glu Val Asp He Ser He Gly Lys Ser Trp Ser 885 890 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 893 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:9: Met Ala Arg Leu Phe Leu Phe Asp Gly Thr Ala Leu Ala Tyr Arg Ala 1 5 10 15 Tyr Tyr Ala Leu Asp Arg Ser Leu Ser Thr Ser Thr Gly He Pro Thr 20 25 30 Asn Ala Val Tyr Asp Val Ala Arg Met Leu Val Lys Phe He Lys Glu 35 40 45 His He He Pro Glu Lys Asp Tyr Ala Ala Val Ala Phe Asp Lys Lys 50 55 60 Ala Ala Thr Phe Arg His Lys Leu Leu Val Ser Asp Lys Ala Gin Arg 65 70 75 80 Pro Lys Thr Pro Ala Leu Leu Val Gin Gin Leu Pro Tyr He Lys Arg 85 90 95 Leu He Glu Ala Leu Gly Phe Lys Val Leu Glu Leu Glu Gly Tyr Glu 100 105 110 Ala Asp Asp He He Ala Thr Leu Ala Val Arg Ala Ala Arg Phe Leu 115 120 125 Met Arg Phe Ser Leu He Thr Gly Asp Lys Asp Met Leu Gin Leu Val 130 135 140 Asn Glu Lys He Lys Val Trp Arg He Val Lys Gly He Ser Asp Leu 145 150 155 160 Glu Leu Tyr Asp Ser Lys Lys Val Lys Glu Arg Tyr Gly Val Glu Pro 165 170 175 His Gin He Pro Asp Leu Leu Ala Leu Thr Gly Asp Asp He Asp Asn 180 185 190 He Pro Gly Val Thr Gly He Gly Glu Lys Thr Ala Val Gin Leu Leu 195 200 205 Gly Lys Tyr Arg Asn Leu Glu Tyr He Leu Glu His Ala Arg Glu Leu 210 215 220 Pro Gin Arg Val Arg Lys Ala Leu Leu Arg Asp Arg Glu Val Ala He 225 230 235 240 Leu Ser Lys Lys Leu Ala Thr Leu Val Thr Asn Ala Pro Val Glu Val 245 250 255 Asp Trp Glu Glu Met Lys Tyr Arg Gly Tyr Asp Lys Arg Lys Leu Leu 260 265 270 Pro He Leu Lys Glu Leu Glu Phe Ala Ser He Met Lys Glu Leu Gin 275 280 285 Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu He Val Lys Asp His 290 295 300 Lys Thr Phe Glu Asp Leu He Glu Lys Leu Lys Glu Val Pro Ser Phe 305 310 315 320 Ala Leu Ala Leu Glu Thr Ser Ser Leu Asp Pro Phe Asn Cys Glu He 325 330 335 Val Gly He Ser Val Ser Phe Lys Pro Lys Thr Ala Tyr Tyr He Pro 340 345 350 Leu His His Arg Asn Ala Gin Asn Leu Asp Glu Thr Leu Val Leu Ser 355 360 365 Lys Leu Lys Glu He Leu Glu Asp Pro Ser Ser Lys He Val Gly Gin 370 375 380 Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val Lys Gly He Ser Pro 385 390 395 400 Val Tyr Pro His Phe Asp Thr Met He Ala Ala Tyr Leu Leu Glu Pro 405 410 415 Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser Leu Lys Phe Leu Gly 420 425 430 Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser Phe Ser Ser Pro Leu 435 440 445 Phe Gly Phe Ser Phe Ala Asp Val Pro Val Asp Lys Ala Ala Asn Tyr 450 455 460 Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu Tyr Lys He Leu Ser 465 470 475 480 Met Lys Leu His Glu Ala Glu Leu Glu Asn Val Phe Tyr Arg He Glu 485 490 495 Met Pro Leu Val Asn Val Leu Ala Arg Met Glu Leu Asn Gly Val Tyr 500 505 510 Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu Glu Tyr Gly Lys Lys 515 520 525 Leu Glu Glu Leu Ala Glu Lys He Tyr Gin He Ala Gly Glu Pro Phe 530 535 540 Asn He Asn Ser Pro Lys Gin Val Ser Lys He Leu Phe Glu Lys Leu 545 550 555 560 Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr Gly Glu Tyr Ser Thr 565 570 575 Arg He Glu Val Leu Glu Glu He Ala Asn Glu His Glu He Val Pro 580 585 590 Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu Lys Ser Thr Tyr He 595 600 605 Asp Thr Leu Pro Lys Leu Val Asn Pro Lys Thr Gly Arg He His Ala 610 615 620 Ser Phe His Gin Thr Gly Thr Ala Thr Gly Arg Leu Ser Ser Ser Asp 625 630 635 640 Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu Glu Gly Lys Glu He 645 650 655 Arg Lys Ala He Val Pro Gin Asp Pro Asp Trp Trp He Val Ser Ala 660 665 670 Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala His Leu Ser Gly Asp 675 680 685 Glu Asn Leu Val Lys Ala Phe Glu Glu Gly He Asp Val His Thr Leu 690 695 700 Thr Ala Ser Arg He Tyr Asn Val Lys Pro Glu Glu Val Asn Glu Glu 705 710 715 720 Met Arg Arg Val Gly Lys Met Val Asn Phe Ser He He Tyr Gly Val 725 730 735 Thr Pro Tyr Gly Leu Ser Val Arg Leu Gly He Pro Val Lys Glu Ala 740 745 750 Glu Lys Met He He Ser Tyr Phe Thr Leu Tyr Pro Lys Val Arg Ser 755 760 765 Tyr He Gin Gin Val Val Ala Glu Ala Lys Glu Lys Gly Tyr Val Arg 770 775 780 Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin Leu Met Ala Arg Asp 785 790 795 800 Lys Asn Thr Gin Ser Glu Gly Glu Arg He Ala He Asn Thr Pro He 805 810 815 Gin Gly Thr Ala Ala Asp He He Lys Leu Ala Met He Asp He Asp 820 825 830 Glu Glu Leu Arg Lys Arg Asn Met Lys Ser Arg Met He He Gin Val 835 840 845 His Asp Glu Leu Val Phe Glu Val Pro Asp Glu Glu Lys Glu Glu Leu 850 855 860 Val Asp Leu Val Lys Asn Lys Met Thr Asn Val Val Lys Leu Ser Val 865 870 875 880 Pro Leu Glu Val Asp He Ser He Gly Lys Ser Trp Ser 885 890 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 610 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: not relevant (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Met Lys Glu Leu Gin Leu Tyr Glu Glu Ala Glu Pro Thr Gly Tyr Glu 1 5 10 15 He Val Lys Asp His Lys Thr Phe Glu Asp Leu He Glu Lys Leu Lys 20 25 30 Glu Val Pro Ser Phe Ala Leu Asp Leu Glu Thr Ser Ser Leu Asp Pro 35 40 45 Phe Asn Cys Glu He Val Gly He Ser Val Ser Phe Lys Pro Lys Thr 50 55 60 Ala Tyr Tyr He Pro Leu His His Arg Asn Ala Gin Asn Leu Asp Glu 65 70 75 80 Thr Leu Val Leu Ser Lys Leu Lys Glu He Leu Glu Asp Pro Ser Ser 85 90 95 Lys He Val Gly Gin Asn Leu Lys Tyr Asp Tyr Lys Val Leu Met Val 100 105 110 Lys Gly He Ser Pro Val Tyr Pro His Phe Asp Thr Met He Ala Ala 115 120 125 Tyr Leu Leu Glu Pro Asn Glu Lys Lys Phe Asn Leu Glu Asp Leu Ser 130 135 140 Leu Lys Phe Leu Gly Tyr Lys Met Thr Ser Tyr Gin Glu Leu Met Ser 145 150 155 160 Phe Ser Ser Pro Leu Phe Gly Phe Ser Phe Ala Asp Val Pro Val Asp 165 170 175 Lys Ala Ala Asn Tyr Ser Cys Glu Asp Ala Asp He Thr Tyr Arg Leu 180 185 190 Tyr Lys He Leu Ser Met Lys Leu His Glu Ala Glu Leu Glu Asn Val 195 200 205 Phe Tyr Arg He Glu Met Pro Leu Val Asn Val Leu Ala Arg Met Glu 210 215 220 Leu Asn Gly Val Tyr Val Asp Thr Glu Phe Leu Lys Lys Leu Ser Glu 225 230 235 240 Glu Tyr Gly Lys Lys Leu Glu Glu Leu Ala Glu Lys He Tyr Gin He 245 250 255 Ala Gly Glu Pro Phe Asn He Asn Ser Pro Lys Gin Val Ser Lys He 260 265 270 Leu Phe Glu Lys Leu Gly He Lys Pro Arg Gly Lys Thr Thr Lys Thr 275 280 285 Gly Glu Tyr Ser Thr Arg He Glu Val Leu Glu Glu He Ala Asn Glu 290 295 300 His Glu He Val Pro Leu He Leu Glu Tyr Arg Lys He Gin Lys Leu 305 310 315 320 Lys Ser Thr Tyr He Asp Thr Leu Pro Lys Leu Val Asn Pro Lys Thr 325 330 335 Gly Arg He His Ala Ser Phe His Gin Thr Gly Thr Ala Thr Gly Arg 340 345 350 Leu Ser Ser Ser Asp Pro Asn Leu Gin Asn Leu Pro Thr Lys Ser Glu 355 360 365 Glu Gly Lys Glu He Arg Lys Ala He Val Pro Gin Asp Pro Asp Trp 370 375 380 Trp He Val Ser Ala Asp Tyr Ser Gin He Glu Leu Arg He Leu Ala 385 390 395 400 His Leu Ser Gly Asp Glu Asn Leu Val Lys Ala Phe Glu Glu Gly He 405 410 415 Asp Val His Thr Leu Thr Ala Ser Arg He Tyr Asn Val Lys Pro Glu 420 425 430 Glu Val Asn Glu Glu Met Arg Arg Val Gly Lys Met Val Asn Phe Ser 435 440 445 He He Tyr Gly Val Thr Pro Tyr Gly Leu Ser Val Arg Leu Asn He 450 455 460 Pro Val Lys Glu Ala Glu Lys Met He He Ser Tyr Phe Thr Leu Tyr 465 470 475 480 Pro Lys Val Arg Ser Tyr He Gin Gin Val Val Ala Glu Ala Lys Glu 485 490 495 Lys Gly Tyr Val Arg Thr Leu Phe Gly Arg Lys Arg Asp He Pro Gin 500 505 510 Leu Met Ala Arg Asp Lys Asn Thr Gin Ser Glu Gly Glu Arg He Ala 515 520 525 He Asn Thr Pro He Gin Gly Thr Ala Ala Asp He He Lys Leu Ala 530 535 540 Met He Asp He Asp Glu Glu Leu Arg Lys Arg Asn Met Lys Ser Arg 545 550 555 560 Met He He Gin Val His Asp Glu Leu Val Phe Glu Val Pro Asp Glu 565 570 575 Glu Lys Glu Glu Leu Val Asp Leu Val Lys Asn Lys Met Thr Asn Val 580 585 590 Val Lys Leu Ser Val Pro Leu Glu Val Asp He Ser He Gly Lys Ser 595 600 605 Trp Ser 610 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide ( ix) FEATURE : (A) NAME/KEY: Modified- site (B) LOCATION: 1..14 (D) OTHER INFORMATION: /note= "'Xaa' is any amino acid" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Arg Xaa Xaa Xaa Lys Xaa Xaa Xaa Phe Xaa Xaa Xaa Tyr Xaa 1 5 10 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE : amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: Arg Arg Ser Ala Lys Ala He Asn Phe Gly Leu He Tyr Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear ( ii) MOLECULE TYPE : peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13 : Arg Arg Ala Ala Lys Thr He Asn Phe Gly Val Leu Tyr Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO:14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE : peptide (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 14 : Arg Asp Asn Ala Lys Thr Phe He Tyr Gly Phe Leu Tyr Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: Arg Arg Val Gly Lys Met Val Asn Phe Ser He He Tyr Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: Arg Gin Ala Ala Lys Ala He Thr Phe Gly He Leu Tyr Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 14 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: Arg Arg Ala Gly Lys Met Val Asn Phe Ser He He Tyr Gly 1 5 10 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE : amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: Pro Ser Phe Ala Leu Asp Leu Glu Thr Ser Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: Pro Val Phe Ala Phe Asp Thr Glu Thr Asp Ser 1 5 10 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 11 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: Gly Pro Val Ala Phe Asp Ser Glu Thr Ser Ala 1 5 10 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION : SEQ ID NO : 21 : Met He Val Ser Asp He Glu Ala Asn Ala 1 5 10 (2) INFORMATION FOR SEQ ID NO:22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: GACGTTTCAA GCGCTAGGGC AAAAGA 26 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 31 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:23: GTATATTATA GAGTAGTTAA CCATCTTTCC A 31 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (xi) SEQUENCE DESCRIPTION: SEQ ID NO:24: Phe Leu Phe Asp Gly Thr 1 5 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 6 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:25: Leu Leu Val Asp Gly His 1 5 (2) INFORMATION FOR SEQ ID NO:26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: Ser Leu He Thr Gly Asp Lys Asp Met Leu 1 5 .10 (2) INFORMATION FOR SEQ ID NO:27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 amino acids (B) TYPE : amino acid (C) STRANDEDNESS: not relevant (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (xi) SEQUENCE DESCRIPTION: SEQ ID NO:27: Arg He Leu Thr Ala Asp Lys Asp Leu Tyr 1 5 10 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:28: GTAGGCCAGG GCTGTGCCGG CAAAGAGAAA TAGTC 35 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 35 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:29: GAAGCATATC CTTGGCGCCG GTTATTATGA AAATC 35 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: CACCAGACGG GTACCGCCAC TGGCAGGTTG 30 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: TATAGAGTAG TTAACCATCT TTCCAACCCG TTTCATTTCT TCGAACAC 48 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:32: TATAGAGTAG TTAACCATCT TTCCAACCCG TTGCATTTCT TCGAACAC 48 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:33: TATAGAGTAG TTAACCATCT TTCCAACCCG GTTCATTTCT TCGAACAC 48 (2) INFORMATION FOR SEQ ID NO:34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: TATAGAGTAG TTAACCATCT TTCCAACCCG ATGCATTTCT TCGAACAC 48 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: AAGATGGTTA ACGCGTCTAT AATATACGG 29 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:36: CAAGAGGCAC AGAGAGTTTC ACC 23 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:37: GTATATTATA GAGGAGTTAA CCATCTTTCC 30 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: AAGATGGTTA ACTTCTCTAT AATATACGG 29 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:39: TATAGAGTAG TTAACCATCT TTCCAACCCG GTACATGTCT TCGTTCAC 48 (2) INFORMATION FOR SEQ ID NO:40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 48 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:40: TATAGAGTAG TTAACCATCT TTCCAACCCG CAACATGTCT TCGTTCAC 48 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:41: CTTGGCCGCC CGATGCATCA GGGGGTC 27 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:42: CTTGGCCGCC CGCTTCATGA GGGGGTCCAC 30 (2) INFORMATION FOR SEQ ID NO:43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 27 baβe pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:43: CTTGGCCGCC CTGTACATCA GGGGGTC 27 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:44: GTATATTATA GAGGTGTTAA CCATCTTTCC 30 (2) INFORMATION FOR SEQ ID NO:45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 34 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:45: GGGAGACCGG AATTCTCCTT CATTAATTCC TATA 34 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 49 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: TGGAGACCCT GGAACTATAG GAATTAATGA AGGAGAATTC CGGTCTCCC 49 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: GTATTTTGGT ATGCTTGTGC 20 (2) INFORMATION FOR SEQ ID NO:48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:48: CTATTTTGGA ATATATGTGC CT 22 (2) INFORMATION FOR SEQ ID NO:49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:49: ACGAACATTC TACAAGTTAC 20 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:50: TTTCAGAGAA ACTGACCTGT 20 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:51: GATAAATGCC AAACATGTTG T 21 (2) INFORMATION FOR SEQ ID NO:52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: TGCTCTCAGG ATTTCCTCCA 20 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: AGCTTGAGAC CTCTGTGTCC 20 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:54: ATTCAGAAGA AACAGTGATG GT 22 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:55: TTGGAGTCGC AAGCTGAACT AGC 23 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: GCCTGAGTGA CAGAGTGAGA ACC 23 (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57: CCCACTAGGT TGTAAGCTCC ATGA 24 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:58: TACTATGTGC CAGGCTCTGT CCTA 24 (2) INFORMATION FOR SEQ ID NO:59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: ACTCATGAAG GTGACAGTTC 20 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: GTGTTGTTGA CCTATTGCAT 20 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61: ATCTCTGTTC CCTCCCTGTT 20 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62: CTTATTGGCC TTGAAGGTAG 20 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: AGCCCGTGTT GGAACCATGA CTG 23 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64: TACATAGCGA GACTCCATCT CCC 23 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:65: TTTATGCGAG CGTATGGATA 20 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: CDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66: CACCACCATT GATCTGGAAG 20 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: CCAACCACAC TGGGAA 16 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: AACAGTTGCC CACGGT 16 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69: CATGAAATGC TGACTGGGTA 20 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70: TCAATTTATG TGCAGCCAAT 20 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: CATAGCGAGA CTCCATCTCC 20 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: GGGAGAGGGC AAAGATCGAT 20 (2) INFORMATION FOR SEQ ID NO:73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73: AACACTAGTG AC-ATTATTTT CA 22 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: AGCTAGGCCT GAAGGCTTCT 20 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:75: CCCTAGTGGA TGATAAGAAT AATC 24 (2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:76: GGACAGATGA TAAATACATA GGATGGATGG 30 (2) INFORMATION FOR SEQ ID NO: 77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77: TTCTCTTACA ACACTGCCCC 20 (2) INFORMATION FOR SEQ ID NO: 78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78: ATTTGGATGG CTTGACAGAG 20 (2) INFORMATION FOR SEQ ID NO: 79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79 ACATTCTAAG ACTTTCCCAA T 21 (2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80: AGAGCATGCA CCCTGAATTG 0 (2) INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81: AAGAACCATG CGATACGACT 20 (2) INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82: CATTCCTAGA TGGGTAAAGC 20 (2) INFORMATION FOR SEQ ID NO: 83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:83: GCTTAGTCAT ACGAGCGG 18 (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84: TCCACAGCCA TGTAAACC 18 (2) INFORMATION FOR SEQ ID NO: 85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 16 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85: CCCCGGAGCA AGTTCA 16 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86: CAGCCCAAAG CCAGATTA 18 (2) INFORMATION FOR SEQ ID NO: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87: ATATGTGAGT CAATTCCCCA AG 22 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 22 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:88: TGTATTAGTC AATGTTCTCC AG 22 (2) INFORMATION FOR SEQ ID NO: 89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 19 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89: CAGCTGCCCT AGTCAGCAC 19 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90: GCTTCCGAGT GCAGGTCACA 20 (2) INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 21 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:91: ATTCTGGGCG CACAAGAGTG A 21 (2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:92 ACATCTCCCC TACCGCTATA 20 (2) INFORMATION FOR SEQ ID NO: 93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE : nucleic acid (C) STRANDEDNESS: both (D) TOPOLOGY: both (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:93: GAAGTTCACC ATCCGGCCGA CCCGTCGCAT TTC 33 - . - T US98/02 1 INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (JAPAN) (PCT Rule \3bis) A. The indications made below relate to the microorganism referred to in the description on page _£2_, line _14_ B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet IS1 Name of depositary institution Agricultural Research Service Culture Collection (NRRL) Address of depositary institution (including postal code and country) 1815 North University Street Peoria, Illinois 61604 United States of America Date of deposit 30 September 1994 Accession Number: NRRL B-21238 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet D Ecoli DH10B(pUC-r«e) D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE Ofthe indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS blank ,f„o, applicable The indications listed below will be submitted to the international Bureau later (specify the general nature ofthe indications, e.g . "Accession Number of Deposit") INDICATIONS RELATING TO A DEPOSITED MICROORGANISM (JAPAN) (PCT Rule Ubis) A. The indications made below relate to the microorganism referred to in the description on page _58_, line _2_ B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet G3 Name of depositary institution Agricultural Research Service Culture Collection (NRRL) Address of depositary institution (including postal code and country) 1815 North University Street Peoria, Illinois 61604 United States of America Date of deposit 30 September 1994 Accession Number: NRRL B-21338 C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet D E.coli DH10B(pUC19-7>2e) D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) E. SEPARATE FURNISHING OF INDICATIONS ik blank ,/ιw, pplicable) The indications listed below will be submitted to the international Bureau later (specify the general nature ofthe indications, e.g , "Accession Number of Deposit")

Claims: 150 WHAT IS CLAIMED IS: 1. A method of identifying, analyzing or typing a polymorphic DNA fragment in a sample of DNA sa id method comprising contacting said sample of DNA with one or more DNA polymerases substantially reduced in the ability to add one or more non-templated nucleotides to the 3 ' terminus of a DNA molecule, amplifying said polymorphic DNA fragment within said sample and analyzing said amplified polymorphic DNA fragment. 2. A method of producing amplified copies of a polymorphic DNA fragment which comprise substantially no non-templated 3' terminal nucleotides, said method comprising contacting a DNA sample with one or more DNA polymerases substantially reduced in the ability to add one or more non-templated nucleotides to the 3' terminus of a DNA molecule and amplifying said polymorphic DNA fragment within said DNA sample. 3. A method of cloning a DNA molecule comprising contacting said DNA molecule with one or more DNA polymerases substantially reduced in the ability to add one or more non-templated nucleotides to the 3' terminus of a DNA molecule, amplifying said DNA molecule and inserting said DNA molecule into a vector. 4. The method of claim 3, wherein said vector is blunt-ended. 5. The method of claim 1, wherein said polymorphic DNA fragment is selected from the group of polymorphic DNA fragments comprising a minisatellite DNA fragment, a microsatellite DNA fragment and a STR DNA fragment. 6. The method of claim 1 , wherein said polymerases are thermostable DNA polymerases. 151 7. The method of claim 6, wherein said thermostable DNA polymerases are Thermotoga DNA polymerases and mutants or derivatives thereof. 8. The method of claim 7, wherein said DNA polymerase is a Tne or Tma DNA polymerase. 9. The method of claim 1, wherein said DNA polymerases are substantially reduced in 3'-5' exonuclease activity. 10. The method of claim 1, wherein said DNA polymerases are substantially reduced in 5'-3' exonuclease activity. 11. The method of claim 9, wherein said DNA polymerases are substantially reduced in 5'-3' exonuclease activity. 12. The method of claim 1 , wherein said DNA polymerases contain one or more modifications or mutations which reduce the ability ofthe polymerase to add one or more non-templated 3' nucleotides to a synthesized nucleic acid molecule. 13. The method of claim 12, wherein said DNA polymerases are substantially reduced in at least one activity selected from the group consisting of: (a) 3'-5' exonuclease activity; and (b) 5'-3' exonuclease activity. 14. The method of claim 13, wherein said polymerases have substantially reduced 3'-5' exonuclease and 5'-3' exonuclease activity. 15. The method of claim 13, wherein said polymerase is substantially 152 reduced in 3'-5' exonuclease activity. 16. The method of claim 12, wherein said polymerases comprise one or more mutations or modifications in the O-helix of said polymerase. 17. The method of claim 16, wherein said O-helix is defined as RXXXKXXXFXXXYX (SEQ LD NO: 11), wherein X is any amino acid. 18. The method of claim 17, wherein said mutation or modification is at position R (Arg) and/or F (Phe) and/or K (Lys) of said O-helix or combinations thereof. 19. The method of claim 16, wherein said mutation or modification is an amino acid substitution at position R and/or F and/or K of said O-helix or combinations thereof. 20. The method of claim 1, wherein said polymerase is selected from the group consisting of: Tne N'Δ219, D323 A; J« NA283, D323A Tne N'Δ284, D323 A; 7we N'Δl93, D323A; 7n D137A D323 Tne D8A D323A; Tne G195D, D323A; Tne G37D, D323A; J« N'Δ283; Tne D137A D323A R722K; Tne D137A D323A R722Y; Tne D137A D323A R722L; Tne D137A D323A R722H; 153 Tne D137A D323 R722Q; Tne D137A D323A F730Y; Tne D137A D323A K726R; Tne D137A D323A K726H; 5 Tne D137A D323A R722K, F730Y; Tne D137A D323A R722K, K726R; Tne D137A D323 R722K, K726H; Tne D137A D323A R722H, F730Y; Tne D137A D323A R722H, K726R; 10 Tne Dl 37A D323 R722H, K726H; Tne D137A D323A R722Q, F730Y; Tne D137A D323A R722Q, K726R; Tne D137A D323A R722Q, K726H; Tne D137A D323A R722N, F730Y; 15 Tne O131A, D323A R722N, K726R; Tne D137A D323A R722N, K726H; Tne D137A D323A F730S; Tne N'Δ283, D323 A R722K/H/Q/NΛ L; Tne N'Δ219, D323A R722K; 20 Tne N'Δ219, D323A F730Y; Tne N'Δ219, D323A K726R; Tne N'Δ219, D323A K726H; Tne D137A D323A F730S, R722K/Y/Q/N/H/L, K726R/H; Tne D137A D323A F730T, R722K7Y/Q/N/H/L, K726R/H; 25 7>te D137A D323A F730T; Tne F730S; Tne F730A; Tne K726R; Jwe K726H; and 30 Tne O131A, D323A R722N. 154 21. A method of determining the relationship between a first individual and a second individual, said method comprising comparing a population of amplified DNA molecules in a sample of DNA from said first individual to that of said second individual prepared according to the method of claim 1. 22. The method of claim 21, wherein said sample of DNA from said first individual is a known sample and said sample of DNA from said second individual is an unknown sample. 23. A kit for the identification, analysis or typing of a polymorphic DNA fragment, said kit comprising one or more DNA polymerases substantially reduced in the ability to add one or more non-templated nucleotides to the 3' terminus of a DNA molecule. 24. The kit of claim 23, said kit further comprising one or more components selected from the group consisting of one or more DNA primers, one or more deoxynucleoside triphosphates, and a buffer suitable for use in the identification, analysis or typing of a polymorphic DNA fragment. 25. The kit of claim 23, wherein said polymerases are thermostable DNA polymerases. 26. The kit of claim 25, wherein thermostable DNA polymerases are Thermotoga DNA polymerases. 27. The kit of claim 23, wherein said DNA polymerase is substantially reduced in 3'-5' exonuclease activity. 28. The kit of claim 23, wherein said DNA polymerase is substantially reduced in 5 '-3' exonuclease activity. 155 29. The kit of claim 23, wherein said DNA polymerases comprise one or more modifications or mutations which reduce the ability ofthe polymerase to add one or more non-templated 3' nucleotides to a synthesized nucleic acid molecule. 30. The kit of claim 29, wherein said polymerases comprise one or more mutations in the O-helix of said polymerase. 31. The kit of claim 30, wherein said O-helix is defined as RXXXKXXXFXXXYX (SEQ LD NO: 11), wherein X is any amino acid. 32. The kit of claim 31, wherein said mutation or modification is at position R (Arg) and/or F (Phe) and/or K (Lys) of said O-helix or combinations thereof. 33. The method of claim 31 , wherein said mutation or modification is an amino acid substitution at position R and/or F and/or K of said O-helix or combinations thereof. 34. A polymerase which has been modified or mutated to reduce, substantially reduce or eliminate the ability ofthe polymerase to add nontemplated 3' nucleotides to a synthesized nucleic acid molecule. 35. The polymerase of claim 34, wherein said polymerase is aDNA or RNA polymerase. 36. The polymerase of claim 34, wherein said polymerase is substantially pure. 37. The polymerase of claim 34, wherein said polymerase is mesophilic or thermostable. 156 38. The polymerase of claim 34, wherein said polymerase is selected from the group consisting of Tne DNA polymerase, Taq DNA polymerase, Tma DNA polymerase, Tth DNA polymerase, Tli DNA polymerase, VENT™ DNA polymerase, Pfu DNA polymerase, DEEPVENT™ DNA polymerase, Pwo DNA polymerase, Bst DNA polymerase, Bca DNA polymerase, Tfl DNA polymerase, and mutants, variants and derivatives thereof. 39. The polymerase of claim 34, wherein said polymerase is substantially reduced in at least one activity selected from the group consisting of: (a) 3'→5' exonuclease activity; and (b) 5'- 3' exonuclease activity. 40. The polymerase of claim 39, wherein said polymerase is substantially reduced in 3'-5' exonuclease activity. 41. The polymerase of claim 39, wherein said polymerase is substantially reduced in 5'-3' exonuclease activity. 42. The polymerase of claim 41, which is modified or mutated to reduce or eliminate 3'-5' exonuclease activity. 43. The polymerase of claim 34, which comprises one or more modifications or mutations in the O-helix of said polymerase. 44. The polymerase of claim 43, wherein said O-helix is defined as RXXXKXXXFXXXYX (SEQ LD NO: 11), wherein X is any amino acid. 45. The polymerase of claim 44, wherein said mutation or modification is at position R (Arg) and/or F (Phe) and/or K (Lys) of said O-helix or combinations thereof. 157 46. The polymerase of claim 44, wherein said mutation or modification is an amino acid substitution at position R and/or F and/or K of said O-helix or combinations thereof. 47. The polymerase of claim 46, wherein R (Arg) is substituted with an amino acid selected from the group consisting of Aa, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Try and Val. 48. The polymerase of claim 46, wherein R (Arg) is substituted with Lys or His. 49. The polymerase of claim 46, wherein F (Phe) is substituted with an amino acid selected from the group consisting of Aa, Asn, Arg, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Lys, Met, Pro, Ser, Thr, Trp, Try and Val. 50. The polymerase of claim 46, wherein K (Lys) is substituted with an amino acid selected from the group consisting of Aa, Arg, Asn, Asp, Cys, Gin, Glu, Gly, His, He, Leu, Met, Phe, Pro, Ser, Thr, Trp, Try and Val. 51. The polymerase of claim 46, wherein K (Lys) is substituted with Arg or His. 52. A mutant Tne DNA polymerase protein selected from the group consisting of: J«e NA219, D323A; Tne N'Δ283, D323A Tne N'Δ284, D323 A 7«e N'Δl93, D323A Tne D137A D323A Tne D8A D323A; Tne G195D, D323A; 158 Tne G37D, D323A; 7we N'Δ283; 7«e D137A D323A R722K; Tne D137A D323 A R722Y; 5 Tne D137A D323A R722L; Tne D137A D323A R722H; 7>te D137A D323A R722Q; Tne D137A D323A F730Y; Tne D137A D323A K726R; 10 Tne D137A D323A K726H; Tne D137A D323A R722K, F730Y; Tne D137A D323A R722K, K726R; Tne D137A D323A R722K, K726H; Tne D137A D323A R722H, F730Y; 15 Tne D137A D323A R722H, K726R; Tne D137A D323A R722H, K726H; Tne D137A D323A R722Q, F730Y; Tne D137A D323A R722Q, K726R; Tne D137A D323A R722Q, K726H; 20 7«e D137 D323A R722N, F730Y; Tne D137A D323A R722N, K726R; 7«e D137A D323 A R722N, K726H; Tne D137A D323A F730S; Tne N'Δ283, D323A R722K7H/Q/N/Y/L; 25 Tne N'Δ219, D323A R722K; Tne N'Δ219, D323A F730Y; 7/?e N'Δ219, D323A K726R; Tne N'Δ219, D323A K726H; Tne D137A D323A F730S, R722K/Y/Q/N/H/L, K726R/H; 30 Tne Dl 37A D323 F730T, R722K/Y/Q/N H/L, K726R/H; Tne D137A D323A F730T; 159 Tne F730S; Tne F730A Tne K726R; Tne K726H; and Tne D137A D323A R722N. 53. A vector comprising a gene encoding the polymerase of claim 34. 54. The vector of claim 53, wherein said gene is operably linked to a promoter. 55. The vector of claim 54, wherein said promoter is selected from the group consisting of a λ-P L promoter, a tac promoter, a trp promoter, and a trc promoter. 56. A host cell comprising the vector of claim 53. 57. A method of producing a polymerase, said method comprising: (a) culturing the host cell of claim 56; (b) expressing said gene; and (c) isolating said polymerase from said host cell. 58. A method of synthesizing a nucleic acid molecule comprising: (a) mixing a nucleic acid template with one or more polymerases of claim 34; and (b) incubating said mixture under conditions sufficient to make a nucleic acid molecule complementary to all or a portion of said template. 59. The method of claim 58, wherein said mixture further comprises one or more nucleotides selected from the group consisting of dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, dUTP, ddATP, ddCTP, ddGTP, ddlTP, 160 ddTTP, [α-S]dATP, [α-S]dTTP, [α-S]dGTP, and [α-S]dCTP. 60. The method of claim 59, wherein one or more of said nucleotides are detectably labeled. 61. A method of sequencing a DNA molecule, comprising: (a) hybridizing a primer to a first DNA molecule; (b) contacting said DNA molecule of step (a) with deoxyribonucleoside triphosphates, one or more DNA polymerases of claim 34, and a terminator nucleotide; (c) incubating the mixture of step (b) under conditions sufficient to synthesize a random population of DNA molecules complementary to said first DNA molecule, wherein said synthesized DNA molecules are shorter in length than said first DNA molecule and wherein said synthesized DNA molecules comprise a terminator nucleotide at their 3' termini; and (d) separating said synthesized DNA molecules by size so that at least a part of the nucleotide sequence of said first DNA molecule can be determined. 62. The method of claim 61, wherein said deoxyribonucleoside triphosphates are selected from the group consisting of dATP, dCTP, dGTP, dTTP, dITP, 7-deaza-dGTP, dUTP, [α-S]dATP, [α-S]dTTP, [α-S]dGTP, and [α-S]dCTP. 63. The method of claim 61, wherein said terminator nucleotide is ddTTP, ddATP, ddGTP, ddlTP or ddCTP. 64. The method of claim 61, wherein one or more of said deoxyribonucleoside triphosphates is detectably labeled. 65. The method of claim 61 , wherein one or more of said terminator 161 nucleotides is detectably labeled. 66. A method for amplifying a double stranded DNA molecule, comprising: (a) providing a first and second primer, wherein said first primer is complementary to a sequence at or near the 3'-termini ofthe first strand of said DNA molecule and said second primer is complementary to a sequence at or near the 3 '-termini ofthe second strand of said DNA molecule; (b) hybridizing said first primer to said first strand and said second primer to said second strand in the presence of the one or more DNA polymerases of claims 34, under conditions such that a third DNA molecule complementary to said first strand and a fourth DNA molecule complementary to said second strand are synthesized; (c) denaturing said first and third strand, and said second and fourth strands; and (d) repeating steps (a) to (c) one or more times. 67. A kit for sequencing, amplifying or sequencing a DNA molecule comprising one or more polymerases of claim 34. 68. The kit of claim 67, further comprising one or more dideoxyribonucleoside triphosphates and/or one or more deoxyribonucleoside triphosphates.

Inventors: CHATTERJEE DEB K, SOLUS JOSEPH, YANG SHUWEI, CHATTERJEE, DEB, K., SOLUS, JOSEPH, YANG, SHUWEI
Applicants: LIFE TECHNOLOGIES INC, LIFE TECHNOLOGIES, INC.
Application year: 1998
Main classification: C12Q1
IPC codes: C12N1, C12N5, C12N9, C12N15, C12Q1